

ONKOLOŠKI
INŠTITUT
LJUBLJANA



INSTITUTE
OF ONCOLOGY
LJUBLJANA

EPIDEMIOLOGIJA IN REGISTER RAKA
EPIDEMIOLOGY AND CANCER REGISTRY

Rak v Sloveniji

2007

Cancer in Slovenia

LET **60** YEARS
REGISTER RAKA REPUBLIKE SLOVENIJE
CANCER REGISTRY OF REPUBLIC OF SLOVENIA



Rak
v Sloveniji

2007

Cancer
in Slovenia

Naslov / Title: Rak v Sloveniji 2007 / Cancer in Slovenia 2007

Uredniški odbor / Editorial Board

Maja Primic Žakelj, glavna urednica / editor-in-chief
Matej Bračko, Marko Hočevar, Mateja Krajc,
Vera Pompe-Kirn, Primož Strojani, Vesna Zadnik,
Branko Zakotnik, Tina Žagar

Računalniška obdelava / EDP analysis

Jurij Modic, Vesna Zadnik, Tina Žagar, Katja Jarm, Cveto Šval

Oblikovanje in priprava za tisk / Design & Typesetting

Studio N, studio za oblikovanje in grafično pripravo

Tisk / Printing

Present d. o. o.

Izdajatelj / Published by

Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, Slovenia
Epidemiologija in register raka / Epidemiology and Cancer Registry
Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia

Naklada / Published in

600 izvodov / 600 copies

Nasvet za citiranje / Recommended reference

Rak v Sloveniji 2007. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2010.

Cancer in Slovenia 2007. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia, 2010.

Osebnosti Registra raka Republike Slovenije / Staff of the Cancer Registry of Republic of Slovenia

Maja Primic Žakelj, vodja / head
Barbara Babuder, Andrej Kirn, Andrej Krašovec, Lavrence Kresnik, Neža Milčič,
Darja Strle, Fani Škrlec, Nataša Šturm in Tina Žagar

Naslov / Correspondence to

Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia
Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana
Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija
Telefon / Phone: + 386 1 5879 450
E-pošta / E-mail: register@onko-i.si
Spletna stran / Web site:
<http://www.onko-i.si/rrs/>
<http://www.onko-i.si/crs/>

Predgovor	7
Uvod	8
Viri podatkov in metode registracije	9
Viri in nabor podatkov	9
Priprava podatkov za računalniško obdelavo	10
Kakovost podatkov RRRS in popolnost registracije	11
Statistične metode	12
Incidenca in umrljivost	12
Grobe in starostno specifične stopnje	12
Starostno standardizirane stopnje	12
Kumulativne incidenčne stopnje in kumulativno tveganje	13
Prevalenca	13
Prebivalstvo Slovenije	14
Rak v Sloveniji 2007	15
Zahvala	17
Reference	29
Foreword	7
Introduction	18
Data sources and methods of registration	20
Data sources and list of data collected	20
Preparation of data for computer processing	21
Data quality and completeness of registration	22
Statistical methods	23
Incidence and mortality	23
Crude and age-specific rates	23
Age-standardised rates	23
Cumulative incidence rate and cumulative risk	24
Prevalence	24
Population of Slovenia	25
Cancer in Slovenia 2007	26
Acknowledgement	28
References	29

Slike / Figures

Slika 1:	Breme raka, Slovenija 2007.	30
Figure 1:	Cancer burden, Slovenia 2007.	
Slika 2:	Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2007.	30
Figure 2:	Percentage distribution of all cancer sites by age groups and by sex, Slovenia 2007.	
Slika 3:	Najpogostejše lokacije raka po spolu in pri obeh spolih skupaj, Slovenija 2007.	31
Figure 3:	The leading cancer sites by sex and in both sexes together, Slovenia 2007.	
Slika 4:	Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu, Slovenija 1950–2007.	32
Figure 4:	Crude and cumulative annual incidence and mortality rates of all cancer sites by sex, Slovenia 1950–2007.	
Slika 5:	Groba letna incidenčna stopnja izbranih rakov po spolu, Slovenija 1950–2007.	33
Figure 5:	Crude annual incidence rate of selected primary cancer sites by sex, Slovenia 1950–2007.	
Slika 6:	Zemljevidi nemelanomskega kožnega raka pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	34
Figure 6:	Maps of non-melanoma skin cancer in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	
Slika 7:	Zemljevidi nemelanomskega kožnega raka pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	35
Figure 7:	Maps of non-melanoma skin cancer in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	
Slika 8:	Zemljevidi raka debelega črevesa in danke pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	36
Figure 8:	Maps of colorectal cancer in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	
Slika 9:	Zemljevidi raka debelega črevesa in danke pri ženskah po upravnih enotah ; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	37
Figure 9:	Maps of colorectal cancer in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	
Slika 10:	Zemljevidi pljučnega raka pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	38
Figure 10:	Maps of lung cancer in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	
Slika 11:	Zemljevidi pljučnega raka pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	39
Figure 11:	Maps of lung cancer in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	
Slika 12:	Zemljevidi raka prostate pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	40
Figure 12:	Maps of prostate cancer in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	
Slika 13:	Zemljevidi raka dojke pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	41
Figure 13:	Maps of breast cancer in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	

Slika 14:	Zemljevidi želodčnega raka pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	42
Figure 14:	Maps of stomach cancer in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	
Slika 15:	Zemljevidi želodčnega raka pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	43
Figure 15:	Maps of stomach cancer in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	
Slika 16:	Zemljevidi kožnega melanoma pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	44
Figure 16:	Maps of skin melanoma in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	
Slika 17:	Zemljevidi kožnega melanoma pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	45
Figure 17:	Maps of skin melanoma in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	
Slika 18:	Zemljevidi raka glave in vratu pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	46
Figure 18:	Maps of head and neck cancer in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	
Slika 19:	Zemljevidi raka sečnega mehurja pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	47
Figure 19:	Maps of bladder cancer in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	
Slika 20:	Zemljevidi raka materničnega telesa pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	48
Figure 20:	Maps of uterine corpus cancer in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	
Slika 21:	Zemljevidi raka materničnega vratu pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.	49
Figure 21:	Maps of uterine cervix cancer in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.	

Podatki v tabelah / Data in tables

Tabela 1:	Opazovana in ocenjena incidenca raka, Slovenija 1998–2007 in 2010.	50
Table 1:	Observed and estimated cancer incidence, Slovenia 1998–2007 and 2010.	
Tabela 2:	Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2007.	51
Table 2:	Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized incidence cancer rates, Slovenia 2007.	
Tabela 3:	Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2007.	52
Table 3:	Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2007.	
Tabela 4:	Incidenca raka po lokaciji, spolu in starosti, Slovenija 2007.	56
Table 4:	Cancer incidence by site, by sex and by age, Slovenia 2007.	

Tabela 5:	Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter kumulativna stopnja (KS) po lokaciji in spolu, Slovenija 2007.	60
Table 5:	Crude and age-specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, Slovenia 2007.	
Tabela 6a:	Incidenca najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2007.	66
Table 6a:	Incidence of most frequent cancer sites by statistical regions and by sex, Slovenia 2007.	
Tabela 6b:	Starostno standardizirana incidenčna stopnja najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2007.	67
Table 6b:	Age-standardised incidence rate of most frequent cancer sites by statistical regions and by sex, Slovenia 2007.	
Tabela 7:	Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2007.	68
Table 7:	Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2007.	
Tabela 8:	Incidenca ne-Hodgkinovih limfomov po lokaciji, spolu in starosti, Slovenija 2007.	77
Table 8:	Incidence of non-Hodgkin's malignant lymphomas by site, by sex and by age, Slovenia 2007.	
Tabela 9:	Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2007.	78
Table 9:	Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2007.	
Tabela 10a:	Število deleži bolnikov, zbolelih leta 2007, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemsko terapijo ali obsevani.	81
Table 10a:	Number of patients diagnosed in 2007, that were treated by surgery, systemic therapy or radiotherapy during their first treatment.	
Tabela 10b:	Število bolnikov, zbolelih v letu 2007, ki so bili v okviru prvega zdravljenja operirani, po lokaciji raka in bolnišnici posega.	82
Table 10b:	Number of patients, diagnosed in 2007, that were treated by surgery during their first treatment by primary sites and treatment institution.	
Tabela 10c:	Število bolnikov, zbolelih v letu 2007, ki so v okviru prvega zdravljenja prejeli sistemsko terapijo, po lokacijah raka in bolnišnici posega.	83
Table 10c:	Number of patients diagnosed in 2007, that were treated by systemic therapy during their first treatment by primary sites and treatment institution.	
Tabela 11:	Prevalenca po spolu in izbrani primarni lokaciji, Slovenija, 31. 12. 2007.	84
Table 11:	Prevalence of cancer patients by sex and by selected primary site, Slovenia, December 31, 2007.	
Tabela 12:	Umrljivost za rakom po lokaciji, spolu in starosti, Slovenija 2007.	85
Table 12:	Mortality by site, by sex and by age, Slovenia 2007.	
Izbor publikacij / Selected publications		88

Ob 60-letnici Registra raka Republike Slovenije

Pred slabim desetletjem sem na velikem mednarodnem kongresu poslušal predavanje enega najuglednejših evropskih biostatistikov, ki je svoje trditve dokazoval s podatki našega, slovenskega Registra raka in je obenem – skoraj kot v opravičilo publiki – našteval dobre lastnosti našega Registra. Njegove besede sem doživel kot veliko priznanje tej naši službi in Onkološkemu inštitutu, osebno pa so me navdale s ponosom.

Na Onkološkem inštitutu Ljubljana, osrednji onkološki ustanovi v Sloveniji, se zavedamo kakovosti in pomena Registra raka Republike Slovenije. Njegovemu razvoju zato posvečamo posebno pozornost. Med drugim ga čaka informacijska posodobitev ter skrb za še večjo točnost zbranih podatkov.

Ob lepem jubileju Registra raka izrekam vsem njegovim nekdanjim in sedanjim sodelavkam in sodelavcem v imenu vseh zaposlenih na Onkološkemu inštitutu iskrene čestitke.

Janez Žgajnar
Strokovni direktor Onkološkega inštituta Ljubljana

On the 60th Anniversary of Cancer Registry of Republic of Slovenia

Less than a decade ago, I had the opportunity to listen to a lecture by an eminent European biostatistician who provided the evidence for the ideas and assumptions presented in his lecture from the data of the Cancer Registry of Slovenia. At the same time, while presenting the evidence, he was also revealing the qualities and advantages of our Registry. I could feel his great appreciation for our Cancer Registry and our Institute in his words, which made me glow with pride. At the Institute of Oncology Ljubljana, the principal national institution for cancer treatment, we are very much aware of the benefits and significant role of Cancer Registry in Slovenian oncology. We are therefore particularly concerned for the further growth of the Registry, including upgrading its information system and thereby also assuring higher level of accuracy in data gathering.

May I, on this important anniversary, take this opportunity to congratulate, on behalf of the employees of the Institute of Oncology Ljubljana and on my own behalf, our colleagues who used to work at the Registry and those who are working there at present for their successes and achievements at work.

Janez Žgajnar
Medical director of Institute of Oncology Ljubljana

Register raka Republike Slovenije (RRRS) je eden najstarejših populacijskih registrov raka v Evropi. Leta 1950 ga je na Onkološkem inštitutu Ljubljana (OI) ustanovila in do leta 1975 vodila pokojna profesorica dr. Božena Ravnihar. Njeno delo je prevzela profesorica dr. Vera Pompe Kirn, ki je do upokojitve leta 2003 skrbela za nadaljnje uveljavljanje RRRS v domačem in mednarodnem merilu. Od leta 2003 je RRRS z Enoto za epidemiologijo posebna služba OI, ki se imenuje Epidemiologija in register raka. V njej delujejo še *bolnišnični register OI*, ki omogoča podrobnejši pregled nad bolniki, zdravljenimi na OI (ne glede na to, kje imajo stalno prebivališče) in RRRS oskrbuje z velikim delom podatkov, *državni register za vodenje in spremljanje organiziranega presejalnega programa za raka materničnega vratu (ZORA)* in – od leta 2007 – *informacijski sistem za vabljenje žensk in za epidemiološko spremljanje organiziranega presejalnega programa za raka dojk (DORA)*.

Podatki o raku, incidenci, preživetju in prevalenci, ki se zbirajo v RRRS, skupaj s podatki o umrljivosti, ki jih zbira in obdeluje Inštitut za varovanje zdravja RS, so osnova za ocenjevanje bremena rakavih bolezni v državi. Pomembni so za načrtovanje in ocenjevanje onkološkega varstva na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, posteljne zmogljivosti); dragoceni so tudi za klinične in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje učinkovitosti presejalnih programov.

Redna letna poročila RRRS so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih z obdelanimi podatki RRRS. Ker nas omejuje tehnologija zbiranja podatkov, saj je njihovih virov več, je za dokončanje letne zbirke podatkov, njihovo analizo in objavo rezultatov potreben čas, ki je pri nas in v drugih državah podoben, običajno 2 leti do 3. V vsakem poročilu pa zadnja leta objavimo še, kakšna je pričakovana incidenca raka v letu, ko je poročilo izdano (v tokratnem poročilu torej za leto 2010); izračunana je s posebno statistično metodo.

RRRS je prva letna poročila izdal v letih 1953–1957 za leta 1951–1955. Prva analiza podatkov za leto 1950 je bila objavljena v *Zdravstvenem vestniku leta 1951*. Podatki za leta 1957–1971 so bili objavljeni v periodičnih publikacijah Svetovne zdravstvene organizacije *Epidemiological and Vital Statistics* in v *World Health Statistics Report*. Od leta 1965 so bili podatki spet redno objavljeni v posebnih letnih poročilih z naslovom *Rak v Sloveniji (1965–1977)* in *Incidenca raka v Sloveniji (1978–2006)*, in sicer v slovenskem in angleškem jeziku. Poleg letnih poročil so objavljene tudi 4 monografije: *Zemljevidi incidence raka v Sloveniji 1978–1987*, *Preživetje bolnikov z rakom v Sloveniji 1963–1990*, *Preživetje bolnikov z rakom v Sloveniji 1983–1997* in *Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji*. Seznam drugih pomembnejših del, objavljenih v zadnjih petih letih, je v dodatku na koncu poročila.

Podatki RRRS so vključeni v številne mednarodne podatkovne zbirke in projekte. Objavljeni so v vseh devetih zvezkih knjige *Rak na petih kontinentih (Cancer Incidence in Five Continents)*, ki jo izdaja Mednarodna agencija za raziskovanje raka, in v podatkovnih zbirkah *EUROCIM*, *GLOBOCAN*, *ACCIS*, *preživetje slovenskih bolnikov pa je obdelano v mednarodnih raziskavah EURO CARE II, EURO CARE III, EURO CARE IV* in *EUNICE*.

Šestdeseta obletnica delovanja RRRS nam je izziv za novost, s katero želimo podatke o raku še bolj približati vsem uporabnikom. Razvijamo namreč *interaktivni državni spletni portal*, ki smo ga poimenovali *SLORA* po začetnih črkah besed »Slovenija in rak«. Dostopen bo na elektronskem naslovu www.slora.si. Omogočal bo preprost in hiter dostop do podatkov o raku v Sloveniji, ki jih zbira RRRS (incidenca, prevalenca in preživetje) ali Inštitut za varovanje zdravja (umrljivost) na ravni države in primerjavo z drugimi državami v Evropski uniji in v svetu. S strokovnimi razlagami bo olajšal razumevanje podatkov in seznanjal vse uporabnike z nevarnostnimi dejavniki raka, možnostmi zgodnjega odkrivanja in uspešnosti zdravljenja raka, s tem pa bo prispeval tudi k vrednotenju učinkovitosti Državnega programa obvladovanja raka. S komunikacijskim mostom med uporabniki in strokovnjaki bo prispeval k objektivnemu in verodostojnemu informiranju o raku.

Viri in nabor podatkov

Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve RRRS (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92 in št. 65/00). Osnovni vir podatkov so *prijavnice rakave bolezni*. Regstru jih pošiljajo iz vseh bolnišnic in diagnostičnih centrov v Sloveniji, iz ordinacij osnovnega zdravstvenega varstva pa le izjemoma, če bolnik ni napoten na nadaljnje preiskave in/ali zdravljenje.

S prijavicami zbiramo osebne podatke, podatke o vrsti bolezni (anatomsko mesto raka, histološka oz. citološka diagnoza, stadij po TNM ali drugi klinični klasifikaciji) in o vrsti zdravljenja. Dodatni vir podatkov so zdravniška poročila o vzroku smrti, ki nam jih pošilja Inštitut za varovanje zdravja RS in pa obdukcijski zapisniki z diagnozo maligne bolezni. Veliko časa porabimo za poizvedbe o bolnikih, za katere nimamo popolnih podatkov ali pa dobimo o njih prvo informacijo šele ob smrti.

Za izračun preživetja bolnikov potrebujemo podatek, ki se imenuje *vitalno stanje* (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Te podatke dobimo štirikrat letno iz Centralnega registra prebivalstva, in sicer za vse osebe iz RRRS, ki so po naših podatkih še žive. V letošnjem letu bomo skupaj s prenovo računalniške baze s posebej varovano spletno tehnologijo neposredno povezani s Centralnim registrom prebivalstva (CRP), zato bomo ta podatek lahko pridobivali sproti. Pri izgubljenih osebah upoštevamo kot datum izgube datum zadnje prijave oz. datum izgube, ki nam ga pošlje Centralni register prebivalstva, odvisno od tega, kateri datum je kasnejši. Od leta 1985, odkar RRRS prejema od CRP enotno matično številko občana (EMŠO), je v RRRS odstotni delež izgubljenih manjši od 1 %; pri bolnikih, registriranih v desetletju 1996–2005, je znašal le 0,1 %.

Pri analizi prostorske razporeditve raka upoštevamo Uredbo o standardni klasifikaciji teritorialnih enot – SKTE (2000), ki predpisuje delitev slovenskega ozemlja na 11 ravneh. Točno opredeljevanje stalnih naslovov bolnikov z rakom nam omogoča redna povezava z Registrom prostorskih enot Geodetske uprave RS. V zemljevidih izbranih rakov, prikazanih na Sliki 6, smo uporabili raven delitve SKTE-4, upravne enote. V Tabeli 6 smo do Letnega poročila 2002 prikazovali podatke po 9 zdravstvenih regijah, v skladu z omenjeno uredbo pa smo potem prešli na raven SKTE-3, na 12 statističnih regij.

Slovenske statistične regije



Slovenske upravne enote



Priprava podatkov za računalniško obdelavo

Podatke, prispele v RRRS na prijavnica, posebej usposobljene medicinske sestre najprej kodirajo v skladu z mednarodnimi in v RRRS dogovorjenimi pravili.

Za razvrščanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene, do takrat pa smo uporabljali osmo. Prav pri uvrščanju med maligne bolezni je treba opozoriti še na klasifikacijo morfolologije neoplazem, za katero uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo, od poročila za leto 2001 njeno tretjo izdajo. V tej izdaji je spet nekaj novosti, med drugimi navedba, katere histološke vrste sodijo med maligne. Po tretji reviziji so med maligne uvrščene kronične mieloproliferativne bolezni in mielodisplastični sindromi (sedaj v topografski šifri C96.7). V skladu z novimi pravili tudi mejno malignih tumorjev jajčnikov ne uvrščamo več v kategorijo C56, pač pa v D39.1.

Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene s šifro 234.0 (carcinoma in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepiteljske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepiteljske karcinome dojke, od leta 1995 pa intraepiteljske karcinome mehurja in kožne melanome Clark I.

Ker so podatki o stadiju bolezni po klasifikaciji TNM na prijavnica pogosto pomanjkljivi, za opredelitev stadija bolezni večinoma uporabljamo poenostavljeno razvrščanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, če bolnik poprej ni bil zdravljen. Poenostavljena opredelitev stadijev pri solidnih

tumorjih praviloma sledi klasifikaciji TNM. V omejeni stadij je tako uvrščen primer bolezni, pri katerem je tumor označen s T1 ali T2 (razen pri dojki, malignem melanomu in ščitnici, pri katerih so vključeni tudi tumorji T3, in materničnem vratu, telesu in sarkomih, pri katerih so vključeni le tumorji T1) in pri katerem niso prizadete področne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je primer, pri katerem je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi področne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvrščamo primere, pri katerih je zapisano, da so bili zasevki že v oddaljenih bezgavkah ali organih (M1). Maligni limfomi so opredeljeni po klasifikaciji Ann-Arbor.

Kakovost podatkov RRRS in popolnost registracije

Kakovost podatkov registrov raka osvetljujejo naslednji kazalci: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških poročil o vzroku smrti. Vrednosti teh kazalcev so prikazane v Tabeli 3.

Popolnost registracije kaže delež vseh novih primerov raka na področju, ki ga pokriva register in ki so vključeni v podatkovno zbirko registra. Neposredno jo je mogoče meriti samo s posebnimi raziskavami, namenjenimi oceni popolnosti, npr. s ponovnim pregledom odpustnih diagnoz in popisov bolezni v bolnišnicah ali ambulantah na določenem območju. V Sloveniji takih raziskav zaenkrat še nismo delali, veliko pa nam k popolnosti zajema pomagajo kolegi kliniki, ki jih zanima, kakšno je preživetje bolnikov, zdravljenih pri njih; ko nam pošljejo podatke o svojih skupinah bolnikov, v njih velikokrat najdemo take, ki jih v podatkovni zbirki RRRS še ni.

Na splošno velja, da je popolnost podatkov večja tam, kjer ima register dostop do zdravniških poročil o vzroku smrti. Za tiste, ki so umrli za rakom, pa (še) niso zapisani v registru, RRRS tako išče dodatne podatke. Na ta način se izboljša popolnost registracije rakov s slabo napovedjo izida, ne pa manj usodnih. Domnevamo, da je v Sloveniji – in tudi v drugih evropskih populacijskih registrih raka – manj popolna registracija nemelanomskega kožnega raka in tistih malignomov, ki se zdravijo samo ambulantno.

Incidenca in umrljivost

Incidenca in umrljivost pomenita absolutno število vseh na novo ugotovljenih primerov kake bolezni v točno določeni populaciji oz. število vseh umrlih za to boleznijo v enem koledarskem letu. V incidenco raka ne štejemo novih primarnih rakov parnega organa iste lokacije, če je bila histološka vrsta obeh rakov, npr. leve in desne dojke, enaka. Prav tako v incidenco ne štejemo novega pojava raka iste histološke vrste na istem organu, npr. multiple lezije v debelem črevesu. V incidenco so vključeni primeri bolezni bolnikov s stalnim bivališčem na območju Republike Slovenije ne glede na to, kje so bili bolniki zdravljeni.

Za oceno incidence v letošnjem letu (prikazano v Tabeli 1) je uporabljena metoda po Dybi in Hakulinenu, ki je primerna za napoved incidence v krajšem časovnem obdobju, saj upošteva samo obdobje diagnoze in starost; pri dolgoročnejših napovedih je treba upoštevati tudi vpliv rojstne kohorte.

Grobe in starostno specifične stopnje

Groba incidenčna stopnja je število novih primerov bolezni, preračunana na 100.000 oseb opazovane populacije. Natančneje je definirana kot število novih primerov bolezni v določenem časovnem obdobju, praviloma enem letu (= incidenca), deljeno s številom oseb, ki so na začetku tega obdobja izpostavljene tveganju, da zbolijo; izražamo jo na 100.000 oseb-let. *Starostno specifična stopnja* pove to relativno število (incidenčno stopnjo) v posamezni petletni starostni skupini.

Starostno standardizirane stopnje

Če analiziramo incidenco v daljšem časovnem obdobju (če se starostna struktura prebivalstva v času spreminja) ali če primerjamo incidenco med populacijami z različno starostno strukturo, je treba uporabiti eno od metod starostne standardizacije. Starostno standardizirana stopnja je teoretična incidenčna stopnja, pri kateri predpostavimo, da je starostna struktura opazovane populacije taka kot v standardni populaciji. V Tabeli 2 prikazujemo poleg grobe incidenčne stopnje rakavih bolezni v Sloveniji še starostno standardizirane stopnje na svetovno, evropsko in slovensko standardno populacijo z metodo *neposredne standardizacije*; čim manjši je delež starejšega prebivalstva v standardni populaciji, tem večja je razlika med grobo in starostno standardizirano stopnjo. V Tabeli 6b je za primerjavo incidenčnih stopenj med slovenskimi statističnimi regijami uporabljen slovenski standard, starostna struktura prebivalcev Slovenije ob popisu leta 2002. Uporabljena standardna populacija je vedno enaka za oba spola, kar v posameznih primerih privede do navidez paradoksalne situacije, da so standardizirane stopnje pri enem spolu (ponavadi pri moških, ki so v povprečju mlajši) večje od grobih stopenj, pri drugem spolu pa manjše. V letošnjem letnem poročilu se je tak primer pojavil pri izračunu starostno standardiziranih stopenj s slovenskim standardom (Tabela 2).

Pri prikazih zemljevidov raka (Slika 6) v štirih časovnih obdobjih smo uporabili metodo *posredne standardizacije*. Z njo smo izračunali standardizirani količnik incidence (SKI), ki je razmerje med opazovanim in pričakovanim številom raka v primeru, da bi bile starostno specifične incidenčne stopnje v posameznih upravnih enotah in v vsakem od 4 obdobj take, kot so bile povprečne starostno specifične stopnje v Sloveniji v vsem opazovanem obdobju (1961–2007). SKI je približek relativni ogroženosti z rakom v posamezni upravni enoti v opazovanem časovnem obdobju. Za grafični prikaz smo izračunane vrednosti SKI razdelili v 9 enako velikih razredov. Upravne enote z majhno ogroženostjo so obarvane v odtenkih modre, tiste s

povprečno, rumeno, tiste z večjo, pa v odtenkih rdeče. Različna obarvanost zemljevidov v 4 obdobjih kaže po eni strani časovni trend ogroženosti v posamezni upravni enoti, po drugi pa razlike v ogroženosti z rakom med upravnimi enotami glede na slovensko povprečje v celotnem obdobju 1961–2007.

Kumulativne incidenčne stopnje in kumulativno tveganje

Kumulativna incidenčna stopnja (KS) je petkratna vsota starostno specifičnih incidenčnih stopenj po petletnih starostnih skupinah do 74. leta starosti, preračunana na 100 prebivalcev. Prikazana je v zadnjem stolpiču Tabele 5. Je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativno incidenčno stopnjo smo uporabili za prikaz časovnega trenda incidence in umrljivosti v spodnjem delu Slike 4. Primerjava z obliko krivulje grobe incidenčne stopnje (zgornji del slike 4) kaže, da večanja incidence raka ne moremo pripisati le staranju prebivalstva v Sloveniji, ampak da k njeni rasti prispevajo še drugi nevarnostni dejavniki.

Kumulativno tveganje (KT) je verjetnost posameznika, da zboli za rakom v izbranem starostnem obdobju, npr. do 74. leta starosti, če ne umre prej zaradi drugih vzrokov. Kumulativno tveganje izražamo v odstotkih. Če je kumulativna incidenčna stopnja manjša kot 10/100, jo lahko uporabimo za približek kumulativnemu tveganju. Pri večjih kumulativnih stopnjah pa kumulativno tveganje izračunamo iz kumulativne stopnje po obrazcu: $KT = 100 (1 - e^{-KS/100})$.

Kumulativno incidenčno stopnjo raka dojk pri ženskah 7,3/100 tako lahko uporabimo za oceno kumulativnega tveganja raka dojk, ki je v tem primeru 7,3-odstotno. To pomeni oceno, da bo 7,3 % deklic, rojenih leta 2007, (ali približno ena od 14) do 74. leta starosti verjetno zbolelo za rakom dojk.

Prevalenca

Prevalenca je število vseh bolnikov z rakom, ki so bili živi na izbrani datum, ne glede na to, kdaj so zboleli. Celotna prevalenca obsega vse bolnike, ne glede na to, kako dolgo pred datumom izračuna so zboleli, medtem ko delna prevalenca šteje samo bolnike, ki so do datuma izračuna živi določeno število let po diagnozi (npr. manj kot 1 leto, 1–4, 5–9, 10 let in več). Pri raku so ta obdobja še zlasti pomembna, saj odsevajo število bolnikov v različnih fazah poteka bolezni, npr. enoletna vključuje bolnike v času prvega zdravljenja, od prvega do petega leta bolnike v obdobju rednih kontrolnih kliničnih pregledov, petletna in zlasti še desetletna pa vključuje bolnike, za katere vsaj pri večini rakavih bolezni menimo, da so ozdravljeni.

Prebivalstvo Slovenije

Podatki o številu prebivalcev in o starostni strukturi so ključnega pomena pri izračunavanju in interpretiranju večine kazalnikov bremena raka. Za Slovenijo je točno število in starostna struktura prebivalcev na voljo za popisna leta že ves čas registracije raka. Nacionalni popis prebivalstva je bil napravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izračunu kazalnikov predpostavili, da je bila med dvema popisnima letoma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja Centralni register prebivalstva, je mogoče dobiti točen podatek o številu in starostni strukturi prebivalcev na katerikoli dan. V letnih poročilih uporabljamo podatek o prebivalcih na datum 30. junij posameznega leta, kot ga dobimo iz Statističnega urada RS. Podatki za leto 2007 o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo in po spolu za posamezne statistične regije so navedeni v spodnjih dveh tabelah.

Starostna skupina	Skupaj	Moški	Ženske
0–4	92.074	47.251	44.823
5–9	90.658	46.806	43.852
10–14	98.320	50.493	47.827
15–19	116.906	60.324	56.582
20–24	135.658	70.525	65.133
25–29	153.990	80.515	73.475
30–34	151.880	79.094	72.786
35–39	145.716	75.053	70.663
40–44	157.574	80.259	77.315
45–49	154.407	78.825	75.582
50–54	158.637	81.760	76.877
55–59	138.072	69.941	68.131
60–64	101.952	49.044	52.908
65–69	97.647	44.974	52.673
70–74	85.848	36.020	49.828
75–79	70.016	25.789	44.227
80+	70.051	18.452	51.599
Vse	2.019.406	995.125	1.024.281

Prebivalci Slovenije po starosti in spolu na dan 30. 6. 2007

Statistična regija	Skupaj	Moški	Ženske
Gorenjska	200.585	98.531	102.054
Goriška	119.945	59.605	60.340
JV Slovenija	140.532	70.186	70.346
Koroška	73.594	36.747	36.847
Notranjsko-Kraška	51.830	25.928	25.902
Obalno-Kraška	107.062	53.298	53.764
Osrednjeslovenska	506.829	247.417	259.412
Podravska	320.863	157.765	163.098
Pomurska	121.964	59.164	62.800
Savinjska	260.121	129.234	130.887
Spodnjeposavska	70.839	35.204	35.635
Zasavska	45.242	22.046	23.196
Slovenija	2.019.406	995.125	1.024.281

Prebivalci Slovenije po statističnih regijah in spolu na dan 30. 6. 2007

Leta 2007 je za rakom na novo zbolelo 11.607 ljudi, 6.083 moških in 5.524 žensk, umrlo pa 5.537 ljudi, 3.146 moških in 2.391 žensk. Konec decembra 2007 je živel 76.459 ljudi, ki so kdaj koli od ustanovitve RRRS zboleli za rakom (*Slika 1*). Ocenjujemo, da bo leta 2010 za rakom zbolelo 12.685 prebivalcev Slovenije, 6.683 moških in 6.011 žensk. Ocene incidence za posamezne lokacije raka, skupaj s povprečnimi petletnimi vrednostmi za zadnje 10-letno obdobje, so prikazane v *Tabeli 1*.

Rak je v raznih življenjskih obdobjih različno pogosta bolezen; skoraj izjema je pri mlajših od 19 let. Manj kot 3 % vseh primerov raka je med 20. in 34. letom starosti, več kot tri četrtine bolnic in bolnikov pa zboli po 50. letu. Medtem ko med 35. in 49. letom zboli za rakom nekaj več žensk kot moških (11,7 % žensk in 7,3 % moških), se med 50. in 74. letom to razmerje obrne; delež zbolelih je spet večji med ženskami po 75. letu starosti, tudi zato, ker je njihova pričakovana življenjska doba daljša (*Slika 2*).

Ker na incidenco raka najbolj vpliva starostna struktura prebivalstva, so za verodostojnejšo primerjavo z drugimi državami z različno starostno strukturo v *Tabeli 2* poleg grobih stopenj izračunane tudi starostno standardizirane. Glede na to, da so v uporabi različni standardi, smo uporabili tri standardne populacije, svetovno, evropsko in slovensko.

Prvih pet po številu novih primerov najpogostejših rakov (kože, debelega črevesa in danke, pljuč, dojke in prostate) dosega 56,5-odstotni delež vseh novih primerov rakave bolezni (*Slika 3*). Pri moških je bil leta 2007 najpogostejši rak prostate (*Slika 3*). Na prvem mestu je zamenjal pljučnega raka, ki je bil najpogostejši rak pri moških vse od leta 1967 do leta 2004. Pri ženskah ostaja rak dojk na prvem mestu z 21-odstotnim deležem, sledijo mu kožni rak, rak debelega črevesa in danke ter pljučni rak (*Slika 3*).

Od leta 1950 se je groba incidenčna stopnja raka v Sloveniji zvečala za 505 % pri moških in za 320 % pri ženskah; v zadnjih 10 letih pa za 35 % pri moških in za 27 % pri ženskah. Groba umrljivostna stopnja se je v zadnjih 10 letih zvečala za 18 % pri moških in za 16 % pri ženskah (*Slika 4*). Več kot polovica zvečanja incidence gre na račun staranja prebivalstva, saj se je kumulativna incidenčna stopnja zvečala od leta 1950 pri moških za 230 %, v zadnjih 10 letih za 10 %, pri ženskah pa od leta 1950 za 139 % in v zadnjih 10 letih za 12 %. Starostno standardizirana, kumulativna umrljivostna stopnja se od leta 1985 pri obeh spolih manjša (*Slika 4*). Manjšanje verjetnosti smrti za rakom ob večanju incidence kaže, da je zdravljenje uspešnejše in da vse več bolnikov ozdravi ali živi z rakom, medtem ko jih je poprej več umrlo.

Časovni trend pogostejših rakov pri moških kaže, da se je incidenčna stopnja pljučnega raka večala vse do začetka devetdesetih let prejšnjega stoletja, ko se je ustalila pri 85/100.000; prav tako je ustaljena incidenčna stopnja raka glave in vratu. Pri ženskah se večja pogostost raka dojk, pljučnega raka in raka materničnega telesa, medtem ko se incidenčna stopnja raka materničnega vratu od leta 2003 počasi manjša. Pri obeh spolih se večja pogostost raka debelega črevesa in danke, malignega melanoma in drugih kožnih rakov, podobno kot drugod v svetu pa je želodčnega raka pri obeh spolih počasi vse manj (*Slika 5*).

Zemljevidi ogroženosti z rakom v štirih časovnih obdobjih pri obeh spolih odsevajo po eni strani časovni trend posameznih rakavih bolezni, po drugi strani pa bodisi ustaljeni ali spreminjajoči se zemljepisni vzorec razširjenosti bolezni (*Slika 6*). Tako je npr. ogroženost z rakom dojk večja v predelih zahodne Slovenije, z želodčnim pa na vzhodu. Pri moških je okolica Kočevja že dolga leta področje z večjo ogroženostjo s pljučnim rakom, v severovzhodnem, vinorodnem predelu Slovenije pa je več raka glave in vratu.

Pri večini bolnikov je diagnoza bolezni potrjena mikroskopsko. Iz *Tabele 3* je razvidno, da je bila leta 2007 pri 94 % od 11.607 na novo registriranih primerov raka diagnoza potrjena mikroskopsko (histološko ali citološko), pri 5,6 % z drugimi preiskavami, le 0,4 % primerov pa je bilo vpisanih

le na osnovi zdravniškega poročila o vzroku smrti. Ta, zadnja odstotna vrednost, ki je že več let podobna, odseva število bolnikov, ki verjetno zaradi starosti ali napredovale bolezni niso bili zdravljeni v bolnišnici. Kakšna je bila morfološka slika malignomov pri 10.913 primerih, pri katerih je bila diagnoza potrjena mikroskopsko, kaže *Tabela 7*. V njej so posebej primeri, ki so potrjeni histološko (92 %), in tisti, ki so bili potrjeni samo citološko (8 %).

V *Tabeli 6a* je število novih primerov vseh in izbranih rakov prikazano po statističnih regijah. Te številke so pomembne za načrtovanje zdravstvenih zmogljivosti, starostno standardizirane vrednosti v *Tabeli 6b* pa kažejo razlike v ogroženosti z rakom v posameznih regijah, saj te niso posledica razlik v starostni strukturi prebivalcev.

Tabela 8 kaže starostno porazdelitev ektranodalnih in nodalnih lokacij ne-Hodgkinovih malignih limfomov. Ker je število ektranodalnih lokacij majhno, so prikazane le absolutne številke.

Tabela 9 prikazuje porazdelitev bolnikov po stadiju, v katerem je bila bolezen odkrita. Uporabljena je poenostavljena opredelitev stadijev, ki upošteva vse preiskovalne metode, vključno operacijo in tudi obdukcijo, če le bolnik ni bil poprej zdravljen.

Za leto 2007 prvič prikazujemo osnovne podatke o zdravljenju bolnikov. Iz *Tabele 10a* je razvidno, kako so bili bolniki zdravljeni, v *Tabelah 10b* in *10c* pa, v katerih zdravstvenih ustanovah so bili bolniki v okviru prvega zdravljenja operirani in/ali zdravljeni s sistemskimi zdravili; z obsevanjem se z redkimi izjemami (tujina) zdravijo samo na Onkološkem inštitutu Ljubljana.

Tabela 11 prikazuje prevalenco vseh in pogostejših rakov na dan 31. 12. 2007. V letošnjem poročilu poleg celotne prikazujemo tudi delno, to je prevalenco bolnikov, zbolelih do enega leta pred referenčnim datumom ter v obdobjih 1–4, 5–9 in 10 let in več.

V *Tabeli 12* so uradni podatki o umrljivosti za rakom v letu 2007. Tabela so pripravili na Inštitutu za varovanje zdravja RS.

Zahvala

Zdravniki, medicinske sestre in administrativno osebje iz slovenskih bolnišnic in drugih zdravstvenih ustanov so RRRS pošiljali prijavnice s podatki o novih bolnikih z rakom in njihovi nadaljnji usodi ter nam pomagali dopolniti prijave z manjkajočimi informacijami.

Vsaj polovico podatkov, obdelanih v tem poročilu, sta prispevali sodelavki Bolnišničnega registra Onkološkega inštituta v Ljubljani Ana Dotzauer in Maruška Ferjančič.

Naše delo bi bilo bistveno težje brez dolgoletnega sodelovanja s Centralnim registrom prebivalstva RS, Inštitutom za varovanje zdravja RS in Statističnim uradom RS.

Vsem imenovanim in tudi drugim, ki so kakorkoli prispevali k temu poročilu, se najlepše zahvaljujemo.

Uredniški odbor

Cancer Registry of the Republic of Slovenia (CRRS) is one of the oldest population based cancer registries in Europe. It was founded at the Institute of Oncology Ljubljana (IO) in 1950 by the late Professor Božena Ravnihar, who headed it till 1975. She was succeeded by Professor Vera Pompe-Kirn, who contributed a lot to the further development of the CRRS as well as its recognition at the national and international level all until her retirement in 2003.

Since 2003, the CRRS together with the Unit of Epidemiology is merged in a single Epidemiology and Cancer Registry service. Besides the CRRS, the new service also comprises the *hospital-based Cancer Registry* of the IO Ljubljana, which contributes a considerable part of information to the CRRS and facilitates a more detailed overview of patients treated at the IO Ljubljana, irrespective of their permanent residence. In the last decade, we have established *national registry in charge of coordinating and monitoring organised cervical cancer screening programme* (ZORA), while an *information system DORA to support organized breast screening program* has been underway since 2007. While the existence of these two new registries contributes to a higher quality and completeness of CRRS's data, the latter contribute to the evaluation of the effectiveness of screening programs.

The data on cancer, that are collected by the CRRS, incidence, survival and prevalence, serve together with mortality data, collected by the Institute of Public Health, as the basis for assessing the cancer burden in the country. They are important for planning and evaluation of all levels of cancer control, primary prevention, diagnosis, treatment and rehabilitation, for planning facilities and funding needed for cancer control (personnel, equipment and hospital capacities) as well as for clinical and epidemiological research in Slovenia and in international multicentre studies and for evaluation of effectiveness of the cancer screening programs.


The Annual Reports of CRRS are one of the regular ways of disseminating information on cancer among professionals and all other groups. As we are limited by the technology of data collection because of a variety of data sources, data collection, their linking and publication is rather time consuming (with us and elsewhere) and usually takes two to three years. As preliminary information on expected incidence in the year when the Annual Report is published (in this report for the year 2010), estimated numbers and rates are presented; they are calculated by a special statistical method.

The first annual reports of the CRRS for the period 1951–1955 were issued during the years 1953–1957. The first data analysis for the year 1950 was published in *Zdravstveni vestnik* in 1951. The data for the period 1957–1971 were appearing in the periodicals *Epidemiological and Vital Statistics Report* and *World Health Statistics Report*, both edited by World Health Organization. From 1965 onwards, the data have been published regularly in special bi-lingual (Slovene-English) annual reports, first entitled *Cancer in Slovenia* (1965–1977), and then *Cancer Incidence in Slovenia* (1978–2006).

Besides Annual Reports, four special publications have been published: Atlas of Cancer Incidence in Slovenia 1978–1987, Cancer Patients' Survival in Slovenia 1963–1990, Cancer Patients' Survival in Slovenia 1983–1997 and Survival of Cancer Patients, diagnosed in 1991–2005 in Slovenia. The list of other relevant publications in last five years is at the end of this report.

Data of the CRRS are included in several international databases and projects. They have been published in all nine volumes of the *Cancer Incidence in Five Continents* issued by International Agency for Research on Cancer. The data are included in the international databases EUROCIM, GLOBOCAN and ACCIS. The survival of Slovenian cancer patients is analysed in the international studies EURO CARE II, EURO CARE III, EURO CARE IV and EUNICE.

The sixtieth anniversary of CRRS presents a challenge for us, to work on a new, more user-friendly way of data presentation. Currently, we are preparing an interactive web portal with the name



SLORA, according to the first letters in Slovenian language: “**SLO**venia and **RAK**/cancer”. It will be available at www.slora.si from this autumn on. It will enable a simple access to data on cancer in Slovenia, registered in CRRS (incidence, prevalence and survival) or Institute of Public health (mortality) and comparison with other countries in the European Union and in the world. It will describe the data and inform users with professional explanations about cancer risk factors, about screening and early detection and thus contribute also to the evaluation of National Cancer Control Program. As a communication bridge between professionals and users, it will contribute to better and objective information about cancer.

Data sources and the list of data collected

Notification of cancer has been compulsory in Slovenia since the foundation of the CRRS and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92 and 65/00). The main sources of data are *notifications of cancer*, gathered from all hospitals and diagnostic centres in Slovenia, exceptionally also from primary health care centres in case the patient has not been referred for further diagnostic investigations and/or treatment.

The data, gathered with notifications are identification data, data on the cancer disease (anatomic cancer site, histological or cytological diagnosis and stage by TNM or other clinical classification) and basic data on treatment. Additional sources of information are death certificates that we get from the Institute of Public health of RS. A lot of time of CRRS's staff is needed for queries about patients, from who we do not have all data or we get their data at death only.

Calculation of patient survival requires the patient's *vital status* (a person may be alive, dead or lost to follow-up). This data is obtained quarterly from the Central Population Registry for all persons registered in the CRRS database as alive. In this year, an on-line connection with the Central Population Registry will be established, through a specially secured web technology, together with the upgrade of CRRS's database. This will enable an on-line connection and up-to-date vital status of all patients registered. In lost persons, the date of last notification or the date of loss obtained from the Central Population Registry, whichever first, is considered as date of loss. From 1985, since the uniform personal ID number has been used in Slovenia, in CRRS the percentage of the lost to follow-up is below 1%, in patients registered in the decade between 1996–2005 being 0.1%.

When analysing the spatial distribution of cancer, the new law on regional division of Slovenia is followed, that in the year 2000 introduced the system of division of Slovenian territory at eleven levels. The exact mapping of patients' permanent address is also possible, as we maintain the regular connection with the Registry of spatial units of the Surveying and Mapping Authority. In this report, in cancer maps, presented in Figures 6–21, the division by administrative units was used. In the Table 6, the data have been presented by 9 health regions till the Annual Report 2002, since then, 12 statistical regions have been chosen to present the data.

Statistical regions of Slovenia



Slovenian administrative units



Preparation of data for computer processing

In CRRS specially trained nurses code the data retrieved from notifications in accordance with the internationally and in CRRS agreed rules.

Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related health Problems (ICD-10); before, the 8th revision was used (ICD-8). When classifying tumours as malignant, the behaviour digit of the morphology code of the third edition of International Classification of Diseases for Oncology has been used since the report for the year 2001. In this edition, some changes were introduced in terms of morphology and behaviour code. According to this classification, chronic myeloproliferative disorders and myelodysplastic syndromes are classified as malignant (currently C96.7 topography code), while ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56).

In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Till then, only carcinoma in situ (code 234.0) was registered. Thus, the comparison with the data for the period 1961–1992 is not possible. According to ICD-10, all cervical intraepithelial neoplasm (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast and since 1995, all reported intraepithelial carcinomas of the bladder and all malignant melanomas Clark I have been registered.

As data on stage of disease by TNM Classification System in cancer notification forms are often lacking, a simplified definition of stages at diagnosis is used, classifying them in localised, regional and remote stage of disease. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. In solid tumors, the simplified stage definition generally follows the TNM classification. Localised stage includes all cancers where the tumour has been

classified as T1 and T2 (except in breast, malignant melanoma and thyroid cancer, where T3 is also included, and uterine cervix, uterine corpus and sarcomas, where T1 only is included), where neither regional node involvement nor distant metastases are found (N0, M0). The regional stage includes tumours classified as T3 and T4 (exceptions already mentioned) and/or regional node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). The disease with metastases in distant lymph nodes or organs is classified as the remote stage (M1). Malignant lymphomas are classified according to Ann-Arbor System.

Data quality and completeness of registration

The quality of information can be assessed by the following parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters in the three observation periods are presented in *Table 3*.

The completeness of registration shows the proportion of all new cancer cases in the region covered by the registry, which are included in the registry's data base. It can be measured directly only by means of special surveys for the evaluation of completeness, e.g. by reviewing patient record in the hospitals or outpatient clinics in a particular region. In Slovenia, no such surveys have been carried out so far. However, a considerable contribution towards the completeness of registration is made by our colleagues – clinicians, who send us the data on their groups of patients in order to get information about their survival and among them we often find cases that have not been entered in the CRRS database yet.

The registration is more complete where the registries have access to death certificates, and can send out additional inquiries about disease for the deceased that have not been entered into the database yet. This improves the completeness of registration of cancers with poor prognosis, but not also of less fatal ones. It is presumed that in Slovenia – as well in other European population based cancer registries – registration is less complete in non-melanoma skin cancer and in malignomas that are treated on the out-patient basis only.

Incidence and mortality

Incidence and mortality mean absolute number of all newly diagnosed cases of any disease in a defined population or number of deceased from this disease in one calendar year. New primary cancers of the same histology in paired organs, e. g. on the left and right breast, are not comprised in the incidence figures, neither are any new cancers of the same histology appearing in the same organ, e.g. multiple lesions of the colon. Incidence in CRRS includes all cancer cases with permanent residence in Slovenia, regardless of the country, where they have been treated.

The method by Dyba and Hakulinen was used for estimation of incidence in 2010 (presented in Table 1). This method is suitable for predictions in shorter time period, taking into account the period of diagnosis and the age structure of the population. For long-term predictions the cohort effect should be included also.

Crude and age-specific rates

Crude incidence rate is the number of new cases per 100,000 population. More precisely it is defined as number of new cases in a specified time interval, usually one calendar year, divided by the number of persons at risk of disease at the beginning of time interval; it is expressed per 100,000 person-years. The *age-specific rate* expresses this relative number in an individual five-year age group.

Age-standardised rates

When analysing the incidence rate within longer time period (if the age structure of population changes) or comparing the incidence between populations with different age structure, age-standardisation is needed to adjust the rate for the effect of age. The age-standardised rate is a theoretical incidence rate assuming that the age structure in the observed population is the same as in the standard population. In Table 2, besides crude cancer incidence rates, age-standardised rates by direct method are presented, using World, European and Slovenian standard population; the smaller is the proportion of older population in the standard, the bigger is the difference between crude and standardized rate. In Table 6b the standard is the age structure of Slovenian 2002 census population. The standard population is always the same for both sexes that may in some situations result in standardized rate being bigger than crude in one sex, usually in males that are on average younger and smaller in females. This is the case in rates standardised to Slovenian standard population in Table 2.

Indirect method of standardisation was used to present cancer maps in four time periods (Figures 6–21). In this case, the standardised incidence ratio was calculated, which is the ratio of observed number of cancer cases in every time period and the number that would be expected if a particular administrative unit in every of the four time periods had the same age-specific incidence rates as that in the whole Slovenia in the entire observation period (1961–2007). SIR can be interpreted as the relative risk of cancer in particular administrative unit in a given time period. The values of SIR were divided in 9 equal class intervals. The administrative units with low risk have blue cast, those with average yellow, and those with higher risk the red one. Different colouring of maps in 4 time periods show a time trend in cancer risk on one hand, and on the other the differences in risk between administrative units compared to Slovenian average in the entire time period 1961–2007.

Cumulative incidence rate and cumulative risk

The cumulative incidence rate is five times the sum of the age-specific incidence rates over five-year age groups up to the age of 74 years, calculated per 100 population. It is presented in the last column of Table 5. The cumulative rate can be interpreted as a form of direct age-standardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. The cumulative incidence rate was also used to present the incidence time trend in the lower part of the Figure 4. The comparison to the curves of crude incidence per 100,000 population (upper part of Figure 4) indicates that the increasing cancer incidence rate in both sexes cannot be attributed only to the aging of Slovenian population, but also to additional risk factors.

The cumulative risk (CR) is the risk an individual would have of developing the disease in question during a certain age period, e.g. up to the age of 74, if no other causes of death were in operation. The cumulative risk is expressed per 100 (per cent). If cumulative rate is lower than 10/100, its value is practically equal to that of the cumulative risk. When cumulative rate is greater than 10/100, it should be calculated from cumulative risk according to the following formula: $CR = 100 (1 - e^{-KS/100})$.

Cumulative incidence rate of breast cancer in females can be used to estimate cumulative risk of breast cancer that is in this case 7.3%. This means that 7.3% of women born in 2007 (approximately each 14th woman) are expected to develop breast cancer by their age of 75 in the absence of any other cause of death.

Prevalence

Prevalence is the number of all cancer patients that are alive on a given date, regardless of time, when they were diagnosed with cancer. Lifetime cancer prevalence is defined as all persons living and ever diagnosed with cancer, while partial prevalence counts only those patients, diagnosed with cancer within a defined period of time (e. g. less than 1 year, 1–4 years, 5–9 years, 10 years or more). In cancer these periods are important, as they reflect the number of cancer cases in different course of disease, e. g. the one-year prevalence includes patients during their primary treatment, 1–4 years prevalence those requiring regular follow-up, while 5–9 and especially 10 and more years prevalence includes predominantly those considered cured from cancer.

Population of Slovenia

Population data, especially the number and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration. Census has been performed nearly every 10 years, but till 1985 no data were available for intermediate years, so for this time period it was assumed that the population structure between two censuses was the same. Since the middle of the eighties, the population data are available for any particular date from the Central Population Registry. In CRRS Annual Reports, the number of population on June 30 of a particular year is used, and is obtained from Statistical Office of Republic of Slovenia. In the following tables, numbers of inhabitants of Slovenia by age and by sex and in statistical regions are presented.

Age	Total	Males	Females
0–4	92.074	47.251	44.823
5–9	90.658	46.806	43.852
10–14	98.320	50.493	47.827
15–19	116.906	60.324	56.582
20–24	135.658	70.525	65.133
25–29	153.990	80.515	73.475
30–34	151.880	79.094	72.786
35–39	145.716	75.053	70.663
40–44	157.574	80.259	77.315
45–49	154.407	78.825	75.582
50–54	158.637	81.760	76.877
55–59	138.072	69.941	68.131
60–64	101.952	49.044	52.908
65–69	97.647	44.974	52.673
70–74	85.848	36.020	49.828
75–79	70.016	25.789	44.227
80+	70.051	18.452	51.599
All ages	2.019.406	995.125	1.024.281

Population of Slovenia by age and by sex, June 30, 2007.

Statistical region	Total	Males	Females
Gorenjska	200.585	98.531	102.054
Goriška	119.945	59.605	60.340
JV Slovenija	140.532	70.186	70.346
Koroška	73.594	36.747	36.847
Notranjsko-Kraška	51.830	25.928	25.902
Obalno-Kraška	107.062	53.298	53.764
Osrednjeslovenska	506.829	247.417	259.412
Podravska	320.863	157.765	163.098
Pomurska	121.964	59.164	62.800
Savinjska	260.121	129.234	130.887
Spodnjeposavska	70.839	35.204	35.635
Zasavska	45.242	22.046	23.196
Slovenia	2.019.406	995.125	1.024.281

Population by Slovenian statistical regions and by sex, June 30, 2007.

In 2007, 11,607 patients were diagnosed with cancer, 6,083 males and 5,524 females, and 5,537 patients died from cancer, 3,146 males and 2,391 females. At the end of December 2007, there were 76,459 people alive who were diagnosed with cancer at any time since the foundation of the CRRS (*Figure 1*). It is estimated, that in 2010, there will be 12,685 Slovenian diagnosed with cancer, 6,683 males and 6,011 females. The estimated incidence of different cancer sites together with 5-year average values in the last 10-year period are presented in *Table 1*.

Cancer incidence varies during lifetime; cancer is more an exception till the age of 19. Less than 3% of all cancer is in the age group 20–34, and more than three quarters of all cancer cases occur in patients older than 50 years. The proportion of new cancer patients is a bit higher among females in the age group 35–49 (11.7% of females and 7.3% of males), while this ratio is reversed between the age of 50–74 years; after the age of 75, there is again a higher proportion of cancer among females, also because of their longer life expectancy (*Figure 2*).

As cancer incidence depends on the age structure of a population, in *Table 2* besides crude also age-standardised rates are presented. For better comparison with other countries and as different standard populations are used, three standard populations, World, European and Slovenian were applied.

First five most frequent cancers (skin, colorectal, lung, breast and prostate) comprise 56.6% of all new cancer cases (*Figure 3*). In males, the most frequent cancer site in 2007 was prostate (*Figure 3*). It replaced lung cancer, which was the most frequent in males from 1967 till 2004. In females, breast is in the first place with 21% of all new cases, followed by skin, colorectal and lung (*Figure 3*).

Since 1950, the crude cancer incidence rate in Slovenia increased for 505% in males and for 320% in females; in the last 10 years for 35% in males and 27% in females. The crude mortality rate in the last 10 years increased for 18% in males and 16% in females (*Figure 4*). More than half of the crude incidence rate increase is a consequence of ageing of population, as cumulative incidence rate increased in males since 1950 for 230% in males, for 10% in the last 10 years, and in females for 139% and for 12% in the last 10 years. Age-standardised, cumulative mortality rate is decreasing since 1985 in both sexes (*Figure 4*). The decrease in mortality along with increase in incidence indicates better results of treatment and better survival or cure from cancer.

The time trend of lung cancer incidence in males was increasing till the nineties of the last century, when it stabilised around 85/100,000; similarly, head and neck cancer incidence rate is constant. In females, the incidence of breast, lung and uterine corpus cancer is still increasing, while cervical cancer incidence rate is decreasing since 2003. In both sexes, the incidence of colorectal, skin melanoma and other skin cancer is increasing, while incidence of stomach cancer is decreasing as elsewhere.

Cancer maps in four different time periods in both sexes reflect on one hand the time trend in particular cancer and on the other, similar or changing geographic pattern of risk in different parts of Slovenia (*Figure 6–21*). Thus breast cancer risk is higher in western parts of Slovenia, while stomach in eastern. In males the surrounding of Kočevje is known as high risk region for a longer time period, in wine-growing regions of northeaster part of Slovenia, the risk of head and neck cancer is higher.

In the majority of new cases, the diagnosis was confirmed microscopically. *Table 3* shows that in 2007, in 94% from 11,607 newly diagnosed cancer cases, the diagnosis was confirmed by histology or by cytology, in 5.6% with other investigations and only 0.4% of cases were registered from death certificate only. This latter percentage has been similar for several years and represents those patients that, due to advanced age or disease have not been treated in

the hospital. The morphology of tumours in 10,913 cases, diagnosed microscopically, is presented in *Table 7*. In this table, cases confirmed by histology (92%) and by cytology only (8%) are presented separately.

In *Table 6a*, the number of new cases of all and selected cancer sites by different statistical regions is presented. While these data are important for planning health care facilities, the age-standardised rates in *Table 6b* indicate the differences in the risk of cancer, as these differences are not due to different age structure of population in these regions.

Age distribution of extranodal and nodal sites of non-Hodgkin malignant lymphomas is presented in *Table 8*. Owing to a small number of extranodal sites, only the absolute numbers are given.

In *Table 9*, the distribution of cancer patients by stage at diagnosis is presented. A simplified definition of stages at diagnosis is used, that takes into account all investigation methods, including surgery or autopsy in case the patient has not been treated before death.

In this report, data on treatment of cancer patients are presented for the first time. *Table 10a* presents the mode of treatment, while *Tables 10b and 10c* show the hospital where patients had surgery and/or systemic treatment as primary treatment; radiotherapy is performed at institute of Oncology Ljubljana only (with few exceptions, that have been irradiated abroad).

Data on prevalence of all and most frequent cancers on December 31, 2007 are presented in *Table 11*. In this report, besides lifetime also partial prevalence is presented, including cases diagnosed in the year before the reference date and in the period 1–4, 5–9 and 10 years or more before reference date.

Official data on cancer mortality in 2005 are given in *Table 12*. The table has been prepared at the Institute of Public Health of the Republic of Slovenia.

Acknowledgement

Physicians, nurses, and administrative staff from Slovenian hospitals and other health institutions have provided the data on new cancer patients and their medical history as well as helped us in obtaining additional information when needed.

Our co-workers at the Hospital Registry of the Institute of Oncology Ljubljana, Ana Dotzauer and Maruška Ferjančič, have contributed at least a half of the information presented in this report.

The long-term collaboration with the Population Registry of the Republic of Slovenia, the Institute of Public Health of the Republic of Slovenia and the Statistical Office of the Republic of Slovenia is indispensable for our work.


We thank all of them as well as to all others who have contributed and enabled us to present the results of our work in this report.

Editors

- Ravnihar B, Gruden I. Statističen pregled in kratka analiza prijavljenih rakovnih obolenj iz področja LRS za leto 1950. *Zdrav Vestn* 1951; 20: 264–77.
- Epidemiological and vital statistics report. Geneva: World Health Organization, 1961–1966.
- World health statistics report. Geneva: World Health Organization, 1970–1974.
- Rak v Sloveniji (1965–77). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1967–1980.
- Incidenca raka v Sloveniji (1978–2001). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1981–2004.
- Doll R, Payne P, Waterhouse J, eds. Cancer incidence in five continents. Vol 1. Berlin: Springer, 1966.
- Doll R, Muir C, Waterhouse J, eds. Cancer incidence in five continents. Vol 2. Lyon: International Agency for Research on Cancer, 1970.
- Waterhouse J, Muir C, Correa C, Powell J, eds. Cancer incidence in five continents. Vol 3. Lyon: International Agency for Research on Cancer, 1976 (IARC Sci Publ 15).
- Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. Cancer incidence in five continents. Vol 4. Lyon: International Agency for Research on Cancer, 1982 (IARC Sci Publ 42).
- Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Cancer incidence in five continents. Vol 5. Lyon: International Agency for Research on Cancer, 1987 (IARC Sci Publ 88).
- Parkin DM, Muir C, Whelan S, Gao Y, Ferlay J, Powell J, eds. Cancer incidence in five continents Lyon. Vol 6. International Agency for Research on Cancer, 1992 (IARC Sci Publ 120).
- Parkin DM, Whelan S, Ferlay J, Raymond L, Young J, eds. Cancer incidence in five continents. Vol 7. Lyon: International Agency for Research on Cancer, 1997 (IARC Sci Publ 143).
- Parkin DM, Whelan S, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five continents. Vol 8. Lyon: International Agency for Research on Cancer, 2002 (IARC Sci Publ 155).
- Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, eds. Cancer incidence in five continents. Vol 9. Lyon: International Agency for Research on Cancer, 2002 (IARC Sci Publ 160).
- European Network of Cancer Registries. EUROCIM version 4.0. European incidence database V2.4, ICD-10 dictionary (2003), Lyon 2001.
- Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. Lyon: IARC Press, 2004.
- Steliarova-Foucher E, Berrino F, Coebergh JW et al. ACCISpss 1.01 software for analysis and presentation of data on incidence and survival of children and adolescents in Europe. Lyon: ENCR, 2002.
- Berrino F, Capocaccia R, Esteve J et al, eds. Survival of cancer patients in Europe: the EUROCCARE-2 study. Lyon: International Agency for Research on Cancer, 1999.
- Berrino F, Capocaccia R, Gatta G et al, eds. Survival of cancer patients in Europe: the EUROCCARE-3 study. *Ann Oncol* 2003; 14 (Suppl 5).
- Berrino F, DeAngelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: Results of the EUROCCARE-4 study. *Lancet Oncol* 2007; 8: 773–83.
- Pompe-Kirn V, Primic Žakelj M, Ferligoj A, Škrk J. Zemljevidi incidence raka v Sloveniji 1978–1987 (Atlas of cancer incidence in Slovenia 1978–1987). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1992.
- Pompe-Kirn V, Zakotnik B, Benulič T, Volk N, Škrk J. Preživetje bolnikov z rakom v Sloveniji 1963–1990 (Cancer patients' survival in Slovenia 1963–1990). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1995.
- Pompe-Kirn V, Zakotnik B, Zadnik V. Preživetje bolnikov z rakom v Sloveniji 1983–1997 (Cancer patients' survival in Slovenia 1983–1997). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003.
- Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia). Ljubljana: Onkološki inštitut, 2009.
- Uredba o standardni klasifikaciji teritorialnih enot – SKTE. Ur. l. RS št. 28/2000.
- Savezni zavod za zdravstveno zaščito. Mednarodna klasifikacija bolezni, povreda i uzroka smrti. 8. revizija. Novi Sad: Savezni zavod za zdravstveno zaščito, 1970.
- Inštitut za varovanje zdravja RS. Mednarodna klasifikacija bolezni in sorodnih zdravstvenih problemov za statistične namene. 10. revizija (International statistical classification of diseases and related health problems). Ljubljana: Inštitut za varovanje zdravja, 1995.
- World Health Organisation. International classification of diseases for Oncology. Geneva: World Health Organisation, 2000.
- Jensen OM, Parkin M et al, eds. Cancer registration: principles and methods. Lyon: International Agency for Research on Cancer, 1991. (IARC Sci Publ 95).
- Dos Santos Silva I. Cancer epidemiology: principles and methods. Lyon: International Agency for Research on Cancer, 1999.
- Moller B, Fekjaer H, Hakulinen T et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. *Stat Med* 2003; 15: 2751–66.
- Statistični letopis republike Slovenije 2007. Ljubljana: Statistični urad Republike Slovenije, 2008.


Slika 1: Breme raka, Slovenija 2007.

Figure 1: Cancer burden, Slovenia 2007.




Slika 2: Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2007.

Figure 2: Percentage distribution of all cancer sites by age groups and by sex, Slovenia 2007.




Slika 3: Najpogostejše lokacije raka po spolu in pri obeh spolih skupaj, Slovenija 2007.
Figure 3: The leading cancer sites by sex and in both sexes together, Slovenia 2007.


MOŠKI - MALES



ŽENSKE - FEMALES



MOŠKI IN ŽENSKE - MALES AND FEMALES





* Pojasnilo – Explanation

Debelo črevo in danka – Colorectum: C18–C20

Glava in vrat – Head and neck: C00–C14, C30–C32



NHL: Ne-Hodgkinovi limfomi – NHL: Non-Hodgkin's lymphoma: C82–C85

Slika 4: Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu, Slovenija 1950–2007.
 Figure 4: Crude and cumulative annual incidence and mortality rates of all cancer sites by sex, Slovenia 1950–2007.



Slika 5: Groba letna incidenčna stopnja izbranih rakov po spolu, Slovenija 1950–2007.

Figure 5: Crude annual incidence rate of selected primary cancer sites by sex, Slovenia 1950–2007.




Slika 6: Zemljevidi nemelanomskega kožnega raka pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.

Figure 6: Maps of non-melanoma skin cancer in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.


Koža, brez melanoma – moški
Skin, but melanoma – males

MKB 10/ICD 10: C44



Slika 7: Zemljevidi nemelanomskega kožnega raka pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.

Figure 7: Maps of non-melanoma skin cancer in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.




Slika 8: Zemljevidi raka debelega črevesa in danke pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.

Figure 8: Maps of colorectal cancer in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.


Debelo črevo in danka – moški
Colon and rectum – males

MKB 10/ICD 10: C18–C20



Slika 9: Zemljevidi raka debelega črevesa in danke pri ženskah po upravnih enotah ; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.

Figure 9: Maps of colorectal cancer in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.




Slika 10: Zemljevidi pljučnega raka pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.

Figure 10: Maps of lung cancer in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.


Pljuča – moški
Lung – males

MKB 10/ICD 10: C33–C34



Slika 11: Zemljevidi pljučnega raka pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.


Figure 11: Maps of lung cancer in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.



Slika 12: Zemljevidi raka prostate pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.


Figure 12: Maps of prostate cancer in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.

Prostata – moški
 Prostate – males
 MKB 10/ICD 10: C61



Slika 13: Zemljevidi raka dojke pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.


Figure 13: Maps of breast cancer in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.



Slika 14: Zemljevidi želodčnega raka pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.


Figure 14: Maps of stomach cancer in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.

Želodec – moški
Stomach – males
MKB 10/ICD 10: C16



Slika 15: Zemljevidi želodčnega raka pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.

Figure 15: Maps of stomach cancer in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.




Slika 16: Zemljevidi kožnega melanoma pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.

Figure 16: Maps of skin melanoma in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.


Koža, melanom – moški
Skin, melanoma – males

MKB 10/ICD 10: C43



Slika 17: Zemljevidi kožnega melanoma pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.


Figure 17: Maps of skin melanoma in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.



Slika 18: Zemljevidi raka glave in vratu pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.


Figure 18: Maps of head and neck cancer in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.

Glava in vrat – moški
 Head and neck – males
 MKB 10/ICD 10: C00–C14, C30–C32



Slika 19: Zemljevidi raka sečnega mehurja pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.

Figure 19: Maps of bladder cancer in males by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.




Slika 20: Zemljevidi raka materničnega telesa pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.

Figure 20: Maps of uterine corpus cancer in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.

Maternično telo – ženske
Corpus uteri – females

MKB 10/ICD 10: C54



Slika 21: Zemljevidi raka materničnega vratu pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija 1961–2007.

Figure 21: Maps of uterine cervix cancer in females by administrative units; standardised incidence ratio in 4 time periods, Slovenia 1961–2007.




Tabela 1: Opazovana in ocenjena incidenca raka, Slovenija 1998–2007 in 2010.

Table 1: Observed and estimated cancer incidence, Slovenia 1998–2007 and 2010.

Šifra MKB	Primarna lokacija	Spol	Povprečne letne opazovane vrednosti 1998–2002		Povprečne letne opazovane vrednosti 2003–2007		Ocena za 2010			
			Število	Incidenčna stopnja na 100.000	Število	Incidenčna stopnja na 100.000	Število (95 % napovedni interval)		Incidenčna stopnja na 100.000 (95 % napovedni interval)	
							Estimation for 2010		Incidence rate per 100,000 (95% prediction interval)	
ICD code	Primary site	Sex	Average annual observed values 1998–2002		Average annual observed values 2003–2007		Estimation for 2010			
			Number	Incidence rate per 100,000	Number	Incidence rate per 100,000	Number (95% prediction interval)		Incidence rate per 100,000 (95% prediction interval)	
C00–C96	Vse lokacije All sites	Skupaj/Total	9687	467,3	11010	549,3	12685	12390–12981	621	607–636
		Moški/Males	4765	492,8	5707	580,5	6683	6466–6900	661	639–682
		Ženske/Females	4522	443,1	5303	519,2	6011	5508–6214	583	534–603
C00–C14	Usta in žrelo Mouth and pharynx	M	263	27,3	253	25,7	252	201–305	25	20–30
		Ž	55	5,4	64	6,5	74	52–97	7	5–9
C15	Požiralnik Oesophagus	M	74	7,7	76	7,7	80	56–105	8	6–10
C16	Želodec Stomach	M	293	30,3	290	29,5	277	143–410	27	14–41
		Ž	188	18,5	180	17,7	166	73–266	16	7–26
C18	Debelo črevo Colon	M	331	34,3	389	39,5	455	398–511	45	39–51
		Ž	276	27,0	327	32,0	373	322–424	36	31–41
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	285	29,5	338	34,4	389	337–442	38	33–44
		Ž	207	20,3	236	23,1	262	219–305	25	21–30
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	83	8,6	103	10,5	134	104–164	13	10–16
		Ž	33	3,3	47	4,6	63	42–83	6	4–8
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	49	5,0	56	5,6	65	43–87	6	4–9
		Ž	83	8,1	89	8,7	105	77–134	10	7–13
C25	Trebušna slinavka Pancreas	M	112	11,6	137	13,9	167	135–203	17	13–20
		Ž	119	11,7	142	13,9	165	131–198	16	13–19
C32	Grlo Larynx	M	104	10,7	96	9,7	94	68–121	9	7–12
		Ž	11	1,1	11	1,0	13	3–23	1	0–2
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	810	83,8	903	91,8	946	862–1029	93	85–102
		Ž	239	23,4	305	29,9	383	333–433	37	32–42
C43	Maligni melanom kože Malignant melanoma of skin	M	120	12,4	174	17,7	223	185–261	22	18–26
		Ž	138	13,5	194	19,0	252	213–292	24	21–28
C44	Druge maligne neoplazme kože Skin, other malignomas	M	574	59,3	803	81,7	1042	958–1126	103	95–111
		Ž	634	62,1	888	87,0	1108	1018–1198	108	99–116
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	26	2,7	27	2,8	33	17–49	3	2–5
		Ž	27	2,6	38	3,7	46	0–106	4	0–10
C50	Dojka Breast	M	8	0,9	8	0,8	8	0–18	1	0–2
		Ž	990	97,1	1113	108,9	1218	1127–1310	118	109–127
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–
		Ž	202	19,8	181	17,7	156	124–188	15	12–18
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–
		Ž	281	27,5	295	28,9	318	271–365	31	26–35
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–
		Ž	180	17,6	179	17,5	179	143–214	17	14–21
C61	Prostata Prostate	M	614	63,5	865	88,0	1184	1096–1272	117	108–126
		Ž	–	–	–	–	–	–	–	–
C62	Modo Testis	M	83	8,6	98	9,9	108	80–135	11	8–13
		Ž	–	–	–	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	144	14,9	178	18,1	216	178–254	21	18–25
		Ž	82	8,0	102	10,0	113	85–140	11	8–14
C67	Sečni mehur Bladder	M	163	16,8	197	20,0	220	180–260	22	18–26
		Ž	55	5,4	70	6,8	93	33–153	9	3–15
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	70	7,1	76	7,7	89	64–114	9	6–11
		Ž	54	5,4	63	6,2	70	48–92	7	5–9
C73	Ščitnica Thyroid gland	M	24	2,4	28	2,8	38	4–72	4	0–7
		Ž	69	6,7	105	10,3	130	102–158	13	10–15
C81	Hodgkinova bolezen Hodgkin's disease	M	19	2,0	29	2,9	42	24–59	4	2–6
		Ž	23	2,2	19	1,9	22	8–36	2	1–3
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	110	11,3	113	11,5	125	95–156	12	9–15
		Ž	112	11,0	137	13,4	152	119–184	15	12–18
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	36	3,7	53	5,4	67	46–88	7	5–9
		Ž	47	4,6	55	5,4	60	40–81	6	4–8
C91–C95	Levkemije Leukaemias	M	107	11,1	115	11,7	128	98–158	13	10–16
		Ž	89	8,7	91	8,9	98	72–125	10	7–12

Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2007.

Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardised incidence cancer rates, Slovenia 2007.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število Number	Groba incidenčna stopnja na 100.000 Crude incidence rate per 100,000	SSS* – SVETOVNI STANDARD ASR** – WORLD STANDARD	SSS* – EVROPSKI STANDARD ASR** – EUROPEAN STANDARD	SSS* – SLOVENSKI STANDARD ASR** – SLOVENIAN STANDARD
C00–C96	Vse lokacije All sites	Skupaj/Total	11607	574,77	316,19	448,55	529,54
		Moški/Males	6083	611,28	374,35	545,55	658,03
		Ženske/Females	5524	539,31	277,82	386,19	448,14
C00–C14	Usta in žrelo Mouth and pharynx	M	256	25,73	16,41	22,70	25,64
		Ž	64	6,25	3,55	4,92	5,45
C15	Požiralnik Oesophagus	M	83	8,34	5,05	7,50	8,76
C16	Želodec Stomach	M	280	28,14	16,74	25,05	30,77
		Ž	181	17,67	7,69	11,37	13,68
C18	Debelo črevo Colon	M	431	43,31	25,59	38,49	47,67
		Ž	353	34,46	14,58	21,89	26,75
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	349	35,07	21,12	31,32	38,15
		Ž	259	25,29	11,68	17,11	20,30
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	128	12,86	7,87	11,50	13,82
		Ž	49	4,78	2,36	3,31	3,78
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	55	5,53	3,15	4,98	6,35
		Ž	99	9,67	3,48	5,49	6,97
C25	Trebušna slinavka Pancreas	M	154	15,48	9,18	13,57	16,34
		Ž	146	14,25	6,06	9,13	11,04
C32	Grlo Larynx	M	111	11,15	6,79	9,72	10,98
		Ž	10	0,98	0,63	0,84	0,92
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	882	88,63	53,90	79,08	93,96
		Ž	341	33,29	16,39	23,70	27,44
C43	Maligni melanom kože Malignant melanoma of skin	M	201	20,20	13,27	17,88	20,77
		Ž	236	23,04	15,27	19,27	21,57
C44	Druge maligne neoplazme kože Skin, other malignomas	M	873	87,73	51,21	78,52	97,53
		Ž	935	91,28	39,28	58,27	70,56
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	26	2,61	2,26	2,56	2,78
		Ž	40	3,91	2,52	3,21	3,51
C50	Dojka Breast	M	6	0,60	0,34	0,51	0,65
		Ž	1147	111,98	63,86	87,07	98,51
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–
		Ž	153	14,94	10,45	13,18	14,40
C54	Maternično telo Corpus uteri	M	–	–	–	–	–
		Ž	296	28,90	15,38	21,76	24,56
C56	Jajčnik Ovary	M	–	–	–	–	–
		Ž	174	16,99	9,72	13,20	15,07
C61	Prostata Prostate	M	1032	103,71	61,60	92,33	114,23
		Ž	–	–	–	–	–
C62	Modo Testis	M	89	8,94	7,80	8,11	8,69
		Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	197	19,80	12,60	17,62	20,24
		Ž	103	10,06	5,27	7,22	8,45
C67	Sečni mehur Bladder	M	202	20,30	11,75	18,03	22,69
		Ž	76	7,42	3,12	4,75	5,78
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	81	8,14	6,21	7,53	8,22
		Ž	64	6,25	4,46	5,16	5,64
C73	Ščitnica Thyroid gland	M	29	2,91	1,96	2,55	2,86
		Ž	105	10,25	7,53	9,06	9,84
C81	Hodgkinova bolezen Hodgkin's disease	M	31	3,12	2,59	2,87	3,23
		Ž	17	1,66	1,72	1,70	1,78
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	118	11,86	7,58	10,66	12,74
		Ž	130	12,69	6,40	8,90	10,34
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	59	5,93	3,65	5,34	6,46
		Ž	52	5,08	2,40	3,44	4,06
C91–C95	Levkemije Leukaemias	M	127	12,76	8,46	11,73	13,94
		Ž	99	9,67	6,76	7,56	7,89

*SSS – starostno standardizirana incidenčna stopnja na 100.000

**ASR – age-standardised incidence rate per 100,000

Tabela 3: Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2007.

Table 3: Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2007.

Šifra MKB*	Primarna lokacija	Spol	Število novih primerov	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%**	Število	%**	Število	%**
				ICD No.*	Primary site	Sex	Number of new cases	Microscopically confirmed cases	Confirmed by other investigations
			Number	%**	Number	%**	Number	%**	
C00–C96	Vse lokacije All sites	M+Ž	11607	10913	94,0	650	5,6	44	0,4
		M	6083	5721	94,0	343	5,6	19	0,3
		Ž	5524	5192	94,0	307	5,6	25	0,5
C00	Ustnica Lip	M	17	16	94,1	1	5,9	0	0
		Ž	9	8	–	0	–	1	–
C01	Baza jezika Base of tongue	M	13	13	–	0	–	0	–
		Ž	3	3	–	0	–	0	–
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	30	30	100	0	0	0	0
		Ž	1	1	–	0	–	0	–
C03	Dlesen Gum	M	7	7	–	0	–	0	–
		Ž	3	3	–	0	–	0	–
C04	Ustno dno Floor of mouth	M	29	29	100	0	0	0	0
		Ž	12	12	–	0	–	0	–
C05	Nebo Palate	M	10	10	–	0	–	0	–
		Ž	6	6	–	0	–	0	–
C06	Usta, drugi deli Mouth, other & unspecified parts	M	8	8	–	0	–	0	–
		Ž	5	5	–	0	–	0	–
C07	Parotidna žleza Parotid gland	M	6	6	–	0	–	0	–
		Ž	4	3	–	1	–	0	–
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	1	1	–	0	–	0	–
		Ž	1	1	–	0	–	0	–
C09	Tonzila Tonsil	M	30	30	100	0	0	0	0
		Ž	9	9	–	0	–	0	–
C10	Orofarinks Oropharynx	M	39	39	100	0	0	0	0
		Ž	5	4	–	0	–	1	–
C11	Nazofarinks Nasopharynx	M	8	8	–	0	–	0	–
		Ž	3	3	–	0	–	0	–
C12	Piriformni sinus Pyramiform sinus	M	31	31	100	0	0	0	0
		Ž	3	3	–	0	–	0	–
C13	Hipofarinks Hypopharynx	M	26	24	92,3	2	7,7	0	0
		Ž	0	0	–	0	–	0	–
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	1	0	–	0	–	1	–
		Ž	0	0	–	0	–	0	–
C15	Požiralnik Oesophagus	M	83	76	91,6	7	8,4	0	0
		Ž	14	13	–	1	–	0	–
C16	Želodec Stomach	M	280	269	96,1	10	3,6	1	0,4
		Ž	181	175	96,7	3	1,7	3	1,7
C17	Tanko črevo Small intestine	M	14	14	–	0	–	0	–
		Ž	9	9	–	0	–	0	–
C18	Debelo črevo Colon	M	431	422	97,9	9	2,1	0	0
		Ž	353	338	95,8	12	3,4	3	0,8
C19	Rektosigmoidna zveza Rectosigmoid junction	M	79	79	100	0	0	0	0
		Ž	66	65	98,5	1	1,5	0	0
C20	Rektum Rectum	M	270	267	98,9	3	1,1	0	0
		Ž	193	190	98,4	3	1,6	0	0
C21	Anus in analni kanal Anus and anal canal	M	11	11	–	0	–	0	–
		Ž	14	14	–	0	–	0	–
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	128	75	58,6	52	40,6	1	0,8
		Ž	49	31	63,6	17	34,7	1	2,0
C23	Žolčnik Gallbladder	M	16	9	56,3	7	43,8	0	0
		Ž	45	27	60,0	17	37,8	1	2,2
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	39	26	66,7	13	33,3	0	0
		Ž	54	23	42,6	31	57,4	0	0

Nadaljevanje →
Continued →

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB*	Primarna lokacija	Spol	Število novih primerov	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%**	Število	%**	Število	%**
				ICD No.*	Primary site	Sex	Number of new cases	Microscopically confirmed cases	Confirmed by other investigations
			Number	%**	Number	%**	Number	%**	
C25	Trebušna slinavka Pancreas	M	154	100	64,9	53	34,4	1	0,6
		Ž	146	74	50,7	68	46,6	4	2,7
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	0	0	–	0	–	0	–
		Ž	3	2	–	1	–	0	–
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	9	9	–	0	–	0	–
		Ž	4	4	–	0	–	0	–
C31	Obnosni sinusi Accessory sinuses	M	9	9	–	0	–	0	–
		Ž	2	2	–	0	–	0	–
C32	Grlo Larynx	M	111	111	100	0	0	0	0
		Ž	10	10	–	0	–	0	–
C33	Sapnik Trachea	M	5	5	–	0	–	0	–
		Ž	2	2	–	0	–	0	–
C34	Sapnica in pljuča Bronchus and lung	M	877	800	91,2	71	8,1	6	0,7
		Ž	339	312	92,0	26	7,7	1	0,3
C37	Timus Thymus	M	2	2	–	0	–	0	–
		Ž	1	1	–	0	–	0	–
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	4	4	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	3	3	–	0	–	0	–
		Ž	3	3	–	0	–	0	–
C41	Kosti, sklepi hrustanec, druge Bone and articular cartilage of other and unspecified parts	M	3	2	–	1	–	0	–
		Ž	4	4	–	0	–	0	–
C43	Malignni melanom kože Malignant melanoma of skin	M	201	201	100	0	0	0	0
		Ž	236	236	100	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	M	873	873	100	0	0	0	0
		Ž	935	930	99,5	4	0,4	1	0,1
C45	Mezoteliom Mesothelioma	M	26	25	96,2	1	3,8	0	0
		Ž	3	3	–	0	–	0	–
C46	Kaposijev sarkom Kaposi's sarcoma	M	2	2	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	5	5	–	0	–	0	–
		Ž	1	1	–	0	–	0	–
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	7	7	–	0	–	0	–
		Ž	20	20	100	0	0	0	0
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	19	19	100	0	0	0	0
		Ž	20	20	100	0	0	0	0
C50	Dojka Breast	M	6	5	–	1	–	0	–
		Ž	1147	1126	98,2	19	1,7	2	0,2
C51	Žensko zunanje spolovilo Vulva	M	–	–	–	–	–	–	–
		Ž	53	52	98,1	1	1,9	0	0
C52	Nožnica Vagina	M	–	–	–	–	–	–	–
		Ž	15	15	100	0	0	0	0
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–
		Ž	153	153	100	0	0	0	0
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–
		Ž	296	295	99,7	1	0,3	0	0
C55	Maternica, neopredeljeno Uterus, unspecified	M	–	–	–	–	–	–	–
		Ž	6	4	–	1	–	1	–
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–
		Ž	174	166	95,4	7	4,0	1	0,6

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB*	Primarna lokacija	Spol	Število novih primerov	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%**	Število	%**	Število	%**
				Number of new cases	Microscopically confirmed cases	Confirmed by other investigations	Registered from death certificates only		
ICD No.*	Primary site	Sex	Number	%**	Number	%**	Number	%**	
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	–	–	–	–	–	–	–
		Ž	14	14	–	0	–	0	–
C58	Posteljica Placenta	M	–	–	–	–	–	–	–
		Ž	0	0	–	0	–	0	–
C60	Penis Penis	M	7	7	–	0	–	0	–
		Ž	–	–	–	–	–	–	–
C61	Prostata Prostate	M	1032	980	95,0	48	4,7	4	0,4
		Ž	–	–	–	–	–	–	–
C62	Modo Testis	M	89	89	100	0	0	0	0
		Ž	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	1	1	–	0	–	0	–
		Ž	–	–	–	–	–	–	–
C64	Ledvica razen meha Kidney, except renal pelvis	M	177	167	94,4	9	5,1	1	0,6
		Ž	95	81	85,3	13	13,7	1	1,1
C65	Ledvični meh Renal pelvis	M	20	20	100	0	0	0	0
		Ž	8	7	–	1	–	0	–
C66	Sečevod Ureter	M	6	6	–	0	–	0	–
		Ž	4	4	–	0	–	0	–
C67	Sečni mehur Bladder	M	202	192	95,0	10	5,0	0	0
		Ž	76	73	96,1	3	3,9	0	0
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	3	3	–	0	–	0	–
		Ž	1	1	–	0	–	0	–
C69	Okoli očesni adneksi Eye and adnexa	M	7	6	–	1	–	0	–
		Ž	9	8	–	1	–	0	–
C70	Meninge Meninges	M	0	0	–	0	–	0	–
		Ž	1	1	–	0	–	0	–
C71	Možgani Brain	M	81	75	92,6	4	4,9	2	2,5
		Ž	63	53	84,1	9	14,3	1	1,6
C72	Hrbtini mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS	M	0	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C73	Ščitnica Thyroid gland	M	29	29	100	0	0	0	0
		Ž	105	105	100	0	0	0	0
C74	Nadledvična žleza Adrenal gland	M	2	2	–	0	–	0	–
		Ž	6	4	–	2	–	0	–
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	–	0	–	0	–
		Ž	1	1	–	0	–	0	–
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	3	2	–	1	–	0	–
		Ž	23	12	52,2	11	47,8	0	0
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	14	14	–	0	–	0	–
		Ž	19	19	100	0	0	0	0
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	37	19	51,4	17	45,9	1	2,7
		Ž	64	35	54,7	28	43,8	1	1,6
C79	Metastaze, drugje Metastases of other sites	M	14	9	–	5	–	0	–
		Ž	14	8	–	5	–	1	–
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	48	30	62,5	17	35,4	1	2,1
		Ž	42	21	50,0	20	47,6	1	2,4
C81	Hodgkinova bolezen Hodgkin's disease	M	31	31	100	0	0	0	0
		Ž	17	17	100	0	0	0	0
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	26	26	100	0	0	0	0
		Ž	34	34	100	0	0	0	0
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	72	72	100	0	0	0	0
		Ž	76	76	100	0	0	0	0

Nadaljevanje →
Continued →

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB*	Primarna lokacija	Spol	Število novih primerov	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%**	Število	%**	Število	%**
				Number	%**	Number	%**	Number	%**
ICD No.*	Primary site	Sex	Number of new cases	Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%**	Number	%**	Number	%**
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	11	11	–	0	–	0	–
		Ž	9	9	–	0	–	0	–
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	9	9	–	0	–	0	–
		Ž	11	11	–	0	–	0	–
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	0	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	59	59	100	0	0	0	0
		Ž	52	52	100	0	0	0	0
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M	9	9	–	0	–	0	–
		Ž	11	11	–	0	–	0	–
C91.1–C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	54	54	100	0	0	0	0
		Ž	43	43	100	0	0	0	0
C92	Mieločna levkemija Myeloid leukaemia	M	54	54	100	0	0	0	0
		Ž	35	35	100	0	0	0	0
C93	Monocitna levkemija Monocytic leukaemia	M	2	2	–	0	–	0	–
		Ž	4	4	–	0	–	0	–
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	0	0	–	0	–	0	–
		Ž	1	1	–	0	–	0	–
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	8	8	–	0	–	0	–
		Ž	5	5	–	0	–	0	–
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	53	53	100	0	0	0	0
		Ž	66	66	100	0	0	0	0

Zgoraj neupoštevani

Not included above

Šifra MKB*	Primarna lokacija	Spol	Število novih primerov	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%**	Število	%**	Število	%**
				Number	%**	Number	%**	Number	%**
ICD No.*	Primary site	Sex	Number of new cases	Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%**	Number	%**	Number	%**
D03	Melanom, in situ Melanoma, in situ	M	54	54	100	0	0	0	0
		Ž	66	66	100	0	0	0	0
D05	Dojka, in situ Breast, in situ	M	0	0	–	0	–	0	–
		Ž	86	86	100	0	0	0	0
D06	Maternični vrat, CIN III Cervix uteri, in situ	M	–	–	–	–	–	–	–
		Ž	1114	1114	100	0	0	0	0
D09.0	Sečni mehur, in situ Bladder, in situ	M	129	129	100	0	0	0	0
		Ž	41	41	100	0	0	0	0
D32.0	Meninge, benigna neoplazma Benign neoplasm of meninges	M	14	14	–	0	–	0	–
		Ž	53	49	92,5	4	7,5	0	0
D33.0–D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	2	2	–	0	–	0	–
		Ž	2	1	–	1	–	0	–
D39.1	Jajčnik, neopl. negotovega značaja Ovary, neopl. of uncertain behavior	M	–	–	–	–	–	–	–
		Ž	38	38	100	0	0	0	0
D43.0–D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	6	1	–	5	–	0	–
		Ž	7	1	–	5	–	1	–

* MKB – Mednarodna klasifikacija bolezni, deseta revizija, 1995

* ICD – International Classification of Diseases, Tenth Revision, 1995

** Odstotki niso računani, če je število novih primerov manjše od 15

** Percentages are not calculated when number of new cases is less than 15

Tabela 4: Incidenca raka po lokaciji, spolu in starosti, Slovenija 2007.

Table 4: Cancer incidence by site, by sex and by age, Slovenia 2007.

Šifra MKB	Primarna lokacija	Spol	Vse starosti	Starosti																
				Age																
ICD code	Primary site	Sex	All ages	0	-5	-10	-15	-20	-25	-30	-35	-40	-45	-50	-55	-60	-65	-70	-75	80+
C00–C96	Vse lokacije All sites	M+Ž	11607	20	9	14	22	56	82	122	214	314	561	948	1215	1320	1555	1820	1599	1736
		M	6083	5	5	7	12	31	40	53	81	125	239	464	684	780	960	1053	898	646
		Ž	5524	15	4	7	10	25	42	69	133	189	322	484	531	540	595	767	701	1090
C00	Ustnica Lip	M	17	0	0	0	0	0	0	0	0	0	0	3	1	1	4	3	3	2
		Ž	9	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	2
C01	Baza jezika Base of tongue	M	13	0	0	0	0	0	0	0	0	1	3	2	1	2	2	1	1	0
		Ž	3	0	0	0	0	0	0	0	0	1	0	0	2	0	0	0	0	0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	30	0	0	0	0	0	0	0	1	4	5	2	0	5	5	4	2	2
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
C03	Dlesen Gum	M	7	0	0	0	0	0	0	0	0	0	0	0	2	2	2	0	1	0
		Ž	3	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0
C04	Ustno dno Floor of mouth	M	29	0	0	0	0	0	0	0	0	0	4	5	9	2	4	4	0	1
		Ž	12	0	0	0	0	0	0	0	0	1	1	3	2	2	0	3	0	0
C05	Nebo Palate	M	10	0	0	0	0	0	0	0	0	0	3	2	2	1	2	0	0	0
		Ž	6	0	0	0	0	0	1	0	1	0	0	0	1	1	0	1	1	0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	8	0	0	0	0	0	0	0	0	0	2	2	0	1	1	0	1	1
		Ž	5	0	0	0	0	0	0	0	0	0	0	1	0	2	0	1	1	0
C07	Parotidna žleza Parotid gland	M	6	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	1	2
		Ž	4	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	1	0
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C09	Tonzila Tonsil	M	30	0	0	0	0	0	0	0	0	2	3	6	8	1	5	2	3	0
		Ž	9	0	0	0	0	0	0	0	0	0	0	3	3	1	1	1	0	0
C10	Orofarinks Oropharynx	M	39	0	0	0	0	0	0	0	0	3	6	9	8	4	1	4	3	1
		Ž	5	0	0	0	0	0	0	0	0	1	0	3	0	0	1	0	0	
C11	Nazofarinks Nasopharynx	M	8	0	0	0	0	1	0	0	0	2	1	0	0	1	2	0	1	0
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1
C12	Piriformni sinus Pyriform sinus	M	31	0	0	0	0	0	0	0	0	0	3	9	5	7	3	3	1	0
		Ž	3	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	
C13	Hipofarinks Hypopharynx	M	26	0	0	0	0	0	0	0	0	2	1	5	7	1	4	4	1	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	M	83	0	0	0	0	0	1	0	1	0	4	11	15	9	12	9	9	12
		Ž	14	0	0	0	0	0	0	0	0	0	0	2	1	4	1	1	1	4
C16	Želodec Stomach	M	280	0	0	0	0	1	4	1	0	8	9	15	30	33	44	48	50	37
		Ž	181	0	0	0	1	0	0	1	3	3	7	11	15	12	19	30	25	54
C17	Tanko črevo Small intestine	M	14	0	0	0	0	0	0	0	0	0	0	3	3	2	3	3	0	0
		Ž	9	0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	2	3
C18	Debelo črevo Colon	M	431	0	0	0	0	0	2	1	9	5	11	23	42	44	78	93	68	55
		Ž	353	0	0	0	0	0	1	1	1	3	6	20	24	32	46	68	58	93
C19	Rektosigmoidna zveza Rectosigmoid junction	M	79	0	0	0	0	0	0	0	1	1	3	5	9	8	12	14	16	10
		Ž	66	0	0	0	0	0	0	1	0	1	2	4	9	9	6	12	9	13
C20	Rektum Rectum	M	270	0	0	0	0	0	0	1	3	2	12	22	24	48	40	50	40	28
		Ž	193	0	0	0	0	0	0	1	1	2	3	9	19	25	25	42	22	44
C21	Anus in analni kanal Anus and anal canal	M	11	0	0	0	0	0	0	0	0	0	0	2	1	2	0	1	2	3
		Ž	14	0	0	0	0	0	0	0	0	0	1	0	1	1	2	4	1	4
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	128	0	0	0	0	0	0	0	0	0	5	8	15	23	26	23	17	11
		Ž	49	1	0	0	0	0	0	0	0	0	0	3	7	5	8	7	7	11
C23	Žolčnik Gallbladder	M	16	0	0	0	0	0	0	0	0	0	0	0	1	2	2	5	5	1
		Ž	45	0	0	0	0	0	0	0	0	1	2	2	1	2	1	12	11	13
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	39	0	0	0	0	0	0	0	0	0	2	1	3	5	3	9	6	10
		Ž	54	0	0	0	0	0	0	1	0	1	0	1	3	3	4	9	7	25
C25	Trebušna slinavka Pancreas	M	154	0	0	0	0	0	0	0	2	2	7	16	22	14	29	26	24	12
		Ž	146	0	0	0	0	0	0	0	0	2	5	11	11	16	12	21	30	38
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	3	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	1

Nadaljevanje —>
Continued —>

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB	Primarna lokacija	Spol	Vse starosti	Starosti																
				Age																
ICD code	Primary site	Sex	All ages	0	-5	-10	-15	-20	-25	-30	-35	-40	-45	-50	-55	-60	-65	-70	-75	80+
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	9	0	0	0	0	0	0	0	0	1	1	2	3	0	1	0	1	0
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0
C31	Obnosni sinusi Accessory sinuses	M	9	0	0	0	0	1	0	0	0	1	2	2	2	0	1	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
C32	Grlo Larynx	M	111	0	0	0	0	0	0	0	0	2	4	17	29	10	20	19	7	3
		Ž	10	0	0	0	0	0	0	0	0	0	3	1	2	2	0	1	1	0
C33	Sapnik Trachea	M	5	0	0	0	0	0	0	0	0	0	1	0	1	1	0	1	1	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0
C34	Sapnica in pljuča Bronchus and lung	M	877	0	0	0	0	0	1	0	4	13	30	96	119	139	131	151	109	84
		Ž	339	0	0	0	0	0	1	0	2	6	22	41	47	27	39	46	52	56
C37	Timus Thymus	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	4	0	0	0	0	0	1	2	0	0	0	0	0	1	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C40	Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs	M	3	0	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0	0
		Ž	3	0	0	0	1	0	0	0	0	0	2	0	0	0	0	0	0	0
C41	Kosti, sklepni hrustanec, druge Bone and articular cartilage of other and unspecified parts	M	3	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	1	0
		Ž	4	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	1
C43	Malignni melanom kože Malignant melanoma of skin	M	201	0	0	0	0	4	3	8	12	12	16	25	19	19	31	27	16	9
		Ž	236	0	0	0	1	2	12	9	26	19	28	23	22	19	22	17	18	18
C44	Druge maligne neoplazme kože Skin, other malignomas	M	873	0	0	0	0	4	2	13	9	25	43	85	102	129	156	166	139	
		Ž	935	0	0	1	0	3	0	9	11	20	35	59	56	79	96	128	162	276
C45	Mezoteliom Mesothelioma	M	26	0	0	0	0	0	0	0	0	0	0	2	8	1	8	4	1	2
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1
C46	Kaposijev sarkom Kaposi's sarcoma	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	5	0	0	0	0	0	0	1	0	1	1	1	0	0	0	0	1	0
		Ž	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	7	0	0	0	0	0	1	1	1	1	1	0	0	1	1	0	0	0
		Ž	20	0	0	0	0	0	0	0	0	0	1	2	5	2	3	4	3	0
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	19	0	2	2	0	0	0	1	1	1	1	1	1	2	0	2	3	2
		Ž	20	0	1	0	0	2	1	0	0	2	1	4	2	1	1	2	1	2
C50	Dojka Breast	M	6	0	0	0	0	0	0	0	0	0	0	1	0	2	2	1	0	3
		Ž	1147	0	0	0	0	0	5	15	41	71	104	126	141	141	129	134	100	140
C51	Žensko zunanje spolovilo Vulva	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	53	0	0	0	0	0	0	0	0	1	1	2	2	4	8	8	10	17
C52	Nožnica Vagina	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	15	0	0	0	0	0	0	0	0	2	1	0	2	2	2	2	0	4
C53	Maternični vrat Cervix uteri	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	153	0	0	0	0	0	4	18	14	20	21	25	14	9	7	8	7	6
C54	Maternično telo Corpus uteri	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	296	0	0	0	0	0	1	1	1	7	15	38	47	38	43	32	36	37
C55	Maternica, neopredeljeno Uterus, unspecified	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	3
C56	Jajčnik Ovary	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	174	0	0	0	0	1	2	1	7	7	14	25	16	23	17	26	17	18
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	14	0	0	0	0	0	0	0	0	1	2	1	3	2	3	1	1	0
C58	Posteljica Placenta	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C60	Penis Penis	M	7	0	0	0	0	0	0	0	0	0	0	0	2	2	0	1	2	0
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostata Prostate	M	1032	0	0	0	0	0	0	0	0	1	9	37	97	166	214	232	170	106
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB	Primarna lokacija	Spol	Vse starosti	Starosti																
				Age																
ICD code	Primary site	Sex	All ages	0	-5	-10	-15	-20	-25	-30	-35	-40	-45	-50	-55	-60	-65	-70	-75	80+
C62	Modo Testis	M	89	0	0	0	3	12	17	21	15	10	6	3	1	0	1	0	0	0
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha Kidney, except renal pelvis	M	177	2	0	0	0	0	0	2	2	8	14	24	28	20	27	24	16	10
		Ž	95	1	0	0	0	0	0	0	4	3	4	5	6	9	19	19	5	20
C65	Ledvični meh Renal pelvis	M	20	0	0	0	0	0	0	0	0	0	0	0	6	2	2	4	4	2
		Ž	8	0	0	0	0	0	0	0	0	0	1	2	1	0	1	1	1	1
C66	Sečevod Ureter	M	6	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	2	1
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3
C67	Sečni mehur Bladder	M	202	0	0	0	0	0	0	0	1	1	5	7	15	31	30	40	47	25
		Ž	76	0	0	0	0	0	0	0	0	0	5	7	8	2	7	14	16	17
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
C69	Oko in očesni adneksi Eye and adnexa	M	7	0	0	0	0	0	0	0	0	0	2	1	0	0	3	1	0	0
		Ž	9	0	0	0	0	0	0	1	0	1	0	1	0	0	3	1	1	1
C70	Meninge Meninges	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
C71	Možgani Brain	M	81	1	1	2	1	4	2	3	3	7	6	8	11	9	7	9	4	3
		Ž	63	3	1	0	3	0	0	0	2	1	7	4	4	6	6	12	9	5
C72	Hrbtni mozeg, možganski živci in drugi deli CZS Spinal cord, cranial nerves and other parts of CNS	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	M	29	0	0	0	1	0	1	2	5	3	4	4	2	3	1	3	0	0
		Ž	105	0	0	3	6	6	7	12	5	8	11	16	4	7	9	9	2	2
C74	Nadledvična žleza Adrenal gland	M	2	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
		Ž	6	1	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2	
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1
		Ž	23	0	0	0	1	0	0	1	0	0	0	0	1	2	2	6	3	7
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	14	0	0	0	0	1	0	0	0	0	1	0	5	2	1	0	3	1
		Ž	19	0	0	0	0	0	0	0	0	2	0	2	3	3	1	3	2	3
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	37	0	0	0	0	0	0	0	0	0	2	3	5	2	1	6	9	9
		Ž	64	0	0	0	0	0	0	0	0	0	0	2	2	1	3	12	11	33
C79	Metastaze, drugje Metastases of other sites	M	14	0	0	0	0	0	0	0	0	1	0	0	2	2	2	2	3	2
		Ž	14	0	0	0	0	0	0	0	0	0	1	0	0	2	3	5	3	
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	48	0	0	0	0	0	0	0	0	1	4	2	4	7	5	8	11	6
		Ž	42	0	0	0	0	0	0	0	0	0	1	4	2	3	2	11	6	13
C81	Hodgkinova bolezen Hodgkin's disease	M	31	0	0	0	5	2	2	1	3	2	3	2	1	2	2	1	5	0
		Ž	17	0	0	1	0	7	2	0	1	0	0	1	2	1	2	0	0	0
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	26	0	0	0	0	0	0	2	1	5	1	4	3	6	1	1	0	2
		Ž	34	0	0	0	0	0	0	0	1	0	5	4	6	5	2	4	4	3
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	72	0	0	0	1	1	0	0	3	2	5	6	6	3	10	14	14	7
		Ž	76	0	0	0	2	0	1	0	0	1	3	1	7	8	9	14	8	22
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	11	0	0	0	0	1	1	0	0	3	0	0	2	0	1	0	2	1
		Ž	9	0	0	1	0	0	0	0	0	0	0	1	1	2	2	0	2	0
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	9	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	5
		Ž	11	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	3	5

Nadaljevanje —>
Continued —>

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB	Primarna lokacija	Spol	Vse starosti	Starosti																	
				Age																	
ICD code	Primary site	Sex	All ages	0	-5	-10	-15	-20	-25	-30	-35	-40	-45	-50	-55	-60	-65	-70	-75	80+	
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	59	0	0	0	0	0	0	0	0	1	4	6	4	7	14	9	6	8	
		Ž	52	0	0	0	0	0	0	1	0	0	3	4	1	11	4	7	5	16	
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M	9	0	1	3	1	0	0	2	0	0	0	0	1	0	0	0	1	0	
		Ž	11	5	1	0	0	0	1	0	0	0	0	1	0	0	2	0	0	1	
C91.1-91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	54	0	0	0	0	0	0	0	0	0	2	6	6	6	12	11	4	7	
		Ž	43	0	0	0	0	0	0	0	0	0	0	3	2	2	6	11	5	14	
C92	Mieloična levkemija Myeloid leukaemia	M	54	0	1	0	1	0	1	0	1	2	3	4	4	5	4	8	11	9	
		Ž	35	3	0	0	2	1	0	0	2	1	0	1	3	4	4	1	6	7	
C93	Monocitna levkemija Monocytic leukaemia	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	
		Ž	4	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	8	0	0	0	0	0	0	0	0	0	2	1	0	1	1	0	2	1	
		Ž	5	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	2	
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	53	0	0	0	0	1	0	2	1	2	1	1	0	5	8	9	13	10	
		Ž	66	0	0	0	2	2	2	1	1	6	3	3	4	5	7	10	20		

Zgoraj neupoštevani
Not included above

Šifra MKB	Primarna lokacija	Spol	Vse starosti	Starosti																	
				Age																	
ICD code	Primary site	Sex	All ages	0	-5	-10	-15	-20	-25	-30	-35	-40	-45	-50	-55	-60	-65	-70	-75	80+	
D03	Melanom, in situ Melanoma, in situ	M	54	0	0	0	0	0	2	5	4	0	6	5	7	6	6	6	6	1	
		Ž	66	0	0	0	0	2	3	4	6	9	6	5	3	7	6	7	7	1	
D05	Dojka, in situ Breast, in situ	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	86	0	0	0	0	0	0	0	1	4	10	27	18	5	13	6	1	1	
D06	Maternični vrat, CIN III Cervix uteri, in situ	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	1114	0	0	4	74	260	258	184	128	99	39	27	21	8	8	1	3		
D09.0	Sečni mehur, in situ Bladder, in situ	M	129	0	0	0	0	0	1	0	2	6	9	13	19	23	24	22	10		
		Ž	41	0	0	0	0	0	0	1	0	2	2	10	3	8	4	6	5		
D32.0	Meninge, benigna neoplazma Benign neoplasm of meninges	M	14	0	0	0	0	0	1	0	0	0	1	2	1	1	1	2	5		
		Ž	53	0	0	0	0	1	0	4	2	7	3	6	5	6	7	6	6		
D33.0-33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	2	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0		
		Ž	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0		
D39.1	Jajčnik, neopl. negotovega značaja Ovary, neopl. of uncertain behavior	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
		Ž	38	0	0	0	1	2	2	2	6	8	2	3	2	3	5	1	1		
D43.0-43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	6	0	0	0	1	0	0	0	0	0	0	0	0	0	3	0	2		
		Ž	7	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	3		

Tabela 5: Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter kumulativna stopnja (KS) po lokaciji in spolu, Slovenija 2007.

Table 5: Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, Slovenia 2007.

Šifra MKB	Primarna lokacija	Spol	Vse starosti	Starost																	KS CR
				Age																	
ICD code	Primary site	Sex	All ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	0-74
C00-C96	Vse lokacije All sites	M+Ž	574,8	21,7	9,9	14,2	18,8	41,3	53,3	80,3	146,9	199,3	363,3	597,6	880,0	1294,7	1592,5	2120,0	2283,8	2478,2	37,2
		M	611,3	10,6	10,7	13,9	19,9	44,0	49,7	67,0	107,9	155,7	303,2	567,5	978,0	1590,4	2134,6	2923,4	3482,1	3501,0	44,9
		Ž	539,3	33,5	9,1	14,6	17,7	38,4	57,2	94,8	188,2	244,5	426,0	629,6	779,4	1020,6	1129,6	1539,3	1585,0	2112,4	31,1
C00	Ustnica Lip	M	1,7	0	0	0	0	0	0	0	0	0	0	3,7	1,4	2,0	8,9	8,3	11,6	10,8	0,1
		Ž	0,9	0	0	0	0	0	0	0	1,4	0	0	0	1,5	1,9	0	0	4,5	7,8	0,0
C01	Baza jezika Base of tongue	M	1,3	0	0	0	0	0	0	0	0	1,2	3,8	2,4	1,4	4,1	4,4	2,8	3,9	0	0,1
		Ž	0,3	0	0	0	0	0	0	0	0	1,3	0	0	2,9	0	0	0	0	0	0,0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	3,0	0	0	0	0	0	0	0	1,3	5,0	6,3	2,4	0	10,2	11,1	11,1	7,8	10,8	0,2
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0	0	0	0,0
C03	Dlesen Gum	M	0,7	0	0	0	0	0	0	0	0	0	0	0	2,9	4,1	4,4	0	3,9	0	0,1
		Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	1,9	0	2,3	0
C04	Ustno dno Floor of mouth	M	2,9	0	0	0	0	0	0	0	0	0	5,1	6,1	12,9	4,1	8,9	11,1	0	5,4	0,2
		Ž	1,2	0	0	0	0	0	0	0	0	1,3	1,3	3,9	2,9	3,8	0	6,0	0	0	0,1
C05	Nebo Palate	M	1,0	0	0	0	0	0	0	0	0	0	3,8	2,4	2,9	2,0	4,4	0	0	0	0,1
		Ž	0,6	0	0	0	0	0	1,4	0	1,4	0	0	0	1,5	1,9	0	2,0	2,3	0	0,0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	0,8	0	0	0	0	0	0	0	0	0	2,5	2,4	0	2,0	2,2	0	3,9	5,4	0,0
		Ž	0,5	0	0	0	0	0	0	0	0	0	0	1,3	0	3,8	0	2,0	2,3	0	0,0
C07	Parotidna žleza Parotid gland	M	0,6	0	0	0	0	0	0	0	0	0	0	1,2	0	2,0	2,2	0	3,9	10,8	0,0
		Ž	0,4	0	0	0	0	0	0	0	0	1,3	1,3	0	0	0	1,9	0	2,3	0	0,0
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0,1	0	0	0	0	0	0	0	0	0	0	1,2	0	0	0	0	0	0	0,0
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0,0
C09	Tonzila Tonsil	M	3,0	0	0	0	0	0	0	0	0	2,5	3,8	7,3	11,4	2,0	11,1	5,6	11,6	0	0,2
		Ž	0,9	0	0	0	0	0	0	0	0	0	0	0	3,9	4,4	1,9	2,0	2,0	0	0,1
C10	Orofarinks Oropharynx	M	3,9	0	0	0	0	0	0	0	0	3,7	7,6	11,0	11,4	8,2	2,2	11,1	11,6	5,4	0,3
		Ž	0,5	0	0	0	0	0	0	0	0	1,3	0	3,9	0	0	0	2,0	0	0	0,0
C11	Nazofarinks Nasopharynx	M	0,8	0	0	0	1,4	0	0	0	0	2,5	1,3	0	0	2,0	4,4	0	3,9	0	0,1
		Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0	2,3	1,9	0,0
C12	Piriformni sinus Pyiform sinus	M	3,1	0	0	0	0	0	0	0	0	3,8	11,0	7,1	14,3	6,7	8,3	3,9	0	0	0,3
		Ž	0,3	0	0	0	0	0	0	0	0	0	2,6	1,5	0	0	0	0	0	0	0,0
C13	Hipofarinks Hypopharynx	M	2,6	0	0	0	0	0	0	0	0	2,5	1,3	6,1	10,0	2,0	8,9	11,1	3,9	5,4	0,2
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	2,0	0	0	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C15	Požiralnik Oesophagus	M	8,3	0	0	0	0	1,2	0	1,3	0	5,1	13,5	21,4	18,4	26,7	25,0	34,9	65,0	0,6	
		Ž	1,4	0	0	0	0	0	0	0	0	0	2,6	1,5	7,6	1,9	2,0	2,3	7,8	0,1	
C16	Želodec Stomach	M	28,1	0	0	0	1,4	5,0	1,3	0	10,0	11,4	18,3	42,9	67,3	97,8	133,3	193,9	200,5	1,9	
		Ž	17,7	0	0	0	1,8	0	0	1,4	4,2	3,9	9,3	14,3	22,0	22,7	36,1	60,2	56,5	104,7	0,9
C17	Tanko črevo Small intestine	M	1,4	0	0	0	0	0	0	0	0	0	3,7	4,3	4,1	6,7	8,3	0	0	0,1	
		Ž	0,9	0	0	0	0	1,4	0	0	0	0	0	0	1,9	1,9	2,0	4,5	5,8	0,0	
C18	Debelo črevo Colon	M	43,3	0	0	0	0	2,5	1,3	12,0	6,2	14,0	28,1	60,1	89,7	173,4	258,2	263,7	298,1	3,2	
		Ž	34,5	0	0	0	0	1,4	1,4	1,4	3,9	7,9	26,0	35,2	60,5	87,3	136,5	131,1	180,2	1,8	

Nadaljevanje →
Continued →

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB	Primarna lokacija	Spol	Vse starosti	Starost																	KS CR
				Age																	
ICD code	Primary site	Sex	All ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	0-74
C19	Rektosigmoidna zveza Rectosigmoid junction	M	7,9	0	0	0	0	0	0	0	1,3	1,2	3,8	6,1	12,9	16,3	26,7	38,9	62,0	54,2	0,5
		Ž	6,4	0	0	0	0	0	0	0	1,4	0	1,3	2,6	5,2	13,2	17,0	11,4	24,1	20,3	25,2
C20	Rektum Rectum	M	27,1	0	0	0	0	0	0	1,3	4,0	2,5	15,2	26,9	34,3	97,9	88,9	138,8	155,1	151,7	2,0
		Ž	18,8	0	0	0	0	0	0	1,4	1,4	2,6	4,0	11,7	27,9	47,3	47,5	84,3	49,7	85,3	1,1
C21	Anus in analni kanal Anus and anal canal	M	1,1	0	0	0	0	0	0	0	0	0	0	2,4	1,4	4,1	0	2,8	7,8	16,3	0,1
		Ž	1,4	0	0	0	0	0	0	0	0	0	1,3	0	1,5	1,9	3,8	8,0	2,3	7,8	0,1
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	12,9	0	0	0	0	0	0	0	0	0	6,3	9,8	21,4	46,9	57,8	63,9	65,9	59,6	1,0
		Ž	4,8	2,2	0	0	0	0	0	0	0	0	0	3,9	10,3	9,5	15,2	14,0	15,8	21,3	0,3
C23	Žolčnik Gallbladder	M	1,6	0	0	0	0	0	0	0	0	0	0	0	1,4	4,1	4,4	13,9	19,4	5,4	0,1
		Ž	4,4	0	0	0	0	0	0	0	0	1,3	2,6	2,6	1,5	3,8	1,9	24,1	24,9	25,2	0,2
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	3,9	0	0	0	0	0	0	0	0	0	2,5	1,2	4,3	10,2	6,7	25,0	23,3	54,2	0,2
		Ž	5,3	0	0	0	0	0	0	0	1,4	0	1,3	0	1,3	4,4	5,7	7,6	18,1	15,8	48,5
C25	Trebušna slinavka Pancreas	M	15,5	0	0	0	0	0	0	0	2,7	2,5	8,9	19,6	31,5	28,5	64,5	72,2	93,1	65,0	1,2
		Ž	14,3	0	0	0	0	0	0	0	0	2,6	6,6	14,3	16,1	30,2	22,8	42,1	67,8	73,6	0,7
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,3	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	2,0	0	1,9	0,0
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	0,9	0	0	0	0	0	0	0	0	1,2	1,3	2,4	4,3	0	2,2	0	3,9	0	0,1
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	0	0	1,9	1,9	2,0	0	1,9	0,0
C31	Obnosni sinusi Accessory sinuses	M	0,9	0	0	0	0	1,4	0	0	0	1,2	2,5	2,4	2,9	0	2,2	0	0	0	0,1
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,3	1,9	0,0
C32	Grlo Larynx	M	11,2	0	0	0	0	0	0	0	0	2,5	5,1	20,8	41,5	20,4	44,5	52,7	27,1	16,3	0,9
		Ž	1,0	0	0	0	0	0	0	0	0	0	4,0	1,3	2,9	3,8	0	2,0	2,3	0	0,1
C33	Sapnik Trachea	M	0,5	0	0	0	0	0	0	0	0	0	1,3	0	1,4	2,0	0	2,8	3,9	0	0,0
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	1,5	0	0	2,0	0	0	0,0
C34	Sapnica in pljuča Bronchus and lung	M	88,1	0	0	0	0	0	1,2	0	5,3	16,2	38,1	117,4	170,1	283,4	291,3	419,2	422,7	455,2	6,7
		Ž	33,1	0	0	0	0	0	1,4	0	2,8	7,8	29,1	53,3	69,0	51,0	74,0	92,3	117,6	108,5	1,9
C37	Timus Thymus	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	1,4	2,0	0	0	0	0,0
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0	0	0	0,0
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	0,4	0	0	0	0	0	1,2	2,5	0	0	0	0	0	2,0	0	0	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C39	Druga in slabo opredeljena mesta v dihalih in prsnihih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C40	Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs	M	0,3	0	0	0	0	1,4	0	0	1,3	0	0	0	0	0	2,2	0	0	0	0,0
		Ž	0,3	0	0	0	1,8	0	0	0	0	0	2,6	0	0	0	0	0	0	0	0,0

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	
C41	Kosti, sklejni hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	0,3	0	0	0	0	0	0	1,3	0	0	0	0	1,4	0	0	0	3,9	0	0,0
		Ž	0,4	0	2,3	2,1	0	0	1,4	0	0	0	0	0	0	0	0	0	2,3	0	0,0
C43	Malignni melanom kože Malignant melanoma of skin	M	20,2	0	0	0	0	5,7	3,7	10,1	16,0	15,0	20,3	30,6	27,2	38,7	68,9	75,0	62,0	48,8	1,6
		Ž	23,0	0	0	1,8	3,1	16,3	12,4	36,8	24,6	37,0	29,9	32,3	35,9	41,8	34,1	40,7	34,9	1,5	
C44	Druge maligne neoplazme kože Skin, other malignomas	M	87,7	0	0	0	0	5,0	2,5	17,3	11,2	31,7	52,6	121,5	208,0	286,8	433,1	643,7	753,3	5,8	
		Ž	91,3	0	0	2,1	0	4,6	0	12,4	15,6	25,9	46,3	76,7	82,2	149,3	182,3	256,9	366,3	534,9	4,3
C45	Mezoteliom Mesothelioma	M	2,6	0	0	0	0	0	0	0	0	0	0	2,4	11,4	2,0	17,8	11,1	3,9	10,8	0,2
		Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	2,0	0	1,9	0,0
C46	Kaposijev sarkom Kaposi's sarcoma	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	2,0	0	2,8	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	0,5	0	0	0	0	0	0	1,3	0	1,2	1,3	1,2	0	0	0	0	3,9	0	0,0
		Ž	0,1	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	0	0	0,0
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	0,7	0	0	0	0	0	1,2	1,3	1,3	1,2	1,3	0	0	2,0	2,2	0	0	0	0,1
		Ž	2,0	0	0	0	0	0	0	0	0	0	1,3	2,6	7,3	3,8	5,7	8,0	6,8	0	0,1
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	1,9	0	4,3	4,0	0	0	0	1,3	1,3	1,2	1,3	1,2	1,4	4,1	0	5,6	11,6	10,8	0,1
		Ž	2,0	0	2,3	0	0	3,1	1,4	0	0	2,6	1,3	5,2	2,9	1,9	1,9	4,0	2,3	3,9	0,1
C50	Dojka Breast	M	0,6	0	0	0	0	0	0	0	0	0	0	1,2	0	0	4,4	5,6	3,9	0	0,1
		Ž	112,0	0	0	0	0	0	6,8	20,6	58,0	91,8	137,6	163,9	207,0	266,5	244,9	268,9	226,1	271,3	7,3
C51	Žensko zunanje spolovilo Vulva	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	5,2	0	0	0	0	0	0	0	0	1,3	1,3	2,6	2,9	7,6	15,2	16,1	22,6	32,9	0,2
C52	Nožnica Vagina	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	1,5	0	0	0	0	0	0	0	0	2,6	1,3	0	2,9	3,8	3,8	4,0	0	7,8	0,1
C53	Maternični vrat Cervix uteri	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	14,9	0	0	0	0	0	5,4	24,7	19,8	25,9	27,8	32,5	20,5	17,0	13,3	16,1	15,8	11,6	1,0
C54	Maternično telo Corpus uteri	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	28,9	0	0	0	0	0	1,4	1,4	1,4	9,1	19,8	49,4	69,0	71,8	81,6	64,2	81,4	71,7	1,8
C55	Maternica, neopredeljeno Uterus, unspecified	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	0,6	0	0	0	0	0	0	0	0	0	0	0	1,5	0	1,9	2,0	0	5,8	0,0
C56	Jajčnik Ovary	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	17,0	0	0	0	0	1,5	2,7	1,4	9,9	9,1	18,5	32,5	23,5	43,5	32,3	52,2	38,4	34,9	1,1
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	1,4	0	0	0	0	0	0	0	0	1,3	2,6	1,3	4,4	3,8	5,7	2,0	2,3	0	0,1
C58	Posteljica Placenta	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C60	Penis Penis	M	0,7	0	0	0	0	0	0	0	0	0	0	0	2,9	4,1	0	2,8	7,8	0	0,0
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR	
				0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+		0-74
C61	Prostata Prostate	M	103,7	0	0	0	0	0	0	0	0	1,2	11,4	45,3	138,7	338,5	475,8	644,1	659,2	574,5	8,3	
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Modo Testis	M	8,9	0	0	0	5,0	17,0	21,1	26,6	20,0	12,5	7,6	3,7	1,4	0	2,2	0	0	0	0	0,6
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	0,1	0	0	0	0	0	0	0	0	0	0	1,2	0	0	0	0	0	0	0	0,0
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Ledvica razen meha Kidney, except renal pelvis	M	17,8	4,2	0	0	0	0	0	2,5	2,7	10,0	17,8	29,4	40,0	40,8	60,0	66,6	62,0	54,2	1,4	
		Ž	9,3	2,2	0	0	0	0	0	0	5,7	3,9	5,3	6,5	8,8	17,0	36,1	38,1	11,3	38,8	0,6	
C65	Ledvični meh Renal pelvis	M	2,0	0	0	0	0	0	0	0	0	0	0	0	8,6	4,1	4,4	11,1	15,5	10,8	0,1	
		Ž	0,8	0	0	0	0	0	0	0	0	0	1,3	2,6	1,5	0	1,9	2,0	2,3	1,9	0,0	
C66	Sečevod Ureter	M	0,6	0	0	0	0	0	0	0	0	0	0	1,2	0	2,0	2,2	0	7,8	5,4	0,0	
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,0	0	5,8	0,0	
C67	Sečni mehur Bladder	M	20,3	0	0	0	0	0	0	0	1,3	1,2	6,3	8,6	21,4	63,2	66,7	111,0	182,2	135,5	1,4	
		Ž	7,4	0	0	0	0	0	0	0	0	0	6,6	9,1	11,7	3,8	13,3	28,1	36,2	32,9	0,4	
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	0,3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5,6	0	5,4	0,0	
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	0,0	
C69	Oko in očesni adneksi Eye and adnexa	M	0,7	0	0	0	0	0	0	0	0	2,5	1,2	0	0	6,7	2,8	0	0	0	0,1	
		Ž	0,9	0	0	0	0	0	0	1,4	0	1,3	0	1,3	0	0	5,7	2,0	2,3	1,9	0,1	
C70	Meninge Meninges	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0	0	0	0	0,0	
C71	Možgani Brain	M	8,1	2,1	2,1	4,0	1,7	5,7	2,5	3,8	4,0	8,7	7,6	9,8	15,7	18,4	15,6	25,0	15,5	16,3	0,6	
		Ž	6,2	6,7	2,3	0	5,3	0	0	0	2,8	1,3	9,3	5,2	5,9	11,3	11,4	24,1	20,3	9,7	0,4	
C72	Hrbtni mozeg, možganski živci in drugi deli ČŽS Spinal cord, cranial nerves and other parts of CNS	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C73	Ščitnica Thyroid gland	M	2,9	0	0	0	1,4	0	1,3	2,7	6,2	3,8	4,9	5,7	4,1	6,7	2,8	11,6	0	0	0,2	
		Ž	10,3	0	6,3	0	9,2	8,2	9,6	17,0	6,5	10,6	14,3	23,5	7,6	13,3	18,1	20,3	3,9	0,7		
C74	Nadledvična žleza Adrenal gland	M	0,2	2,1	0	0	0	0	0	0	1,2	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0,6	2,2	0	0	0	0	0	0	0	0	0	0	1,9	1,9	2,0	0	3,9	0,0		
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0	0	0	0,0		
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	0,3	0	0	0	0	0	0	0	0	0	0	0	2,0	0	0	3,9	5,4	0,0		
		Ž	2,2	0	0	0	1,5	0	0	1,4	0	0	0	1,5	3,8	3,8	12,0	6,8	13,6	0,1		
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	1,4	0	0	0	1,4	0	0	0	0	1,3	0	7,1	4,1	2,2	0	11,6	5,4	0,1		
		Ž	1,9	0	0	0	0	0	0	0	2,6	0	2,6	4,4	5,7	1,9	6,0	4,5	5,8	0,1		

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	3,7	0	0	0	0	0	0	0	0	0	2,5	3,7	7,1	4,1	2,2	16,7	34,9	48,8	0,2
		Ž	6,2	0	0	0	0	0	0	0	0	0	0	0	2,6	2,9	1,9	5,7	24,1	24,9	64,0
C79	Metastaze, druge Metastases of other sites	M	1,4	0	0	0	0	0	0	0	0	1,2	0	0	2,9	4,1	4,4	5,6	11,6	10,8	0,1
		Ž	1,4	0	0	0	0	0	0	0	0	0	0	1,3	0	0	3,8	6,0	11,3	5,8	0,1
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	4,8	0	0	0	0	0	0	0	0	1,2	5,1	2,4	5,7	14,3	11,1	22,2	42,7	32,5	0,3
		Ž	4,1	0	0	0	0	0	0	0	0	1,3	5,2	2,9	5,7	3,8	22,1	13,6	25,2	0,2	
C81	Hodgkinova bolezen Hodgkin's disease	M	3,1	0	0	0	8,3	2,8	2,5	1,3	4,0	2,5	3,8	2,4	1,4	4,1	4,4	2,8	19,4	0	0,2
		Ž	1,7	0	0	2,1	0	10,7	2,7	0	1,4	0	0	1,3	2,9	1,9	3,8	0	0	0	0,1
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	2,6	0	0	0	0	0	0	2,5	1,3	6,2	1,3	4,9	4,3	12,2	2,2	2,8	0	10,8	0,2
		Ž	3,3	0	0	0	0	0	0	0	1,4	0	6,6	5,2	8,8	9,5	3,8	8,0	9,0	5,8	0,2
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	7,2	0	0	0	1,7	1,4	0	0	4,0	2,5	6,3	7,3	8,6	6,1	22,2	38,9	54,3	37,9	0,5
		Ž	7,4	0	0	0	3,5	0	1,4	0	0	1,3	4,0	1,3	10,3	15,1	17,1	28,1	18,1	42,6	0,4
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	1,1	0	0	0	0	1,4	1,2	0	0	3,7	0	0	2,9	0	2,2	0	7,8	5,4	0,1
		Ž	0,9	0	0	2,1	0	0	0	0	0	0	0	1,3	1,5	3,8	3,8	0	4,5	0	0,1
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	0,9	2,1	0	0	0	0	0	0	0	0	0	0	0	0	0	2,8	7,8	27,1	0,0
		Ž	1,1	0	0	0	0	0	0	0	0	0	0	1,3	0	3,8	0	0	6,8	9,7	0,0
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	5,9	0	0	0	0	0	0	0	0	1,2	5,1	7,3	5,7	14,3	31,1	25,0	23,3	43,4	0,4
		Ž	5,1	0	0	0	0	0	0	1,4	0	0	4,0	5,2	1,5	20,8	7,6	14,0	11,3	31,0	0,3
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M	0,9	0	2,1	5,9	1,7	0	0	2,5	0	0	0	0	1,4	0	0	0	3,9	0	0,1
		Ž	1,1	11,2	2,3	0	0	0	1,4	0	0	0	0	1,3	0	0	3,8	0	0	1,9	0,1
C91.1-91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	5,4	0	0	0	0	0	0	0	0	0	2,5	7,3	8,6	12,2	26,7	30,5	15,5	37,9	0,4
		Ž	4,2	0	0	0	0	0	0	0	0	0	0	3,9	2,9	3,8	11,4	22,1	11,3	27,1	0,2
C92	Mieloična levkemija Myeloid leukaemia	M	5,4	0	2,1	0	1,7	0	1,2	0	1,3	2,5	3,8	4,9	5,7	10,2	8,9	22,2	42,7	48,8	0,3
		Ž	3,4	6,7	0	0	3,5	1,5	0	0	2,8	1,3	0	1,3	4,4	7,6	7,6	2,0	13,6	13,6	0,2

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB	Primarna lokacija	Spol	Vse starosti	Starost																	KS CR	
				Age																		
ICD code	Primary site	Sex	All ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	0-74	
C93	Monocitna levkemija	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,9	5,4	0,0	
	Monocytic leukaemia	Ž	0,4	2,2	0	0	0	0	0	0	0	0	0	0	1,3	1,5	0	0	0	0	1,9	0,0
C94	Druge opredeljene levkemije	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Other leukaemias of specified cells	Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0	0	0	0	0	0,0
C95	Levkemija z neopredeljenim celičnim tipom	M	0,8	0	0	0	0	0	0	0	0	0	2,5	1,2	0	2,0	2,2	0	7,8	5,4	0,0	
	Leukaemia, unspecified cell type	Ž	0,5	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0	4,0	0	3,9	0,0	
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotornega ali sorodnega tkiva	M	5,3	0	0	0	1,4	0	2,5	1,3	2,5	1,3	1,2	0	10,2	17,8	25,0	50,4	54,2	0,3		
	Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	Ž	6,4	0	0	0	3,1	2,7	2,7	1,4	1,3	7,9	3,9	4,4	7,6	9,5	14,0	22,6	38,8	0,3		

Zgoraj neupoštevani

Not included above

Šifra MKB	Primarna lokacija	Spol	Vse starosti	Starost																	KS CR
				Age																	
ICD code	Primary site	Sex	All ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	0-74
D03	Melanom, in situ	M	5,4	0	0	0	0	0	2,5	6,3	5,3	0	7,6	6,1	10,0	12,2	13,3	16,7	23,3	5,4	0,4
	Melanoma, in situ	Ž	6,4	0	0	0	3,1	4,1	5,5	8,5	11,6	7,9	6,5	4,4	13,2	11,4	14,0	15,8	1,9	0,5	
D05	Dojka, in situ	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Breast, in situ	Ž	8,4	0	0	0	0	0	0	1,4	5,2	13,2	35,1	26,4	9,5	24,7	12,0	2,3	1,9	0,6	
D06	Maternični vrat, CIN III	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Cervix uteri, in situ	Ž	108,8	0	0	7,1	113,6	353,9	354,5	260,4	165,6	131,0	50,7	39,6	39,7	15,2	16,1	2,3	5,8	7,7	
D09.0	Sečni mehur, in situ	M	13,0	0	0	0	0	0	1,3	0	2,5	7,6	11,0	18,6	38,7	51,1	66,6	85,3	54,2	1,0	
	Bladder, in situ	Ž	4,0	0	0	0	0	0	0	1,4	0	2,6	2,6	14,7	5,7	15,2	8,0	13,6	9,7	0,3	
D32.0	Meninge, benigna neoplazma	M	1,4	0	0	0	0	0	1,3	0	0	0	1,2	2,9	2,0	2,2	2,8	7,8	27,1	0,1	
	Benign neoplasm of meninges	Ž	5,2	0	0	0	0	1,4	0	5,7	2,6	9,3	3,9	8,8	9,5	11,4	14,0	13,6	11,6	0,3	
D33.0-33.2	Možgani, benigna neoplazma	M	0,2	0	0	0	1,4	0	0	0	1,2	0	0	0	0	0	0	0	0	0	0,0
	Benign neoplasm of brain	Ž	0,2	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	1,9	0,0	
D39.1	Jajčnik, neopl. negotovega značaja	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Ovary, neopl. of uncertain behavior	Ž	3,7	0	0	0	1,5	2,7	2,7	2,8	7,8	10,6	2,6	4,4	3,8	5,7	10,0	2,3	1,9	0,3	
D43.0-43.2	Možgani, neopredeljeno	M	0,6	0	0	0	1,4	0	0	0	0	0	0	0	0	0	8,3	0	10,8	0,0	
	CNS, uncertain or unknown	Ž	0,7	0	0	0	0	0	0	0	0	0	1,3	1,5	1,9	0	2,0	0	5,8	0,0	

Tabela 6a: Incidenca najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2007.

Table 6a: Incidence of most frequent cancer sites by statistical regions and by sex, Slovenia 2007.

Statistična regija Statistical region	Spol Sex	Skupaj All sites	Lokacija (šifre MKB-10) Site (ICD-10 codes)										Drugo Other	D06**
			C00-C96	C16	C18	C19	C20	C34	C44	C50	C53	C54		
Slovenija, skupaj Slovenia, total	M	6083	280	431	79	270	877	873	6	–	–	1032	2232	–
	Ž	5524	181	353	66	193	339	935	1147	153	296	–	1860	1114
Pomurska	M	393	15	24	10	20	47	63	0	–	–	92	122	–
	Ž	360	15	24	3	17	10	79	68	12	17	–	115	58
Podravska	M	895	61	63	8	34	137	95	1	–	–	168	328	–
	Ž	758	41	59	12	38	41	87	181	25	43	–	231	204
Koroška	M	237	18	16	3	11	37	35	0	–	–	39	78	–
	Ž	184	7	5	1	6	14	50	28	6	10	–	57	50
Savinjska	M	637	36	54	11	32	90	73	0	–	–	100	241	–
	Ž	645	23	39	7	25	42	70	131	26	40	–	242	170
Zasavska	M	151	6	9	2	5	26	23	0	–	–	23	57	–
	Ž	126	2	15	1	4	14	12	26	5	7	–	40	27
Spodnjeoposavska	M	208	11	25	2	13	25	24	1	–	–	35	72	–
	Ž	160	8	9	4	10	10	11	37	5	10	–	56	37
Jugovzhodna Slovenija	M	436	15	26	13	24	61	63	1	–	–	76	157	–
	Ž	376	15	28	1	12	23	76	68	4	23	–	126	81
Osrednjeslovenska	M	1646	71	102	11	67	231	261	3	–	–	296	601	–
	Ž	1570	34	104	17	52	111	296	321	36	80	–	518	319
Gorenjska	M	673	20	44	5	29	112	128	0	–	–	97	238	–
	Ž	579	12	28	6	12	32	147	114	13	26	–	189	69
Notranjsko-kraška	M	154	5	13	5	4	27	15	0	–	–	25	60	–
	Ž	129	1	6	4	1	6	22	33	5	8	–	43	19
Goriška	M	362	14	30	7	13	47	53	0	–	–	48	150	–
	Ž	346	6	21	6	8	25	40	68	8	21	–	143	35
Obalno-kraška	M	291	8	25	2	18	37	40	0	–	–	33	128	–
	Ž	291	17	15	4	8	11	45	72	8	11	–	100	45

Opis šifer MKB/Description of the ICD code

C16 Želodec
StomachC18 Debelo črevo
ColonC19 Rektosigmoidna zveza
Rectosigmoid junctionC20 Rektum
RectumC34 Sapnica in pljuča
Bronchus and lungC44 Druge maligne neoplazme kože
Skin, other malignomasC50 Dojka
BreastC53 Maternični vrat
Cervix uteriC54 Maternično telo
Corpus uteriC61 Prostata
ProstateD06 Maternični vrat, in situ (CIN III)
Cervix uteri, in situ (CIN III)

* Neupoštevano v skupnem številu: D06 – Maternični vrat, in situ (CIN III)

* Not included in All sites: D06 – Cervix uteri, in situ (CIN III)

** Standard – prebivalstvo Slovenije po popisu 2002

** Standard – population of Slovenia according to census 2002

Tabela 6b: Starostno standardizirana* incidenčna stopnja najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2007.

Table 6b: Age standardised* incidence rate of most frequent cancer sites by statistical regions and by sex, Slovenia 2007.

Statistična regija Statistical region	Spol Sex	Skupaj All sites C00-C96	Lokacija (šifre MKB-10) Site (ICD-10 codes)										Drugo Other	D06**
			C16	C18	C19	C20	C34	C44	C50	C53	C54	C61		
Slovenija, skupaj Slovenia, total	M	658,0	30,8	47,7	8,7	29,5	93,4	97,5	0,7	–	–	114,2	235,6	–
	Ž	448,1	13,7	26,8	5,2	15,1	27,3	70,6	98,5	14,4	24,6	–	152,1	114,2
Pomurska	M	721,4	28,2	46,9	19,0	34,9	83,3	119,4	0,0	–	–	179,9	209,9	–
	Ž	439,8	18,9	29,6	3,9	20,8	12,4	84,2	92,2	17,4	23,6	–	136,9	97,6
Podravska	M	598,1	41,7	43,9	5,9	22,8	87,3	66,0	0,7	–	–	117,2	212,7	–
	Ž	382,3	18,8	26,6	5,8	18,7	21,4	40,3	96,2	15,1	21,5	–	118,0	130,4
Koroška	M	721,1	61,8	47,3	9,0	31,8	112,9	113,2	0,0	–	–	111,2	234,0	–
	Ž	435,3	16,5	9,7	2,5	14,8	34,8	111,0	71,1	16,7	25,1	–	133,1	139,9
Savinjska	M	553,6	33,2	49,7	10,0	27,9	77,2	64,4	0,0	–	–	85,2	205,9	–
	Ž	427,9	14,7	23,6	4,2	15,9	27,6	44,0	90,6	19,2	27,0	–	161,0	135,8
Zasavska	M	721,3	31,9	42,1	7,5	24,2	124,1	108,7	0,0	–	–	113,1	269,7	–
	Ž	429,3	7,0	53,5	3,9	15,3	48,0	34,7	93,4	20,3	21,8	–	131,5	125,9
Spodnjeposavska	M	620,3	35,3	75,9	6,6	37,2	72,2	74,0	3,3	–	–	106,6	209,2	–
	Ž	363,2	16,4	19,4	8,2	21,6	22,7	21,0	91,8	13,4	21,8	–	127,0	109,8
Jugovzhodna Slovenija	M	714,0	25,2	43,4	21,0	40,5	98,9	108,9	1,6	–	–	128,8	245,8	–
	Ž	477,6	17,5	33,2	1,3	14,4	30,0	92,1	90,9	6,5	29,5	–	162,1	122,4
Osrednjeslovenska	M	717,9	29,7	45,6	5,4	30,1	100,4	116,9	1,3	–	–	131,6	256,9	–
	Ž	510,0	10,3	32,0	5,6	16,8	34,2	90,6	109,4	13,4	26,3	–	171,6	128,3
Gorenjska	M	736,0	22,6	48,2	5,3	31,0	120,2	143,8	0,0	–	–	108,6	256,3	–
	Ž	481,0	9,5	22,0	4,4	8,4	27,4	115,4	102,8	12,8	22,5	–	155,9	71,0
Notranjsko-kraška	M	616,9	18,3	52,6	20,8	16,9	107,0	60,0	0,0	–	–	104,0	237,2	–
	Ž	391,1	3,6	18,1	11,1	1,7	14,2	57,9	112,4	17,8	25,1	–	129,2	76,9
Goriška	M	620,0	24,2	50,4	11,2	23,0	82,9	92,4	0,0	–	–	84,2	251,7	–
	Ž	445,3	7,1	23,0	7,9	8,5	34,4	44,0	90,0	13,4	28,2	–	188,9	62,5
Obalno-kraška	M	547,6	14,8	48,0	2,5	34,2	67,0	76,8	0,0	–	–	62,0	242,3	–
	Ž	423,5	19,8	21,2	6,6	10,0	14,3	63,4	109,0	12,2	16,2	–	150,8	88,2

Opis šifer MKB/Description of the ICD code

C16 Želodec
Stomach

C18 Debelo črevo
Colon

C19 Rektosigmoidna zveza
Rectosigmoid junction

C20 Rektum
Rectum

C34 Sapnica in pljuča
Bronchus and lung

C44 Druge maligne neoplazme kože
Skin, other malignomas

C50 Dojka
Breast

C53 Maternični vrat
Cervix uteri

C54 Maternično telo
Corpus uteri

C61 Prostata
Prostate

D06 Maternični vrat, in situ (CIN III)
Cervix uteri, in situ (CIN III)

* Neupoštevano v skupnem številu: D06 – Maternični vrat, in situ (CIN III)

* Not included in All sites: D06 – Cervix uteri, in situ (CIN III)

** Standard – prebivalstvo Slovenije po popisu 2002

** Standard – population of Slovenia according to census 2002

Tabela 7: Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2007.

Table 7: Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2007.

Histološka vrsta Histologic type	Skupaj All sites		Lokacija (šifre MKB–10) Site (ICD–10 codes)																							
			C00–C96		C00		C01		C02		C03		C04		C05		C06		C07		C08		C09			
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C		
Vse vrste/All types	10151	762	24	0	16	0	31	0	10	0	40	1	16	0	13	0	9	0	2	0	39	0				
Small cell carcinoma	162	59	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Non-small cell carcinoma	51	37	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Squamous cell carcinoma	1338	69	22	–	14	–	31	–	9	–	39	1	11	–	11	–	2	–	–	–	–	38	–			
Basal cell carcinoma	1389	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Transitional cel carcinoma	286	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Adenocarcinoma	5216	171	1	–	–	–	–	–	1	–	1	–	2	–	1	–	5	–	1	–	–	–	–	–		
Other specified carcinomas	166	22	–	–	–	–	–	–	–	–	–	–	3	–	1	–	–	–	–	1	–	–	–	–		
Carcinoma, unspecified	162	133	1	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	2	–	–	–	–	–		
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant melanoma	459	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Fibrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Fibrohistiocytic sarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Liposarcoma	16	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Leiomyosarcoma	14	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Synovial sarcoma	8	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Angiosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–		
Kaposi sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Osteosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chondrosarcoma	9	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Ewing sarcoma/PNET	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other specified sarcomas	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Sarcoma, unspecified	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant complex mixed and stromal tumors	27	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant mesothelioma	26	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant gonadal stromal tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Dysgerminoma and seminoma	48	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other malignant germ cell tumors	38	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant trophoblastic tumors	11	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant gliomas	125	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant neuroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant meningioma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Non Hodgkin lymphoma	219	29	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Hodgkin lymphoma	44	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Plasma cell tumors	98	13	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chronic lymphoid leukemia	45	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Leukemia except chronic lymphoid	96	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other lymphoreticular neoplasms	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chronic myeloproliferative diseases	18	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Myelodysplastic syndromes	21	34	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other specified malignant tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant tumor, unspecified	3	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Lokacija (šifre MKB–10) Site (ICD–10 codes)																					
			C00–C96		C10		C11		C12		C13		C14		C15		C16		C17		C18		C19	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	10151	762	43	0	11	0	34	0	23	1	0	0	89	0	437	7	23	0	754	6	144	0		
Small cell carcinoma	162	59	–	–	–	–	–	–	–	–	–	–	–	–	1	–	1	–	2	–	–	–		
Non-small cell carcinoma	51	37	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Squamous cell carcinoma	1338	69	41	–	10	–	34	–	23	1	–	–	70	–	2	–	–	–	–	–	–			
Basal cell carcinoma	1389	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Transitional cel carcinoma	286	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Adenocarcinoma	5216	171	–	–	1	–	–	–	–	–	–	–	16	–	412	1	19	–	725	2	140	–		
Other specified carcinomas	166	22	2	–	–	–	–	–	–	–	–	–	1	–	1	–	–	–	2	–	–			
Carcinoma, unspecified	162	133	–	–	–	–	–	–	–	–	–	–	2	–	15	5	1	–	25	4	3	–		
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Malignant melanoma	459	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Fibrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Fibrohistiocytic sarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Liposarcoma	16	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Leiomyosarcoma	14	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Synovial sarcoma	8	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Angiosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Kaposi sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Osteosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Chondrosarcoma	9	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Ewing sarcoma/PNET	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Other specified sarcomas	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Sarcoma, unspecified	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Malignant complex mixed and stromal tumors	27	1	–	–	–	–	–	–	–	–	–	–	–	–	6	1	2	–	–	–	–			
Malignant fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Malignant mesothelioma	26	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Malignant gonadal stromal tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Dysgerminoma and seminoma	48	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Other malignant germ cell tumors	38	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Malignant trophoblastic tumors	11	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Malignant gliomas	125	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Malignant neuroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Malignant meningioma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Non Hodgkin lymphoma	219	29	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Hodgkin lymphoma	44	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Plasma cell tumors	98	13	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Chronic lymphoid leukemia	45	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Leukemia except chronic lymphoid	96	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Other lymphoreticular neoplasms	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Chronic myeloproliferative diseases	18	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Myelodysplastic syndromes	21	34	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Other specified malignant tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			
Malignant tumor, unspecified	3	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–			

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Lokacija (šifre MKB–10) Site (ICD–10 codes)																					
			C00–C96		C20		C21		C22		C23		C24		C25		C26		C30		C31		C32	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	10151	762	456	1	25	0	83	23	31	5	45	4	140	34	1	1	13	0	11	0	120	1		
Small cell carcinoma	162	59	–	–	–	–	–	–	–	–	–	–	3	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	51	37	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1338	69	–	–	15	–	–	–	–	–	–	–	–	–	–	–	4	–	5	–	115	1		
Basal cell carcinoma	1389	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cel carcinoma	286	0	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	5216	171	444	1	7	–	80	21	28	4	43	2	126	25	1	1	3	–	2	–	1	–		
Other specified carcinomas	166	22	1	–	–	–	–	–	2	–	–	–	–	–	–	–	1	–	3	–	1	–		
Carcinoma, unspecified	162	133	8	–	–	–	–	2	1	1	2	1	9	9	–	–	–	–	1	–	3	–		
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	459	7	1	–	1	–	–	–	–	–	–	–	–	–	–	–	4	–	–	–	–	–	–	–
Fibrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	16	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	14	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	8	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	4	0	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	9	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	4	0	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	27	1	2	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–
Malignant fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	26	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	48	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	38	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	11	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	125	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	219	29	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	44	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	98	13	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	45	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	96	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	18	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	21	34	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	3	6	–	–	–	–	–	–	–	–	–	1	1	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Lokacija (šifre MKB–10) Site (ICD–10 codes)																			
			C00–C96		C33		C34		C37		C38		C39		C40		C41		C43		C44	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	10151	762	7	0	874	238	3	0	4	0	0	0	6	0	6	0	432	5	1752	51	26	2
Small cell carcinoma	162	59	1	–	143	59	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	51	37	–	–	51	36	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1338	69	5	–	283	50	–	–	–	–	–	–	–	–	–	–	–	–	–	355	11	–
Basal cell carcinoma	1389	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1376	39	–
Transitional cel carcinoma	286	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	5216	171	–	–	307	59	1	–	–	–	–	–	–	–	–	–	–	–	–	16	–	–
Other specified carcinomas	166	22	1	–	69	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Carcinoma, unspecified	162	133	–	–	17	12	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–
Malignant thymoma	2	0	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	459	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	432	5	–	–	–	–
Fibrosarcoma	5	0	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	6	0	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	4	–	–
Liposarcoma	16	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	14	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	8	1	–	–	1	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–
Chondrosarcoma	9	0	–	–	1	–	–	–	–	–	–	–	4	–	3	–	–	–	–	–	–	–
Ewing sarcoma/PNET	5	0	–	–	–	–	–	–	–	–	–	–	1	–	2	–	–	–	–	–	–	–
Other specified sarcomas	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	13	0	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	27	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	26	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	26	2
Malignant gonadal stromal tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	48	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	38	0	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	11	0	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	125	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	219	29	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	44	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	98	13	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	45	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	96	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	18	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	21	34	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	3	6	–	–	1	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Lokacija (šifre MKB–10) Site (ICD–10 codes)																							
			C00–C96		C46		C47		C48		C49		C50		C51		C52		C53		C54		C55			
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C		
Vse vrste/All types	10151	762	2	0	6	0	27	0	38	1	1053	78	52	0	15	0	153	0	294	1	4	0				
Small cell carcinoma	162	59	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–		
Non-small cell carcinoma	51	37	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Squamous cell carcinoma	1338	69	–	–	–	–	–	–	–	–	1	–	36	–	12	–	121	–	–	–	–	–	–	–		
Basal cell carcinoma	1389	39	–	–	–	–	–	–	–	–	–	–	11	–	1	–	1	–	–	–	–	–	–	–		
Transitional cel carcinoma	286	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Adenocarcinoma	5216	171	–	–	–	–	13	–	–	–	1019	8	–	–	–	–	23	–	243	1	–	–	–	–		
Other specified carcinomas	166	22	–	–	–	–	–	–	–	–	9	–	–	–	1	–	6	–	41	–	–	–	–	–		
Carcinoma, unspecified	162	133	–	–	–	–	–	–	–	–	22	70	–	–	1	–	1	–	1	–	–	–	–	–		
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant melanoma	459	7	–	–	–	–	–	–	–	–	–	–	5	–	–	–	–	–	–	–	–	–	–	–		
Fibrosarcoma	5	0	–	–	–	–	–	–	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Fibrohistiocytic sarcoma	6	0	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Liposarcoma	16	0	–	–	–	–	7	–	8	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Leiomyosarcoma	14	1	–	–	–	–	2	–	2	–	–	–	–	–	–	–	–	–	–	2	–	3	–	–		
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Synovial sarcoma	8	1	–	–	–	–	–	–	6	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Angiosarcoma	4	0	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Kaposi sarcoma	2	0	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Osteosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chondrosarcoma	9	0	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Ewing sarcoma/PNET	5	0	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other specified sarcomas	4	0	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Sarcoma, unspecified	13	0	–	–	–	–	1	–	8	–	–	–	–	–	–	–	–	–	–	1	–	6	–	1		
Malignant complex mixed and stromal tumors	27	1	–	–	–	–	1	–	–	–	–	–	–	–	–	–	1	–	6	–	1	–	–	–		
Malignant fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant mesothelioma	26	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant gonadal stromal tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Dysgerminoma and seminoma	48	0	–	–	–	–	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other malignant germ cell tumors	38	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant trophoblastic tumors	11	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant gliomas	125	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant neuroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant meningioma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant nerve sheath tumors	6	0	–	–	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Non Hodgkin lymphoma	219	29	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Hodgkin lymphoma	44	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Plasma cell tumors	98	13	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chronic lymphoid leukemia	45	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Leukemia except chronic lymphoid	96	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other lymphoreticular neoplasms	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chronic myeloproliferative diseases	18	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Myelodysplastic syndromes	21	34	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other specified malignant tumors	2	0	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant tumor, unspecified	3	6	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Lokacija (šifre MKB–10) Site (ICD–10 codes)																							
			C00–C96		C56		C57		C58		C60		C61		C62		C63		C64		C65		C66			
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C		
Vse vrste/All types	10151	762	161	5	14	0	0	0	7	0	976	4	89	0	1	0	234	14	27	0	10	0				
Small cell carcinoma	162	59	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Non-small cell carcinoma	51	37	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Squamous cell carcinoma	1338	69	–	–	–	–	–	–	6	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–		
Basal cell carcinoma	1389	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Transitional cel carcinoma	286	0	–	–	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	27	–	9	–		
Adenocarcinoma	5216	171	146	1	11	–	–	–	–	–	950	3	–	–	–	–	228	11	–	–	–	–	–	–		
Other specified carcinomas	166	22	7	–	1	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Carcinoma, unspecified	162	133	1	4	2	–	–	–	–	–	24	1	–	–	–	–	2	3	–	–	–	–	–	–		
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant melanoma	459	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Fibrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Fibrohistiocytic sarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Liposarcoma	16	0	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–		
Leiomyosarcoma	14	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–		
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Synovial sarcoma	8	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Angiosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Kaposi sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Osteosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chondrosarcoma	9	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Ewing sarcoma/PNET	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other specified sarcomas	4	0	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Sarcoma, unspecified	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant complex mixed and stromal tumors	27	1	3	–	–	–	–	–	–	–	–	–	–	–	–	–	3	–	–	–	–	–	–	–		
Malignant fibroepithelial tumors	2	0	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant mesothelioma	26	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant gonadal stromal tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Dysgerminoma and seminoma	48	0	1	–	–	–	–	–	–	–	–	–	44	–	–	–	–	–	–	–	–	–	–	–		
Other malignant germ cell tumors	38	0	1	–	–	–	–	–	–	–	–	–	35	–	–	–	–	–	–	–	–	–	–	–		
Malignant trophoblastic tumors	11	0	–	–	–	–	–	–	–	–	–	–	10	–	–	–	–	–	–	–	–	–	–	–		
Malignant gliomas	125	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant neuroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant meningioma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Non Hodgkin lymphoma	219	29	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Hodgkin lymphoma	44	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Plasma cell tumors	98	13	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chronic lymphoid leukemia	45	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Leukemia except chronic lymphoid	96	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other lymphoreticular neoplasms	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chronic myeloproliferative diseases	18	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Myelodysplastic syndromes	21	34	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other specified malignant tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant tumor, unspecified	3	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Lokacija (šifre MKB–10) Site (ICD–10 codes)																							
			C00–C96		C67		C68		C69		C70		C71		C72		C73		C74		C75		C76			
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C		
Vse vrste/All types	10151	762	265	0	4	0	14	0	1	0	125	3	0	0	132	2	6	0	1	0	9	5				
Small cell carcinoma	162	59	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Non-small cell carcinoma	51	37	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Squamous cell carcinoma	1338	69	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–		
Basal cell carcinoma	1389	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Transitional cel carcinoma	286	0	243	–	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Adenocarcinoma	5216	171	5	–	1	–	2	–	–	–	–	–	–	–	131	1	3	–	1	–	–	5	3			
Other specified carcinomas	166	22	4	–	–	–	–	–	–	–	–	–	–	–	1	1	–	–	–	–	–	–	–	–		
Carcinoma, unspecified	162	133	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	1			
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant melanoma	459	7	–	–	–	–	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Fibrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Fibrohistiocytic sarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Liposarcoma	16	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Leiomyosarcoma	14	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–		
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Synovial sarcoma	8	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Angiosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–		
Kaposi sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Osteosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chondrosarcoma	9	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Ewing sarcoma/PNET	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other specified sarcomas	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Sarcoma, unspecified	13	0	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–		
Malignant complex mixed and stromal tumors	27	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–		
Malignant fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant mesothelioma	26	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant gonadal stromal tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Dysgerminoma and seminoma	48	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other malignant germ cell tumors	38	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant trophoblastic tumors	11	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant gliomas	125	3	–	–	–	–	–	–	–	–	125	3	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant neuroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2	–	–	–	–	–	–	–		
Malignant meningioma	1	0	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Non Hodgkin lymphoma	219	29	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Hodgkin lymphoma	44	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Plasma cell tumors	98	13	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chronic lymphoid leukemia	45	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Leukemia except chronic lymphoid	96	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other lymphoreticular neoplasms	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chronic myeloproliferative diseases	18	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Myelodysplastic syndromes	21	34	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other specified malignant tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant tumor, unspecified	3	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Lokacija (šifre MKB–10) Site (ICD–10 codes)																							
			C00–C96		C77		C78		C79		C80		C81		C82		C83		C84		C85		C88			
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C		
Vse vrste/All types	10151	762	24	9	29	25	15	2	29	22	44	4	53	7	136	12	18	2	12	8	0	0				
Small cell carcinoma	162	59	2	–	–	–	2	–	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Non-small cell carcinoma	51	37	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Squamous cell carcinoma	1338	69	10	4	2	–	–	–	2	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Basal cell carcinoma	1389	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Transitional cel carcinoma	286	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Adenocarcinoma	5216	171	6	4	22	13	6	2	17	8	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other specified carcinomas	166	22	2	–	–	–	2	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Carcinoma, unspecified	162	133	1	1	4	10	3	–	4	8	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant melanoma	459	7	2	–	–	1	2	–	1	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Fibrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Fibrohistiocytic sarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Liposarcoma	16	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Leiomyosarcoma	14	1	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Synovial sarcoma	8	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Angiosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Kaposi sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Osteosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chondrosarcoma	9	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Ewing sarcoma/PNET	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other specified sarcomas	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Sarcoma, unspecified	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant complex mixed and stromal tumors	27	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant mesothelioma	26	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant gonadal stromal tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Dysgerminoma and seminoma	48	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other malignant germ cell tumors	38	0	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant trophoblastic tumors	11	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant gliomas	125	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant neuroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant meningioma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Non Hodgkin lymphoma	219	29	–	–	–	–	–	–	–	–	–	–	53	7	136	12	18	2	12	8	–	–	–	–		
Hodgkin lymphoma	44	4	–	–	–	–	–	–	–	–	44	4	–	–	–	–	–	–	–	–	–	–	–	–		
Plasma cell tumors	98	13	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chronic lymphoid leukemia	45	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Leukemia except chronic lymphoid	96	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other lymphoreticular neoplasms	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chronic myeloproliferative diseases	18	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Myelodysplastic syndromes	21	34	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other specified malignant tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant tumor, unspecified	3	6	–	–	–	1	–	–	–	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–		

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Lokacija (šifre MKB–10) Site (ICD–10 codes)													
			C00–C96		C90		C91		C92		C93		C94		C95	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	10151	762	98	13	62	55	66	23	5	1	1	0	7	6	39	80
Small cell carcinoma	162	59	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	51	37	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1338	69	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Basal cell carcinoma	1389	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cel carcinoma	286	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	5216	171	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified carcinomas	166	22	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Carcinoma, unspecified	162	133	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	459	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	16	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	14	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	8	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	9	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	27	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	26	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	48	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	38	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	11	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	125	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	219	29	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	44	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	98	13	98	13	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	45	46	–	–	45	46	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	96	39	–	–	17	9	66	23	5	1	1	–	7	6	–	–
Other lymphoreticular neoplasms	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	18	46	–	–	–	–	–	–	–	–	–	–	–	–	18	46
Myelodysplastic syndromes	21	34	–	–	–	–	–	–	–	–	–	–	–	–	21	34
Other specified malignant tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	3	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Tabela 8: Incidenca ne-Hodgkinovih limfomov* po lokaciji, spolu in starosti, Slovenija 2007.

Table 8: Incidence of non-Hodgkin's malignant lymphomas* by site, by sex and by age, Slovenia 2007.

Šifra MKB-8 ICD-8 code	Lokacija Site	Spol Sex	Vse starosti All ages	Starosti Age																
				0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80+
	Vse lokacije All sites	Skupaj Total	248	1	0	1	3	2	2	2	5	11	14	17	25	26	25	34	35	45
Moški Male		118	1	0	0	1	2	1	2	4	10	6	10	11	9	12	16	18	15	
Ženske Female		130	0	0	1	2	0	1	0	1	1	8	7	14	17	13	18	17	30	
143	Dlesni Gum	M	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
146	Orofarinks Oropharynx	M	7	0	0	0	0	0	0	0	0	0	1	2	1	0	0	1	2	0
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1
149	Žrelo, neoznačeno Pharynx, not specified	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
150	Požiralnik Oesophagus	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
151	Želodec Stomach	M	11	0	0	0	0	0	0	0	0	1	0	0	0	2	3	2	2	1
		Ž	14	0	0	0	0	0	0	0	0	0	0	0	2	3	2	3	1	3
152	Tanko črevo Small intestine	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
153	Debelo črevo Colon	M	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
157	Trebušna slinavka Pancreas	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
160	Nos, obnosne votline, drugo Nose, sinuses, etc.	M	2	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
161	Grlo Larynx	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
162	Sapnik, sapnica, pljuča Trachea, bronchus, lung	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Ž	2	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1
170	Kosti Bone	M	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
171	Mehka tkiva Soft tissues	M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2
173	Koža, drugi malignomi Skin, other malignancies	M	3	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	1	0
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	2
174	Dojka Breast	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
182	Maternica, telo, drugo Uterus, corpus, etc.	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
183	Jajčnik, jajcevod, drugo Ovary, Fallopian tube, other	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	
186	Modo Testis	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
190	Okno Eye	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
		Ž	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0
191	Možgani Brain	M	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0
193	Ščitnica Thyroid	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
202	Bezgavke Lymph nodes	M	81	1	0	0	1	1	1	2	4	6	4	7	9	3	7	12	11	12
		Ž	87	0	0	0	0	0	1	0	1	1	7	7	9	10	10	11	12	18

* Vključeni so samo citološko in histološko potrjeni primeri

* All cases included have been verified citologically and histologically

Tabela 9: Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2007.

Table 9: Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2007.

Šifra MKB ICD code	Primarna lokacija Primary site	Stanje									
		Spol	Število novih primerov	Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
		Sex	Number of new cases	Localized		Regional		Distant		Unknown	
		Number	%*	Number	%*	Number	%*	Number	%*		
C00 – C96	Vse lokacije All sites	M+Ž	11563	5315	46,0	3179	27,5	2660	23,0	409	3,5
		M	6064	2686	44,3	1676	27,6	1455	24,0	247	4,1
		Ž	5499	2629	47,8	1503	27,3	1205	21,9	162	2,9
C00	Ustnica Lip	M	17	13	76,5	3	17,6	0	0	1	5,9
		Ž	8	8	–	0	–	0	–	0	–
C01	Baza jezika Base of tongue	M	13	4	–	9	–	0	–	0	–
		Ž	3	0	–	3	–	0	–	0	–
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	30	12	40,0	18	60,0	0	0	0	0
		Ž	1	1	–	0	–	0	–	0	–
C03	Dlesen Gum	M	7	1	–	6	–	0	–	0	–
		Ž	3	3	–	0	–	0	–	0	–
C04	Ustno dno Floor of mouth	M	29	11	37,9	16	55,2	2	6,9	0	0
		Ž	12	2	–	10	–	0	–	0	–
C05	Nebo Palate	M	10	4	–	6	–	0	–	0	–
		Ž	6	6	–	0	–	0	–	0	–
C06	Usta, drugi deli Mouth, other & unspecified parts	M	8	3	–	5	–	0	–	0	–
		Ž	5	4	–	1	–	0	–	0	–
C07	Parotidna žleza Parotid gland	M	6	1	–	5	–	0	–	0	–
		Ž	4	2	–	2	–	0	–	0	–
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	1	1	–	0	–	0	–	0	–
		Ž	1	1	–	0	–	0	–	0	–
C09	Tonzila Tonsil	M	30	12	40,0	17	56,7	1	3,3	0	0
		Ž	9	0	–	8	–	1	–	0	–
C10	Orofarinks Oropharynx	M	39	9	23,1	30	76,9	0	0	0	0
		Ž	4	0	–	3	–	1	–	0	–
C11	Nazofarinks Nasopharynx	M	8	3	–	4	–	1	–	0	–
		Ž	3	0	–	3	–	0	–	0	–
C12	Piriformni sinus Pyriform sinus	M	31	2	6,5	29	93,5	0	0	0	0
		Ž	3	1	–	2	–	0	–	0	–
C13	Hipofarinks Hypopharynx	M	26	1	3,8	22	84,6	2	7,7	1	3,8
		Ž	0	0	–	0	–	0	–	0	–
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	–	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–	0	–
C15	Požiralnik Oesophagus	M	83	19	22,9	34	41,0	24	28,9	6	7,2
		Ž	14	2	–	6	–	5	–	1	–
C16	Želodec Stomach	M	279	49	17,6	105	37,6	109	39,1	16	5,7
		Ž	178	42	23,6	57	32,0	58	32,6	21	11,8
C17	Tanko črevo Small intestine	M	14	1	–	8	–	5	–	0	–
		Ž	9	2	–	2	–	5	–	0	–
C18	Debelo črevo Colon	M	431	42	9,7	260	60,3	117	27,1	12	2,8
		Ž	350	40	11,4	218	62,3	83	23,7	9	2,6
C19	Rektosigmoidna zveza Rectosigmoid junction	M	79	13	16,5	49	62,0	16	20,3	1	1,3
		Ž	66	8	12,1	36	54,5	20	30,3	2	3,0
C20	Rektum Rectum	M	270	35	13,0	160	59,3	62	23,0	13	4,8
		Ž	193	35	18,1	112	58,0	37	19,2	9	4,7
C21	Anus in analni kanal Anus and anal canal	M	11	5	–	5	–	1	–	0	–
		Ž	14	10	–	3	–	0	–	1	–
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	127	45	35,4	14	11,0	46	36,2	22	17,3
		Ž	48	10	20,8	7	14,6	26	54,2	5	10,4
C23	Žolčnik Gallbladder	M	16	2	12,5	2	12,5	10	62,5	2	12,5
		Ž	44	4	9,1	15	34,1	22	50,0	3	6,8
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	39	10	25,6	17	43,6	8	20,5	4	10,3
		Ž	54	12	22,2	18	33,3	9	16,7	15	27,8
C25	Trebušna slinavka Pancreas	M	153	7	4,6	50	32,7	80	52,3	16	10,5
		Ž	142	5	3,5	51	35,9	72	50,7	14	9,9
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	0	0	–	0	–	0	–	0	–
		Ž	3	1	–	1	–	1	–	0	–

Nadaljevanje →
Continued →

Tabela 9: Nadaljevanje.

Table 9: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Stanje									
		Spol	Število novih primerov	Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
		Sex	Number of new cases	Localized		Regional		Distant		Unknown	
		Number	%*	Number	%*	Number	%*	Number	%*		
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	9	3	–	6	–	0	–	0	–
		Ž	4	1	–	2	–	1	–	0	–
C31	Obnosni sinusi Accessory sinuses	M	9	1	–	5	–	3	–	0	–
		Ž	2	0	–	2	–	0	–	0	–
C32	Grlo Larynx	M	111	67	60,4	41	36,9	2	1,8	1	0,9
		Ž	10	7	–	3	–	0	–	0	–
C33	Sapnik Trachea	M	5	1	–	4	–	0	–	0	–
		Ž	2	0	–	1	–	1	–	0	–
C34	Sapnica in pljuča Bronchus and lung	M	871	125	14,4	308	35,4	401	46,0	37	4,2
		Ž	338	52	15,4	131	38,8	142	42,0	13	3,8
C37	Timus Thymus	M	2	1	–	0	–	1	–	0	–
		Ž	1	0	–	0	–	0	–	1	–
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	4	0	–	2	–	2	–	0	–
		Ž	0	0	–	0	–	0	–	0	–
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	–	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–	0	–
C40	Kosti, sklepnih hrustanec udov Bone and articular cartilage of limbs	M	3	0	–	3	–	0	–	0	–
		Ž	3	1	–	2	–	0	–	0	–
C41	Kosti, sklepnih hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	3	1	–	1	–	1	–	0	–
		Ž	4	1	–	2	–	1	–	0	–
C43	Malignni melanom kože Malignant melanoma of skin	M	201	160	79,6	30	14,9	4	2,0	7	3,5
		Ž	236	196	83,1	34	14,4	4	1,7	2	0,8
C44	Druge maligne neoplazme kože Skin, other malignomas	M	873	849	97,3	20	2,3	1	0,1	3	0,3
		Ž	934	914	97,9	18	1,9	0	0	2	0,2
C45	Mezoteliom Mesothelioma	M	26	12	46,2	7	26,9	5	19,2	2	7,7
		Ž	3	0	–	2	–	1	–	0	–
C46	Kaposijev sarkom Kaposi's sarcoma	M	2	2	–	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–	0	–
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	5	2	–	3	–	0	–	0	–
		Ž	1	1	–	0	–	0	–	0	–
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	7	2	–	4	–	1	–	0	–
		Ž	20	1	5,0	6	30,0	11	55,0	2	10,0
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	19	8	42,1	7	36,8	4	21,1	0	0
		Ž	20	8	40,0	8	40,0	3	15,0	1	5,0
C50	Dojka Breast	M	6	3	–	2	–	1	–	0	–
		Ž	1145	575	50,2	477	41,7	87	7,6	6	0,5
C51	Žensko zunanje spolovilo Vulva	M	–	–	–	–	–	–	–	–	–
		Ž	53	29	54,7	22	41,5	2	3,8	0	0
C52	Nožnica Vagina	M	–	–	–	–	–	–	–	–	–
		Ž	15	6	40,0	8	53,3	0	0	1	6,7
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–	–
		Ž	153	93	60,8	51	33,3	8	5,2	1	0,7
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–	–
		Ž	296	209	70,6	63	21,3	18	6,1	6	2,0
C55	Maternica, neopredeljeno Uterus, unspecified	M	–	–	–	–	–	–	–	–	–
		Ž	5	1	–	3	–	0	–	1	–
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–	–
		Ž	173	30	17,3	15	8,7	126	72,8	2	1,2
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	–	–	–	–	–	–	–	–	–
		Ž	14	6	–	1	–	7	–	0	–
C58	Posteljica Placenta	M	–	–	–	–	–	–	–	–	–
		Ž	0	0	–	0	–	0	–	0	–
C60	Penis Penis	M	7	4	–	3	–	0	–	0	–
		Ž	–	–	–	–	–	–	–	–	–
C61	Prostata Prostate	M	1028	661	64,3	237	23,1	64	6,2	66	6,4
		Ž	–	–	–	–	–	–	–	–	–

Tabela 9: Nadaljevanje.

Table 9: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Stanje									
		Spol	Število novih primerov	Omejen		Razširjen		Razsejan		Neznani	
				Število	%*	Število	%*	Število	%*	Število	%*
		Sex	Number of new cases	Localized		Regional		Distant		Unknown	
		Number	%*	Number	%*	Number	%*	Number	%*		
C62	Modo Testis	M	89	67	75,3	13	14,6	9	10,1	0	0
		Ž	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	1	1	–	0	–	0	–	0	–
		Ž	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha Kidney, except renal pelvis	M	176	115	65,3	24	13,6	37	21,0	0	0
		Ž	94	57	60,6	14	14,9	19	20,2	4	4,3
C65	Ledvični meh Renal pelvis	M	20	8	40,0	6	30,0	5	25,0	1	5,0
		Ž	8	3	–	4	–	1	–	0	–
C66	Sečevod Ureter	M	6	3	–	3	–	0	–	0	–
		Ž	4	3	–	1	–	0	–	0	–
C67	Sečni mehur Bladder	M	202	148	73,3	37	18,3	12	5,9	5	2,5
		Ž	76	44	57,9	19	25,0	11	14,5	2	2,6
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	3	1	–	2	–	0	–	0	–
		Ž	1	1	–	0	–	0	–	0	–
C69	Okoli očesni adneksi Eye and adnexa	M	7	7	–	0	–	0	–	0	–
		Ž	9	6	–	3	–	0	–	0	–
C70	Meninge Meninges	M	0	0	–	0	–	0	–	0	–
		Ž	1	1	–	0	–	0	–	0	–
C71	Možgani Brain	M	79	79	100	0	0	0	0	0	0
		Ž	62	62	100	0	0	0	0	0	0
C72	Hrbtini mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS	M	0	0	–	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–	0	–
C73	Ščitnica Thyroid gland	M	29	15	51,7	12	41,4	2	6,9	0	0
		Ž	105	89	84,8	12	11,4	3	2,9	1	1,0
C74	Nadledvična žleza Adrenal gland	M	2	0	–	0	–	2	–	0	–
		Ž	6	2	–	2	–	2	–	0	–
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	–	0	–	0	–	0	–
		Ž	1	1	–	0	–	0	–	0	–
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	3	0	–	1	–	2	–	0	–
		Ž	23	0	0	7	30,4	11	47,8	5	21,7
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	14	0	–	0	–	0	–	14	–
		Ž	19	0	0	0	0	4	21,1	15	78,9
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	36	0	0	0	0	36	100	0	0
		Ž	63	0	0	0	0	63	100	0	0
C79	Metastaze, drugje Metastases of other sites	M	14	0	–	0	–	14	–	0	–
		Ž	13	0	–	0	–	13	–	0	–
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	47	0	0	0	0	47	100	0	0
		Ž	41	0	0	0	0	41	100	0	0

Šifra MKB ICD code	Primarna lokacija Primary site	Stadij (Ann–Arbor)									
		Spol	Število primerov	I		II		III+IV		Neznani	
				Število	%*	Število	%*	Število	%*	Število	%*
		Sex	Number of new cases	I		II		III+IV		Unknown	
		Number	%*	Number	%*	Number	%*	Number	%*		
C81	Hodgkinova bolezen Hodgkin's disease	M	31	7	22,6	4	12,9	19	61,3	1	3,2
		Ž	17	0	0	7	41,2	10	58,8	0	0
C82– C85	Ne-Hodgkinov limfom Non-Hodgkin's lymphoma	M	118	27	22,9	17	14,4	58	49,2	16	13,6
		Ž	130	29	22,3	25	19,2	59	45,4	17	13,1

* Odstotki niso računani pri številih pod 15

* Percentages are not calculated for less than 15 cases

Tabela 10a: Število in deleži bolnikov, zbolelih leta 2007, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemske terapijo ali obsevani.

Table 10a: Number of patients diagnosed in 2007, that were treated by surgery, systemic therapy or radiotherapy during their first treatment.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število operiranih Number of treated by surgery		Število zdravljenih s sistemske terapijo Number of treated systemic therapy		Število obsevanih Number of treated by radiotherapy	
			Število Number	%*	Število Number	%*	Število Number	%*
C00–C96	Vse lokacije All sites	11607	7125	61,4	3598	31,0	2368	20,4
C00–C14	Usta in žrelo Mouth and pharynx	320	180	56,3	71	22,2	219	68,4
C15	Požiralnik Oesophagus	97	20	20,6	26	26,8	32	33,0
C16	Želodec Stomach	461	226	49,0	114	24,7	67	14,5
C18	Debelo črevo Colon	784	661	84,3	203	25,9	10	–
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	608	479	78,8	252	41,4	212	34,9
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	177	18	10,2	22	12,4	3	–
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	154	48	31,2	4	–	0	–
C25	Trebušna slinavka Pancreas	300	53	17,7	49	16,3	6	–
C32	Grlo Larynx	121	41	33,9	14	–	111	91,7
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1223	214	17,5	448	36,6	501	41,0
C43	Maligni melanom kože Malignant melanoma of skin	437	431	98,6	4	–	19	4,3
C44	Druge maligne neoplazme kože Skin, other malignomas	1808	1634	90,4	12	–	98	5,4
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	66	54	81,8	21	31,8	24	36,4
C50	Dojka Breast	1153	988	85,7	973	84,4	538	46,7
C53	Maternični vrat Cervix uteri	153	104	68,0	21	13,7	37	24,2
C54	Maternično telo Corpus uteri	296	256	86,5	7	–	68	23,0
C56	Jajčnik Ovary	174	147	84,5	122	70,1	1	–
C61	Prostata Prostate	1032	510	49,4	509	49,3	81	7,8
C62	Modo Testis	89	88	98,9	54	60,7	1	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	300	238	79,3	22	7,3	7	–
C67	Sečni mehur Bladder	278	246	88,5	44	15,8	23	8,3
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	145	105	72,4	59	40,7	74	51,0
C73	Ščitnica Thyroid gland	134	128	95,5	119	88,8	11	–
C81	Hodgkinova bolezen Hodgkin's disease	48	1	–	42	87,5	23	47,9
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	248	41	16,5	151	60,9	75	30,2
C90	Difuzni plazmocitom in maligne neoplazme plazmoцитov Multiple myeloma and malignant plasma cell neoplasms	111	4	–	59	53,2	28	25,2
C91–C95	Levkemije Leukaemias	226	2	–	82	36,3	9	–

* Odstotki niso računani, če je število zdravljenih manjše od 15

* Percentages are not calculated for less than 15 new cases

Tabela 10b: Število bolnikov, zbolelih v letu 2007, ki so bili v okviru prvega zdravljenja operirani*, po lokaciji raka in bolnišnici posega.

Table 10b: Number of patients, diagnosed in 2007, that were treated by surgery during their first treatment* by primary sites and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število operiranih Number of treated by surgery	Splošna bolnišnica Celje	Splošna bolnišnica Jesenice	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	11607	7125	422	207	141	2574	1046	1085	277	267	273	396	329	108
C00–C14	Usta in žrelo Mouth and pharynx	320	180	2	0	0	124	1	47	4	2	0	0	0	0
C15	Požiralnik Oesophagus	97	20	0	0	0	17	0	3	0	0	0	0	0	0
C16	Želodec Stomach	461	226	11	8	11	98	9	59	5	3	4	11	1	6
C18	Debelo črevo Colon	784	661	51	51	36	226	21	105	38	39	36	30	10	18
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	608	479	33	22	20	166	55	74	28	17	21	16	16	11
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	177	18	0	0	0	10	1	7	0	0	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	154	48	0	2	7	25	0	8	1	0	0	2	2	1
C25	Trebušna slinavka Pancreas	300	53	0	0	8	32	0	12	0	0	0	0	0	1
C32	Grlo Larynx	121	41	0	0	0	27	0	13	0	0	1	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1223	214	0	1	0	152	3	51	0	0	1	0	3	3
C43	Malignni melanom kože Malignant melanoma of skin	437	431	44	11	4	162	72	36	11	5	18	10	41	17
C44	Druge maligne neoplazme kože Skin, other malignomas	1808	1634	99	97	5	600	38	156	126	67	110	76	250	10
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	66	54	2	2	1	7	34	4	1	0	0	1	1	1
C50	Dojka Breast	1153	988	48	2	12	4	602	198	6	69	14	30	1	2
C53	Maternični vrat Cervix uteri	153	104	4	1	3	51	9	14	2	1	2	3	0	14
C54	Maternično telo Corpus uteri	296	256	23	2	5	124	31	37	4	7	4	9	0	10
C56	Jajčnik Ovary	174	147	15	1	2	52	32	28	3	3	3	3	0	5
C61	Prostata Prostate	1032	510	36	0	3	184	0	82	23	10	23	148	0	1
C62	Modo Testis	89	88	3	0	5	45	0	17	4	1	5	7	0	1
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	300	238	16	0	4	120	0	34	10	12	13	29	0	0
C67	Sečni mehur Bladder	278	246	20	0	7	128	0	41	7	22	8	13	0	0
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	145	105	0	0	0	85	0	20	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	134	128	0	0	2	15	102	5	0	0	0	1	3	0
C81	Hodgkinova bolezen Hodgkin's disease	48	1	0	0	0	0	0	0	0	0	0	1	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	248	41	4	4	3	16	5	4	0	2	3	0	0	0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	111	4	0	0	0	2	0	1	0	0	1	0	0	0
C91–C95	Levkemije Leukaemias	226	2	0	1	0	0	0	0	1	0	0	0	0	0

* Bolniki, ki so bili v okviru prvega zdravljenja operirani več kot enkrat, so vključeni le s prvo operacijo

* Patients that undergone multiple surgery procedures in the course of first treatment were included with first procedure only

** V posamezni ustanovi so operirali manj kot 30 bolnikov

** Less than 30 patients were treated by surgery in individual institution

Tabela 10c: Število bolnikov, zbolelih v letu 2007, ki so v okviru prvega zdravljenja prejeli sistemske terapijo*, po lokacijah raka in bolnišnici posega.

Table 10c: Number of patients diagnosed in 2007, that were treated by systemic therapy during their first treatment* by primary sites and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število zdravljenih s sistemsko terapijo Number of treated systemic therapy	Splošna bolnišnica Celje	Bolnišnica Golnik	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	11607	3598	129	79	15	300	2511	357	34	57	25	30	42	19
C00–C14	Usta in žrelo Mouth and pharynx	320	71	1	0	0	1	69	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	97	26	0	0	0	0	26	0	0	0	0	0	0	0
C16	Želodec Stomach	461	114	0	0	0	0	111	0	0	0	0	2	0	1
C18	Debelo črevo Colon	784	203	19	0	0	3	175	1	0	0	0	5	0	0
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	608	252	9	0	1	1	239	1	0	0	0	1	0	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	177	22	1	0	0	12	3	6	0	0	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	154	4	0	0	0	0	3	1	0	0	0	0	0	0
C25	Trebušna slinavka Pancreas	300	49	0	0	0	6	41	1	0	0	0	0	0	1
C32	Grlo Larynx	121	14	0	0	0	1	13	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1223	448	0	77	0	0	355	14	0	0	0	0	0	2
C43	Maligni melanom kože Malignant melanoma of skin	437	4	0	0	0	0	4	0	0	0	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	1808	12	3	0	0	0	1	5	0	0	1	0	2	0
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	66	21	1	0	0	2	17	0	1	0	0	0	0	0
C50	Dojka Breast	1153	973	25	1	3	1	719	187	0	25	1	5	2	4
C53	Maternični vrat Cervix uteri	153	21	0	0	0	0	21	0	0	0	0	0	0	0
C54	Maternično telo Corpus uteri	296	7	0	0	0	0	3	4	0	0	0	0	0	0
C56	Jajčnik Ovary	174	122	0	0	0	0	102	20	0	0	0	0	0	0
C61	Prostata Prostate	1032	509	48	0	8	162	80	97	22	26	18	5	36	7
C62	Modo Testis	89	54	0	0	0	0	54	0	0	0	0	0	0	0
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	300	22	0	0	0	9	10	2	0	1	0	0	0	0
C67	Sečni mehur Bladder	278	44	2	0	0	10	29	0	2	0	1	0	0	0
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	145	59	0	0	0	7	52	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	134	119	0	0	1	2	113	0	0	0	0	1	2	0
C81	Hodgkinova bolezen Hodgkin's disease	48	42	0	0	0	4	38	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	248	151	1	1	0	7	135	2	2	1	0	1	0	1
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	111	59	8	0	0	19	5	6	7	2	3	6	0	3
C91–C95	Levkemije Leukaemias	226	82	11	0	2	45	7	10	0	2	1	4	0	0

* Bolniki, ki so v okviru prvega zdravljenja prejeli več kot eno vrsto sistemskega zdravljenja, so vključeni le enkrat

* Patients that undergone multiple systemic treatments in the course of first treatment were included with first treatment only

** V posamezni ustanovi so zdravili manj kot 10 bolnikov

** Less than 10 patients were treated in individual institution

Tabela 11: Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2007.

Table 11: Prevalence of cancer patients by sex and by selected primary site, Slovenia, December 31, 2007.

Šifra MKB ICD code	Primarna lokacija* Primary site*	Spol Sex	Leta po diagnozi Years after diagnosis				Celokupna prevalenca Overall prevalence
			<1	1–4	5–9	10+	31.12.2007
C00–C96	Vse lokacije All sites	Skupaj Total	7963	21720	16549	24444	70676
		Moški Males	4036	10056	6884	8111	29087
		Ženske Females	3927	11664	9665	16333	41589
C00–C14	Usta in žrelo Mouth and pharynx	M	216	474	305	488	1483
		Ž	54	163	135	169	521
C15	Požiralnik Oesophagus	M	46	32	16	30	124
C16	Želodec Stomach	M	167	308	205	339	1019
		Ž	112	212	162	314	800
C18	Debelo črevo Colon	M	331	813	553	460	2157
		Ž	269	698	504	592	2063
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	284	727	450	426	1887
		Ž	212	486	344	500	1542
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	53	38	5	11	107
		Ž	14	16	4	13	47
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	29	29	21	21	100
		Ž	48	39	15	25	127
C25	Trebušna slinavka Pancreas	M	67	29	16	14	126
		Ž	54	41	14	14	123
C32	Grlo Larynx	M	102	240	219	308	869
		Ž	10	29	27	45	111
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	473	589	248	354	1664
		Ž	204	228	109	106	647
C43	Malignni melanom kože Malignant melanoma of skin	M	197	523	347	324	1391
		Ž	232	601	480	718	2031
C44	Druge maligne neoplazme kože Skin, other malignomas	M	855	2711	1945	2151	7662
		Ž	922	3082	2211	2909	9124
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	23	64	59	136	282
		Ž	36	87	57	161	341
C50	Dojka Breast	M	5	20	21	21	67
		Ž	1093	3664	3094	4135	11986
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–
		Ž	143	590	679	2280	3692
C54	Maternično telo Corpus uteri	M	–	–	–	–	–
		Ž	280	934	953	1715	3882
C56	Jajčnik Ovary	M	–	–	–	–	–
		Ž	155	387	320	659	1521
C61	Prostata Prostate	M	952	2311	1299	355	4917
		Ž	–	–	–	–	–
C62	Modo Testis	M	88	375	387	773	1623
		Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	163	419	280	293	1155
		Ž	76	239	188	283	786
C67	Sečni mehur Bladder	M	162	423	225	282	1092
		Ž	58	138	81	112	389
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	49	83	55	148	335
		Ž	34	57	50	111	252
C73	Ščitnica Thyroid gland	M	27	94	79	109	309
		Ž	100	383	276	425	1184
C81	Hodgkinova bolezen Hodgkin's disease	M	28	99	74	261	462
		Ž	17	67	91	227	402
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	93	264	217	321	895
		Ž	108	347	219	310	984
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	45	97	36	21	199
		Ž	37	81	31	24	173
C91–C95	Levkemije Leukaemias	M	87	200	178	198	663
		Ž	64	140	134	240	578

* Pri posameznih lokacijah je pri prikazu prevalenca oseba z več raki vključena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z več raki šteje le enkrat

* For persons with more than one cancer the person is included as a prevalent cancer in each cancer site, but in the all sites group each person is counted once only

Tabela 12: Umrljivost za rakom po lokaciji, spolu in starosti, Slovenija 2007.

Table 12: Mortality by site, by sex and by age, Slovenia 2007.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starosti Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80–
C00 – C97	Vse lokacije All sites	M+Ž	5537	5	0	3	6	6	10	22	38	81	145	307	486	534	705	894	966	1329
		M	3146	3	0	2	4	4	7	13	23	43	84	192	308	349	448	560	547	559
		Ž	2391	2	0	1	2	2	3	9	15	38	61	115	178	185	257	334	419	770
C00	Ustnica Lip	M	4	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	1	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C01	Baza jezika Base of tongue	M	3	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	13	0	0	0	0	0	0	0	0	1	2	1	2	2	1	2	2	2
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1
C04	Ustno dno Floor of mouth	M	9	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1
C05	Nebo Palate	M	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	11	0	0	0	0	0	0	0	0	0	0	2	1	2	2	0	2	2
		Ž	3	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	1	0
C07	Parotidna žleza Parotid gland	M	6	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	3
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C09	Tonzila Tonsil	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C10	Orofarinks Oropharynx	M	38	0	0	0	0	0	0	0	0	1	4	8	5	9	6	1	3	1
		Ž	6	0	0	0	0	0	0	0	0	0	1	1	0	1	1	0	2	0
C11	Nazofarinks Nasopharynx	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
C12	Piriformni sinus Pyriform sinus	M	4	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	1	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C13	Hipofarinks Hypopharynx	M	24	0	0	0	0	1	0	0	0	2	4	4	6	3	2	2	0	0
		Ž	4	0	0	0	0	0	0	0	0	1	2	0	0	1	0	0	0	0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	10	0	0	0	0	0	0	0	0	0	0	2	2	2	1	1	2	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0
C15	Požiralnik Oesophagus	M	84	0	0	0	0	0	0	0	0	2	5	8	15	9	12	8	11	14
		Ž	15	0	0	0	0	0	0	0	0	0	0	0	2	3	0	1	3	6
C16	Želodec Stomach	M	218	0	0	0	0	2	2	1	3	4	9	14	27	43	38	31	44	44
		Ž	142	0	0	0	0	0	1	1	0	6	6	5	7	14	19	25	58	58
C17	Tanko črevo Small intestine	M	6	0	0	0	0	0	0	0	0	0	0	2	1	0	2	1	0	0
		Ž	7	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	5
C18	Debelo črevo Colon	M	256	0	0	0	0	1	0	1	1	5	13	17	27	40	54	44	53	53
		Ž	200	0	0	0	0	0	1	1	0	0	3	14	13	29	25	42	42	72
C19	Rektosigmoidna zveza Rectosigmoid junction	M	42	0	0	0	0	0	0	0	0	1	1	2	4	4	6	18	6	6
		Ž	29	0	0	0	0	0	0	0	0	0	1	2	4	1	3	6	12	12
C20	Rektum Rectum	M	134	0	0	0	0	0	0	0	2	3	5	5	17	14	36	31	21	21
		Ž	114	0	0	0	0	0	0	0	0	1	3	6	7	13	16	20	48	48
C21	Anus in analni kanal Anus and anal canal	M	4	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	1	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	114	0	0	0	0	0	0	0	0	4	4	14	14	16	26	21	15	15
		Ž	68	0	0	0	0	0	0	0	0	1	3	4	7	6	12	15	20	20
C23	Žolčnik Gallbladder	M	17	0	0	0	0	0	0	0	0	0	0	0	0	4	1	8	4	4
		Ž	52	0	0	0	0	0	0	0	0	0	2	5	2	3	10	11	19	19
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	23	0	0	0	0	0	0	0	1	0	0	2	2	4	6	4	4	4
		Ž	41	0	0	0	0	0	0	0	0	0	0	2	2	0	4	6	10	17
C25	Trebušna slinavka Pancreas	M	158	0	0	0	0	0	0	0	1	2	9	19	23	17	19	22	27	19
		Ž	141	0	0	0	0	0	0	0	0	1	0	3	9	17	13	27	29	42
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	10	0	0	0	0	0	0	0	0	1	1	0	1	0	1	4	2	2
		Ž	12	0	0	0	0	0	0	0	0	0	0	0	2	1	0	1	8	8
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
C31	Obnosni sinusi Accessory sinuses	M	3	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
C32	Grlo Larynx	M	45	0	0	0	0	0	0	0	0	0	4	8	8	8	4	6	7	7
		Ž	5	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	2	0

Tabela 12: Nadaljevanje.

Table 12: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starosti Age																		
				Age																		
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80–		
C33	Sapnik Trachea	M	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
C34	Sapnica in pljuča Bronchus and lung	M	830	0	0	0	0	0	0	0	2	10	17	66	118	105	139	156	124	93		
		Ž	295	0	0	0	0	0	0	0	3	9	7	20	32	26	38	39	50	71		
C37	Timus Thymus	M	4	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	1	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	9	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	2	1	3	
		Ž	8	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	1	1	3	
C40	Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs	M	5	0	0	0	0	0	1	1	1	0	0	0	1	0	0	0	0	1	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
C41	Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	9	0	0	0	0	1	0	1	0	2	1	0	0	3	0	0	1	0	0	
		Ž	3	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	1	0	0	0
C43	Malignni melanom kože Malignant melanoma of skin	M	64	0	0	0	0	0	1	0	3	2	3	5	6	8	9	10	9	8		
		Ž	41	0	0	0	0	1	1	1	1	3	2	4	0	4	3	5	3	13		
C44	Druge maligne neoplazme kože Skin, other malignomas	M	12	0	0	0	0	0	1	0	0	0	0	0	1	0	3	2	5			
		Ž	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	6		
C45	Mezoteliom Mesothelioma	M	25	0	0	0	0	0	0	0	0	0	0	1	9	3	7	1	3	1		
		Ž	8	0	0	0	0	0	0	0	0	1	0	0	0	1	3	0	0	3		
C46	Kaposijev sarkom Kaposi's sarcoma	M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C47	Periferni živci in avtonomno živčevje Peripheral and autonomic nervous system	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	4	0	0	0	0	0	1	0	0	0	1	0	0	1	0	0	1	0	1	
		Ž	17	0	0	0	0	0	0	0	0	0	0	0	0	1	2	3	7	4		
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	3	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	1	0	1	
		Ž	9	0	0	0	0	0	0	0	0	1	1	3	1	0	0	0	0	0	3	
C50	Dojka Breast	M	3	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0		
		Ž	399	0	0	0	0	0	0	2	2	13	14	17	35	34	41	36	86	119		
C51	Žensko zunanje spolovilo Vulva	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	20	0	0	0	0	0	0	0	0	0	0	1	0	1	2	3	5	8		
C52	Nožnica Vagina	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0		
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	44	0	0	0	0	0	0	1	1	6	4	6	3	3	3	5	11			
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	45	0	0	0	0	0	0	0	0	0	0	1	3	6	7	9	5	14		
C55	Maternica, neopredeljeno Uterus, unspecified	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	34	0	0	0	0	0	0	0	1	1	0	8	1	3	6	2	12			
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	133	0	0	0	0	0	1	0	3	8	10	12	10	15	28	22	24			
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	11	0	0	0	0	0	0	0	0	0	0	1	2	0	2	3	3			
C60	Penis Penis	M	3	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	1			
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C61	Prostata Prostate	M	347	0	0	0	0	0	0	0	0	0	0	6	15	38	75	73	140			
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C62	Modo Testis	M	9	0	0	0	0	1	0	0	2	2	0	1	0	1	0	1	1	0		
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha Kidney, except renal pelvis	M	80	0	0	0	0	0	0	0	2	4	2	6	11	11	12	7	17	8		
		Ž	52	0	0	0	0	1	0	0	0	0	0	2	2	4	5	10	6	22		
C65	Ledvični meh Renal pelvis	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0		
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0		
C66	Sečevod Ureter	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2		
C67	Sečni mehur Bladder	M	130	0	0	0	0	0	0	0	0	0	2	4	6	6	9	33	38	32		
		Ž	38	0	0	0	0	0	0	0	0	0	3	1	0	1	1	6	5	21		
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1		
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0		
C69	Okno in očesni adneksi Eye and adnexa	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0		
		Ž	2	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0		
C70	Meninge Meninges	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		Ž	7	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	4		
C71	Možgani Brain	M	82	3	0	1	2	0	1	3	3	3	8	10	13	10	2	10	4	9		
		Ž	55	0	0	0	0	0	0	1	1	3	2	8	0	5	10	12	5	8		

Nadaljevanje →
Continued →

IZBOR PUBLIKACIJ, ki so jih sodelavci Epidemiologije in Registra raka objavili v zadnjih petih letih (tudi v sodelovanju z drugimi raziskovalci)

SELECTED PUBLICATIONS, published by the members of Epidemiology and Cancer Registry in the last five years (also in cooperation with other researchers)

2005

- Bray F, Carstensen B, Moller H, Zappa M, Žakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. *Cancer Epidemiol Biomarkers Prev* 2005; 14: 2191–9.
- Brennan P, Scelo G, Hemminki K, Mellekjaer L, Tracey E, Pompe-Kirn V, et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. *Br J Cancer* 2005; 93: 159–66.
- Hemminki K, Scélo G, Boffetta P, Mellekjaer L, Tracey E, Andersen A, Pompe-Kirn V, et al. Second primary malignancies in patients with male breast cancer. *Br J Cancer* 2005; 92: 1288–92.
- Kobal AB, Horvat M, Prezelj M, Pompe-Kirn V, Zadnik V, Osredkar J, et al. Vpliv elementarnega živega srebra na peroksidacijo lipidov in funkcijsko sposobnost posameznih tarčnih organov pri prebivalcih mesta Idrija in delavcih rudnika: zaključno poročilo raziskovalnega projekta (skrajšana verzija). *Idrij Razgl* 2005; 50: 20–30.
- Norčič G, Repše S, Pompe-Kirn V. Rak debelega črevesa in danke v Sloveniji - razlike v kirurškem zdravljenju in preživetju bolnikov. *Zdrav vestn* 2005; 74: 12, 767–70.
- Pompe-Kirn V. Podrobnejši pregled trenda incidence raka ščitnice v obdobju 1983–2002 v Sloveniji. *Onkologija* 2005; 9: 12–4.
- Primic Žakelj M. Epidemiology of breast cancer: incidence and mortality trends, prevention and control. 3rd Sarajevo breast cancer conference. Sarajevo: ESO, 2005: 15–27.
- Primic Žakelj M. Prenovljeni evropski kodeks proti raku. In: Štabuc B, ed. Poročilo Zveze in regijskih društev za boj proti raku Slovenije: leto 2004. Ljubljana: Zveza društev za boj proti raku Slovenije, 2005: 6–11.
- Primic Žakelj M. Zgodnje odkrivanje pogostejših rakov pri starejših. In: Turk J, ed. Zdrava poznejša leta. Ljubljana: Društvo za zdravje srca in ožilja Slovenije, 2005: 97–110.
- Primic Žakelj M, Zadnik V. Epidemiologija raka dojk v Sloveniji in v svetu. In: Štabuc B, ed. Poročilo Zveze in regijskih društev za boj proti raku Slovenije: leto 2004. Ljubljana: Zveza društev za boj proti raku Slovenije, 2005: 13–6.
- Primic Žakelj M, Zadnik V. Presejanje in zgodnje odkrivanje raka. In: Štabuc B, ed. Zgodnje odkrivanje raka - izzivi za prihodnost. XIII. seminar "In memoriam dr. Dušana Reje", Zbornik. Ljubljana: Zveza slovenskih društev za boj proti raku, 2005: 8–13.
- Primic Žakelj M, Zadnik V. Raziskovalno delo službe epidemiologija in registri raka na Onkološkem inštitutu. In: Bilban M, ed. Cvahtetovi dnevi javnega zdravja 2005. Ljubljana: Medicinska fakulteta, 2005: 125–34.
- Primic Žakelj M, Zadnik V, Žagar T. Epidemiološki podatki o raku materničnega vratu v Sloveniji. In: Takač I, ed. 50 let laboratorija za ginekološko citologijo v Mariboru. Mednarodni znanstveni simpozij. Maribor: Splošna bolnišnica, 2005: 151–60.
- Primic-Žakelj M, Zadnik V, Žagar T. Is cancer epidemiology different in Western Europe to that in Eastern Europe? *Ann Oncol* 2005; 16 Suppl 2: ii 27–9.
- Zadnik V: Evropska raziskava vplivov dejavnikov tveganja na zbolevanje za rakom dojk pri mladih ženskah: podatki za Slovenijo. In: Bilban M, ed. Cvahtetovi dnevi javnega zdravja 2005. Ljubljana: Medicinska fakulteta, 2005: 135–49.
- Zadnik V, Primic Žakelj M. Epidemiologija želodčnega raka. In: Omejc M, Repše S, eds. Kirurgija želodca - standardi in novosti. Simpozij. Ljubljana: Klinični oddelek za abdominalno kirurgijo, SPS Kirurška klinika, Klinični center, 2005: 122–7.
- Žagar T, Primic Žakelj M, Zadnik V. Povezovanje Registra raka za Slovenijo s sorodnimi državnimi podatkovnimi zbirkami. In: Tkačik B, Urbas M, eds. Komuniciranje z dajalci in uporabniki statističnih podatkov ter podpora EMU in Lizbonski strategiji. 15. statistični dnevi. Ljubljana: Statistični urad Republike Slovenije, Statistično društvo Slovenije, 2005: 268–77.
- Žagar T. Lifetables for Slovenia 1982–2004. Rostock: Max Planck, 2005: 1–94.
<http://www.lifetable.de/cgi-bin/country.plx?country=Slovenia>.

2006

- Hertl K, Primic Žakelj M, Žgajnar J, Kocijančič I. Performance of opportunistic breast cancer screening in Slovenia. *Neoplasma* 2006; 53: 237–41.
- Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Pompe-Kirn V, et al. Risk of second cancer among women with breast cancer. *Int J Cancer* 2006; 118: 2285–92.
- Pompe-Kirn V, Primic Žakelj M. Ali vemo, koliko je raka prostate v Sloveniji in kaj vpliva na razvoj te bolezni? *Onkologija* 2006; 10: 9–13.
- Pompe-Kirn V. Obolenost za rakom dojk med ženskami, vključenimi v pilotno študijo. *Onkologija* 2006; 10: 96–8.
- Primic Žakelj M, Zadnik V, Žagar T. Breast cancer risk factors. *Liječ Vjesn* 2006; 128, Suppl 3: 49–50.
- Primic Žakelj M, Zadnik V, Žagar T. Epidemiologija raka debelega črevesa in danke (Epidemiology of colorectal cancer. In: Repše S, Štor Z eds. *Kirurgija raka debelega črevesa in danke: standardi in novosti. Zbornik simpozija (Standards & novelties: proceedings of the symposium, Ljubljana 2006. Ljubljana: Kirurška šola, Klinični oddelek za abdominalno kirurgijo, Kirurška klinika, Klinični center, 2006: 14–20.*
- Primic Žakelj M, Zadnik V, Žagar T. Ali se učinki programa ZORA že kažejo v incidenci invazivskega raka materničnega vratu. In: Možina A ed. *Dan ginekološke onkologije: rak jajčnikov. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo: Ginekološka klinika, Klinični center, 2006: 55–6.*
- Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scelo G, Pukkala E, Pompe-Kirn V, et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. *J Clin Endocrinol Metab* 2006; 91: 1819–25.
- Scélo G, Boffetta P, Hemminki K, Pukkala E, Olsen JH, Andersen A, Pompe-Kirn V, et al. Associations between small intestine cancer and other primary cancers: an international population-based study. *Int J Cancer* 2006; 118: 189–96.
- Shen M, Boffetta P, Olsen JH, Andersen A, Hemminki K, Pukkala E, Pompe-Kirn V, et al. A pooled analysis of second primary pancreatic cancer. *Am J Epidemiol* 2006; 163: 502–11.
- Snoj M, Zadnik V. Starostnik z rakom - kirurški bolnik. In: Smrkolj V ed. *Kirurgija v starostnem obdobju: zbornik povzetkov. Ljubljana: Združenje kirurgov Slovenije, 2006: 28–36.*
- Strojman P, Šmid A, Čizmarevič B, Žagar T, Auersperg M. Verrucous carcinoma of the larynx: determining the best treatment option. *Eur J Surg Oncol* 2006; 32: 984–8.
- Steliarova-Foucher E, Kaatsch P, Lacour B, Pompe-Kirn V, Eser S, Miranda A, et al. Quality, comparability and methods of analysis of data on childhood cancer in Europe (1978–1997): report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006; 42: 1915–51.
- Zadnik V, Primic Žakelj M. Breme želodčnega raka v svetu in Sloveniji (The burden of stomach cancer worldwide and in Slovenia). In: *Zbornik predavanj XII. podiplomskega tečaja kirurgije, 10.–11. februar 2006. Ljubljana: Kirurška klinika, Klinični center, 2006: 77–80.*
- Zadnik V, Reich BJ. Analysis of the relationship between socioeconomic factors and stomach cancer incidence in Slovenia. *Neoplasma* 2006; 53: 103–10.
- Zadnik V. Geografska analiza razporejanja incidence raka. *Onkologija* 2006; 10: 92–5.
- Zadnik V, Žagar T, Primic Žakelj M. Pojavljanje raka v občini Brežice v primerjavi z ostalo Slovenijo: geografska analiza incidence raka v občini Brežice na podlagi podatkov Registra raka za Slovenijo: zaključno poročilo. Ljubljana: Onkološki inštitut, 2006.
- Zadnik V, Žagar T, Primic Žakelj M. The geographical variation of cervical cancer screening efficiency in Slovenia. In: Batagelj V, Ferligoj A, Žiberna A, eds. *Data science and classification: program and abstracts. Ljubljana: Center of Methodology and Informatics, Institute of Social Sciences at Faculty of Social Sciences, 2006: 173.*
- Žagar T, Primic Žakelj M, Zadnik V. Pretok in uporaba informacij v Registru raka - najstarejšem zdravstvenem registru v Sloveniji. *Bilt ekon organ inform zdrav* 2006; 22: 6.
- Žagar T, Zadnik V, Pohar M, Primic Žakelj M. Complete yearly life tables by sex for Slovenia, 1982–2004, and their use in public health [Popolne letne tablice umrljivosti za Slovenijo po spolu, 1982–2004, in možnosti uporabe v javnem zdravju]. *Radiol Oncol* 2006; 40: 115–24.

2007

- Arbyn M, Primic Žakelj M, Raifu AO, Grce M, Paraskevaidis E, Diakomanolis E, et al. The burden of cervical cancer in South-East Europe at the beginning of the 21st century. *Coll Antropol* 2007; 31 Suppl 2: 7–10.
- Bidoli E, Zadnik V, De Dottori M, Zanier L, Serraino D. Prostate cancer pattern in the bordering areas of Friuli-Venezia Giulia, Italy, and Slovenia, 1995–2003. In: Primic Žakelj M, Žagar T, Zadnik V, eds. *At the crossroad of tradition and new technologies in cancer registration. The role of cancer registries in cancer control: programme and book of abstracts. Ljubljana: Institute of Oncology, 2007.*

- Bizjak-Ogrinc U, Čufer T, Pompe-Kirn V. Survival of patients with invasive urinary bladder cancer in Slovenia regarding to stage of disease and treatment in years 1987–1997. In: Primic-Žakelj M, Žagar T, Zadnik V, eds. At the crossroad of tradition and new technologies in cancer registration. The role of cancer registries in cancer control: programme and book of abstracts. Ljubljana: Institute of Oncology, 2007.
- Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Tracey E, Pompe-Kirn V, et al. Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. *J Natl Cancer Inst* 2007; 10: 790–800.
- Primic-Žakelj M. Epidemiologija raka pri moških in ženskah. In: Mlakar-Mastnak D, Lokar K, eds. Ženske, moški in rak. Ljubljana: Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in babiške nege Slovenije - Zvezi društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije; 2007.
- Primic-Žakelj M. Obvladovanje raka v Sloveniji. In: Kraigher A, Berger T, Piškur-Kosmač D, eds. 4. slovenski kongres preventivne medicine, Portorož, 17. do 19. maj 2007. Izzivi javnega zdravja v tretjem tisočletju: knjiga izvečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva; 2007.
- Primic-Žakelj M. Rak materničnega vratu v Sloveniji in program ZORA. In: Kraigher A, Berger T, Piškur-Kosmač D, eds. 4. slovenski kongres preventivne medicine, Portorož, 17. do 19. maj 2007. Izzivi javnega zdravja v tretjem tisočletju: knjiga izvečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva; 2007.
- Primic-Žakelj M, Zadnik V, Žagar T. Rak v Sloveniji. *Zdrav Vest* 2007; 76: 775–80.
- Primic-Žakelj M, Žagar T. Breast cancer epidemiology in Slovenia. *Senologie* 2007; 4: 205.
- Primic-Žakelj M, Žagar T, Zadnik V. Epidemiologija malignega melanoma. *Radiol Oncol* 2007; 41 Suppl 1: S1–S12.
- Primic-Žakelj M, Žagar T, Zadnik V. Epidemiologija pljučnega raka. In: Rott T, Luzar B, eds. Pljučni rak - današnje stanje in perspektive. Ljubljana: Inštitut za patologijo, Medicinska fakulteta, 2007.
- Ravnik M, Arko D, Žagar T, Primic-Žakelj M, Čufer T. Breast cancer and second malignancies. *Senologie* 2007; 4: 209.
- Richiardi L, Scélo G, Boffetta P, Hemminki K, Pukkala E, Olsen JH, Pompe-Kirn V, et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. *Int J Cancer* 2007; 120: 623–31.
- Riska A, Pukkala E, Scélo G, Mellekmjaer L, Hemminki K, Weiderpass E, Pompe-Kirn V, et al. Second primary malignancies in females with primary fallopian tube cancer. *Int J Cancer* 2007; 120: 2047–51.
- Scélo G, Boffetta P, Autier P, Hemminki K, Pukkala E, Olsen JH, Pompe-Kirn V. Associations between ocular melanoma and other primary cancers: an international population-based study. *Int J Cancer* 2007; 120: 152–9.
- Scélo G, Boffetta P, Corbex M, Chia KS, Hemminki K, Friis S, Pompe-Kirn V, et al. Second primary cancers in patients with nasopharyngeal carcinoma: a pooled analysis of 13 cancer registries. *Cancer Causes Control* 2007; 18: 269–78.
- Tuohimaa P, Pukkala E, Scélo G, Olsen JH, Brewster DH, Hemminki K, Pompe-Kirn V, et al. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. *Eur J Cancer* 2007; 43: 1701–12.
- Zadnik V, Pompe-Kirn V. Effects of 500-year mercury mining and milling on cancer incidence in the region of Idrija, Slovenia. *Coll Antropol* 2007; 31: 897–903.
- Zver S, Zadnik V, Bunc M, Rogel P, Černelč P, Koželj M. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. *Int J Hematol* 2007; 85: 408–14.
- Žagar T, Droljc A. Connection of Cancer Registry of Slovenia to other state databases. In: Primic-Žakelj M, Žagar T, Zadnik V, eds. At the crossroad of tradition and new technologies in cancer registration. The role of cancer registries in cancer control: programme and book of abstracts. Ljubljana: Institute of Oncology, 2007.
- Žagar T, Zadnik V, Primic-Žakelj M. Različne možnosti prikazovanja geografskega razporejanja incidence raka na materničnem vratu v Sloveniji. In: Kraigher A, Berger T, Piškur-Kosmač D, eds. 4. slovenski kongres preventivne medicine, Portorož, 17. do 19. maj 2007. Izzivi javnega zdravja v tretjem tisočletju: knjiga izvečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva; 2007.

2008

- Baili P, Micheli A, De Angelis R, Weir HK, Primic-Žakelj M, Pompe-Kirn V, et al. Life tables for world-wide comparison of relative survival for cancer (CONCORD study). *Tumori* 94: 658–68.
- Besic N, Cernivc B, de Grève J, Lokar K, Krajc M, Novakovic S, et al. BRCA2 gene mutations in Slovenian male breast cancer patients. *Genet Test* 2008; 12: 203–9.
- Chuang S, Hashibe M, Scelo G, Brewster DH, Pukkala E, Pompe-Kirn V, et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. *Cancer Epidemiol Biomarkers Prev* 2008; 17: 1543–9.
- Chuang S, Scelo G, Tonita JM, Tamaro S, Jonasson JG, Pompe-Kirn V, et al. Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries. *Int J Cancer* 2008; 123: 2390–6.
- Glumac N, Hocevar M, Zadnik V, Snoj M. Sentinel lymph node micrometastasis may predict non-sentinel involvement in cutaneous melanoma patients. *J Surg Oncol* 2008; 98: 46–8.

- Gondos A, Bray F, Brewster DH, Coebergh JWW, Hakulinen T, Primic Žakelj M, et al. Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries. *Eur J Cancer* 2008; 44: 1463–75.
- Gouveia J, Coleman MP, Haward R, Zanetti R, Hakama M, Primic-Žakelj M, et al. Improving cancer control in the European Union: conclusions from the Lisbon round-table under the Portuguese EU Presidency, 2007. *Eur J Cancer* 2008; 44: 1457–62.
- Krajc M. Screening. In: Kovačič L, Zaletel-Kragelj L, eds. *Management in health care practice: a handbook for teachers, researchers and health professionals*. Lage: Hans Jacobs Publishing Company; 2008. p. 286–307.
- Krajc M, Teugels E, Zgajnar J, Goelen G, Besic N, Novakovic S, et al. Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. *BMC Med Genet* 2008; 9:83–91.
- Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Pompe-Kirn V, et al. Risk of second malignant neoplasms after childhood central nervous system malignant tumours: an international study. *Eur J Cancer* 2008; 44: 830–9.
- Primic-Žakelj M. Cancer epidemiology. In: Schrijvers D, Zakotnik B, eds. *ESMO handbook of cancer prevention*. London: Informa Healthcare; 2008. p. 1–9.
- Primic-Žakelj M, Zadnik V. Rak pri starejših. In: Bilban M, ed. *Zbornik prispevkov Cvahtetovih dnevov*. Ljubljana: Katedra za javno zdravje; 2008.
- Primic-Žakelj M, Zadnik V, Žagar T. Karcinom debelega črevesa in danke v Sloveniji in v Evropi (Colorectal cancer in Slovenia and in Europe). In: Luzar B, Cerar A, Štabuc B, eds. *Tumorji debelega črevesa in danke*. Ljubljana: Inštitut za patologijo, Medicinska fakulteta; 2008.
- Primic-Žakelj M, Žagar T. Cancer control in Slovenia: achievements, shortcomings and opportunities. In: Coleman MP, ed. *Responding to the challenge of cancer in Europe*. Ljubljana: Institute of Public Health of the Republic of Slovenia; 2008.
- Primic-Žakelj M, Žagar T, Zadnik V. Lung cancer in Slovenia (Pljučni rak v Sloveniji). *Endosk rev* 2008; 13: 5–13.
- Repše-Fokter A, Primic-Žakelj M. Auditing screening laboratories in Slovenia. *Cytopathology* 2008; 19 Suppl 1: 20.
- Repše-Fokter A, Primic-Žakelj M. Cervical cancer screening in Slovenia. *Cytopathology* 2008; 19 Suppl 1: 3.
- Robins G, Crabtree JE, Bailey A, Forman D, Pompe-Kirn V, et al. International variation in *Helicobacter pylori* infection and rates of oesophageal cancer. *Eur J Cancer*. 2008; 44: 726–32.
- Rojnik K, Naversnik K, Mateovič-Rojnik T, Primic Žakelj M. Probabilistic cost-effectiveness modeling of different breast cancer screening policies in Slovenia. *Value Health* 11: 139–48.
- Sant M, Allemani C, De Angelis R, Carbone A, de Sanjosè S, Pompe-Kirn V, et al. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. *Eur J Cancer* 2008; 44: 579–87.
- Tercej M, Ales A, Rott T, Sever N, Prodnik L, Primic-Žakelj M, et al. DNA-based sputum cell image analysis for lung cancer in a clinical setting. *Acta Cytol* 2008; 52: 584–90.
- Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Primic Žakelj M, Pompe-Kirn V, et al. Survival in patients with uveal melanoma in Europe. *Arch Ophthalmol* 2008; 126: 1413–8.
- Zadnik V, Ivanuš U, Florjančič M, Primic-Žakelj M. Vloga registra ZORA pri obvladovanju bremena raka materničnega vratu v Sloveniji (The role of ZORA registry in cervical cancer burden control in Slovenia). *Bilt-ekon organ inform zdrav* 2008; 24:179–83.
- Zadnik V, Primic-Žakelj M. Rak pri ženskah. In: Štabuc B, Primic Žakelj M, Klemenčič M, Piškur J, eds. *Rak rodil*. Ljubljana: Zveza slovenskih društev za boj proti raku; 2008.
- Zadnik V, Žagar T, Drobne S, Primic Zakelj M. Estimation of cancer burden in Brezice municipality, a community neighboring Krsko nuclear power plant in Slovenia. *Croat Med J* 2008; 49: 257–66.
- Zadnik V, Žagar T, Primic-Žakelj M. Ginekološki raki v Sloveniji (Gynecological cancers in Slovenia). In: Takač I, ed. *80 let hospitalne ginekologije in porodništva v Maribor: mednarodni znanstveni simpozij*. Maribor: Univerzitetni klinični center Maribor; 2008.
- Zver S, Zadnik V, Černelc P, Kozelj M. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. *Int J Hematol*. 2008; 88: 227–36.
- Zwitter M, Primic-Žakelj M. Lung cancer in Europe. In: Parikh PM, ed. *Lung cancer*. Mumbai: Green Room Media & Event Management Services; 2008. p. 350–7.

2009

- Anttila A, Ronco G, Primic-Žakelj M, Pogačnik A, Uršič-Vrščaj M, Zadnik V, et al. Description of the national situation of cervical cancer screening in the member states of the European Union. *Eur J Cancer* 2009; 45: 2685–708.
- Berrino F, Verdecchia A, Lutz JM, Lombardo C, Micheli A, Primic-Žakelj M, et al. Comparative cancer survival information in Europe. *Eur J Cancer* 2009; 45: 901–8.

- Ciccolallo L, Licitra L, Cantú G, Gatta G, Pompe-Kirn V, Primic Žakelj M, et al. Survival from salivary glands adenoid cystic carcinoma in European populations. *Oral Oncol* 2009; 45: 669–74.
- De Angelis R, Francisci S, Baili P, Marchesi F, Roazzi P, Primic Žakelj M, et al. The EURO CARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. *Eur J Cancer* 2009; 45: 909–30.
- Francisci S, Capocaccia R, Grande E, Santaquilani M, Simonetti A, Primic Žakelj M, et al. The cure of cancer: a European perspective. *Eur J Cancer* 2009; 45: 1067–79.
- Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Primic Žakelj M, et al. Survival of European children and young adults with cancer diagnosed 1995–2002. *Eur J Cancer* 2009; 45: 992–1005.
- Gondos A, Bray F, Hakulinen T, Brenner H, Usel M, Žakelj MP, et al. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. *Ann Oncol* 2009; 20: 564–73.
- Lepage C, Ciccolallo L, De Angelis R, Bouvier AM, Pompe-Kirn V, Primic Žakelj M, et al. European disparities in malignant digestive endocrine tumours survival. *Int J Cancer* 2009; available from: <http://www.ncbi.nlm.nih.gov/pubmed/19569047>.
- Nicula FA, Anttila A, Neamtiu L, Žakelj MP, Tachezy R, Chil A, et al. Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union. *Eur J Cancer* 2009; 45: 2679–84.
- Pasanisi P, Hédelin G, Berrino J, Chang-Claude J, Primic Žakelj M, Zadnik V, et al. Oral contraceptive use and BRCA penetrance: a case-only study. *Cancer Epidemiol Biomarkers Prev* 2009; 18: 2107–13.
- Primic Žakelj M, Pogačnik A, Uršič-Vrščaj M, Ivanuš U. Presejalni program ZORA po petih letih delovanja že kaže pomembne javnozdravstvene rezultate. *Onkologija* 2009; 13: 4–6.
- Primic Žakelj M, Zadnik V, Žagar T. Epidemiologija kožnega raka (Epidemiology of skin cancer). In: Luzar B, Jurčić V, Pižem J, Calonje E, eds. XL. memorialni sestanek profesorja Janeza Plečnika z mednarodnim simpozijem, 3.–4. december 2009, Ljubljana. *Novosti v dermatopatologiji*. Ljubljana: Inštitut za patologijo, Medicinska fakulteta; 2009.
- Primic Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia). Ljubljana: Onkološki inštitut; 2009.
- Primic Žakelj M, Krajc M, Zadnik V. Državni presejalni programi za raka (National cancer screening programs). *Farm vestn* 2009; 60: 90–4.
- Primic Žakelj M, Zadnik V. Epidemiologija raka prostate (Epidemiology of prostate cancer). In: Kramer F, ed. *Rak prostate: zbornik predavanj*. Slovenj Gradec: Oddelek za urologijo, Splošna bolnišnica Slovenj Gradec; 2009.
- Primic Žakelj M, Žgajnar J. Cervical and breast cancer screening in Slovenia. Public service review, European Union. 2009; 18: 272.
- Quaglia A, Tavilla A, Shack L, Brenner H, Janssen-Heijnen M, Primic Žakelj M, et al. The cancer survival gap between elderly and middle-aged patients in Europe is widening. *Eur J Cancer* 2009; 45: 1006–16.
- Repše-Fokter A, Fležar M, Pogačnik A, Snoj V. Review of negative or low grade smears in women with invasive cervical cancer in Slovenia. *Virchows Arch* 2009; 455 Suppl,1: S6–S7.
- Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Primic Žakelj M, et al. Process performance of cervical screening programmes in Europe. *Eur J Cancer* 2009; 45: 2659–70.
- Rosso S, De Angelis R, Ciccolallo L, Carrani E, Soerjomataram I, Primic Žakelj M, et al. Multiple tumours in survival estimates. *Eur J Cancer* 2009; 45: 1080–94.
- Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Primic Žakelj M, et al. EURO CARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. *Eur J Cancer* 2009 Apr; 45(6): 931–91.
- Snoj Z, Primic Žakelj M, Ličina M, Pregelj P. Psychosocial correlates of progesterone receptors in breast cancer. *Depress Anxiety* 2009; 26: 544–9.
- Trapido EJ, Primic Žakelj M, Pogacnik A, Ursic-Vrscaj M, Krajc M, Lesnicar H, et al. Critical factors influencing the establishment, maintenance and sustainability of population-based cancer control programs. *Tumori* 2009; 95: 637–45.
- Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Primic Žakelj M, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. *Eur J Cancer* 2009; 45: 1042–66.
- Zadnik V, Žagar T, Primic Žakelj M. Pridobivanje in uporaba georeferenciranih podatkov v registru raka Republike Slovenije (Georeferenced data acquisition and usage in the cancer registry of Republic of Slovenia). *Bilt-ekon organ inform zdrav* 2009; 25 (izr. št.): 14.
- Zwitter M, Kovač V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. *J Thorac Oncol* 2009; 4: 1148–55.
- Žagar T, Zadnik V, Primic Žakelj M. Register raka Republike Slovenije in pridobivanje informacij o bolnikih iz drugih državnih podatkovnih zbirk po elektronski poti (Cancer Registry of Slovenia obtains patient information from other state databases via electronic mediums). In: Orel M, ed. *Nova vizija tehnologij prihodnosti*. Ljubljana: Evropska hiša; 2009.